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Abstract 
 
Autophagy is an evolutionarily conserved process across eukaryotes that is responsible for 
degradation of cargo such as aggregate-prone proteins, pathogens, damaged organelles, 
macromolecules etc. via its delivery to lysosomes. The process is known to involve the 
formation of a double-membraned structure, called autophagosome, that engulfs the cargo 
destined for degradation and delivers its contents by fusing with lysosomes. This process 
involves several proteins at its core which include two transmembrane proteins, ATG9 and 
VMP1. While ATG9 and VMP1 has been discovered for about a decade and half, the 
trafficking and function of these proteins remain relatively unclear. My work in this thesis 
identifies and characterises a novel trafficking route for ATG9 and VMP1 and shows that both 
these proteins traffic via the dynamin-independent ARF6-associated pathway. Moreover, I also 
show that these proteins physically interact with each other. In addition, the tools developed 
during these studies helped me identify a new role for the most common autophagy receptor 
protein, p62. I show that p62 can specifically associate with and sequester LC3-I in autophagy-
impaired cells (ATG9 and ATG16 null cells) leading to formation of LC3-positive structures 
that can be misinterpreted as mature autophagosomes. Perturbations in the levels of p62 were 
seen to affect the formation of these LC3-positive structures in cells. This observation, 
therefore, questions the reliability of LC3-immunofluorescence assays in autophagy-impaired 
cells as method of assessing autophagy and points towards the homeostatic function played by 
p62 in autophagy-impaired cells. 
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Abstract 
 
Autophagy is an evolutionarily conserved process across eukaryotes that is responsible for 
degradation of cargo such as aggregate-prone proteins, pathogens, damaged organelles, 
macromolecules etc. via its delivery to lysosomes. The process is known to involve the 
formation of a double-membraned structure, called autophagosome, that engulfs the cargo 
destined for degradation and delivers its contents by fusing with lysosomes. This process 
involves several proteins at its core which include two transmembrane proteins, ATG9 and 
VMP1. While ATG9 and VMP1 has been discovered for about a decade and half, the 
trafficking and function of these proteins remain relatively unclear. My work in this thesis 
identifies and characterises a novel trafficking route for ATG9 and VMP1 and shows that both 
these proteins traffic via the dynamin-independent ARF6-associated pathway. Moreover, I also 
show that these proteins physically interact with each other. In addition, the tools developed 
during these studies helped me identify a new role for the most common autophagy receptor 
protein, p62. I show that p62 can specifically associate with and sequester LC3-I in autophagy-
impaired cells (ATG9 and ATG16 null cells) leading to formation of LC3-positive structures 
that can be misinterpreted as mature autophagosomes. Perturbations in the levels of p62 were 
seen to affect the formation of these LC3-positive structures in cells. This observation, 
therefore, questions the reliability of LC3-immunofluorescence assays in autophagy-impaired 
cells as method of assessing autophagy and points towards the homeostatic function played by 
p62 in autophagy-impaired cells. 
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1. Introduction 
 
1.1. Autophagy 
 
Cellular homeostasis includes processes that are involved in maintaining the steady state inside 
the cell. A notable process amongst these, involved in roles beyond maintaining cellular 
homeostasis, is autophagy. Recent studies have shown autophagy to play a role in multitude of 
functions like degradation o aggregate-prone proteins, pathogens, damaged organelles, 
macromolecules etc. and not simply maintaining cellular homeostasis (Bento et al., 2016b; 
Ravikumar et al., 2009). 
 
Autophagy is an evolutionarily conserved catabolic process responsible for the bulk 
degradation of cytosolic cargo by delivering them to lysosomes. There are three different types 
of autophagy: macroautophagy, microautophagy and chaperone-mediated autophagy, 
classified on the basis of the mode of cargo delivery to the lysosomes (Fig 1.1 a) (Jimenez-
Sanchez et al., 2012). 
 
1.1.1. Chaperone-mediated autophagy 
 
Chaperone-mediated autophagy is a highly selective autophagic process that involves binding 
of the substrate to a chaperone and co-chaperones facilitating its transport across the lysosomal 
membrane. Studies have shown that starvation for about 8-10 hours activates CMA (Cuervo et 
al., 1995). The substrates destined for degradation by this mode of autophagy are characterised 
by a KFERQ-like motif that is recognised by the chaperone HSC70 (heat shock cognate protein 
of 70 kDa) and co-chaperones like CHIP (carboxy terminus of HSC70-interacting protein), 
HSP40 (heat shock protein 40), HOP (HSP70-HSP90 organising protein). This targets the 
substrate to the lysosomal membrane and promotes its interaction with LAMP2A (lysosomal-
associated membrane protein type 2A), while promoting the unfolding of the substrate. This is 
followed by the translocation of the unfolded protein substrate across the lysosomal membrane 
into the lysosomal lumen for degradation (Jimenez-Sanchez et al., 2012; Kaushik and Cuervo, 
2018). 
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1.1.2. Microautophagy 
 
Microautophagy involves the engulfment of the cargo to be degraded via the invagination of 
the lysosomal membrane. While studies in yeast have provided some mechanistic insights into 
the process, its role in mammalian cells remains unclear. The yeast studies have shown the 
requirement of TOR and EGO protein complexes to regulate and facilitate microautophagy in 
yeast. This study also proposes that microautophagy plays a role in the decrease of the 
lysosomal size on macroautophagy induction (Dubouloz et al., 2005). 
 
1.1.3. Macroautophagy 
 
Macroautophagy constitutes the major form of autophagy in cells and hereafter will be referred 
to simply as ‘autophagy’ in this thesis. While this process was considered to be largely non-
specific, recent studies have shown the process to be specific for certain substrates. A few 
examples of these processes include clearance of damaged organelles like mitochondria – 
mitophagy, peroxisomes – pexophagy, aggregate-prone proteins – aggrephagy, etc (Ashrafi 
and Schwarz, 2013; Jr et al., 2005; Stolz et al., 2014). 
 
Autophagy involves the formation of double-membraned autophagosomes that engulf cargoes 
destined for lysosomal degradation. The autophagosome has been proposed to be derived from 
a cytoplasmic, cup-shaped structure named phagophore. The phagophore encapsulates and 
sequesters the cargo to be degraded by elongation of its edges, finally resulting in closure by 
sealing off the ends. The autophagosomes then fuse with lysosomes to form structures called 
‘autolysosomes’, where the contents are degraded and recycled back in the form of amino acids 
and other similar macromolecules (Fig 1.1 b) (Rubinsztein et al., 2012). 
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Fig 1.1 a) A schematic showing various forms of autophagy classified as chaperone-mediated, micro and 
macroautophagy. The schematic of chaperone-mediated autophagy shows the binding of the cargo to Hsp and its 
delivery to lysosomes. The schematic of microautophagy highlights the engulfment of cargo by micro-
invagination of the lysosomal membrane. The schematic of the process of macroautophagy shows the general 
process of cargo degradation by its delivery to the lysosomes. Please refer to the legend for description of various 
symbols. b) A detailed schematic depicting the various steps involved in the process of macroautophagy as 
described in the section 1.1. The process involves formation of double-membrane cup-shaped structure to engulf 
cargo destined for degradation by the lysosomal hydrolases. The process has been identified to consist of distinct 
structures such as phagophore – a precursor for autophagosome formation and autophagosome – a double-
membraned structure enclosing cargo to be degraded. Autolysosomes are formed upon fusion of completed 
autophagosomes with lysosomes. The LC3-II molecules labelling the cytosolic face of the autophagosomes are 
recycled back while the LC3-II molecules on the lumenal side are degraded by the lysosomal hydrolases. Please 
refer to the legend for description of various symbols. 
a) 
b) 
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1.2. Protein complexes involved in autophagy 
 
The understanding of the autophagy machinery was vastly improved since the identification of 
the ‘AuTophagy-related Genes - ATG’ in yeast using genetic studies (Thumm et al., 1994; 
Tsukada and Ohsumi, 1993). While more than 35 autophagy genes have been identified to date, 
Apg1/Atg1 – a Ser/Thr kinase, was the first gene to be identified and studied. The products of 
these ATG genes usually exist as a part of a protein complex to achieve a defined function. The 
various protein complexes involved in the process of autophagy are as follows: 
 
1.2.1. ULK1/2 complex 
 
This complex consists of ULK1 (unc-51-like kinase 1) or its homologue ULK2 together with 
ATG13, ATG101 and FIP200 (focal adhesion kinase (FAK)-family interacting protein of 200 
kDa). This complex can be activated in mammalian cells under nutrient-deprived conditions 
such as glucose (AMPK-dependent) or amino acid starvation (AMPK-independent). Upon 
glucose deprivation, AMPK (adenosine-monophosphate-activated protein kinase) 
phosphorylates ULK1/2 on Ser317 and 777, hence activating the complex and autophagy. 
However, under nutrient-rich conditions, the kinase mTOR (mammalian target of rapamycin) 
phosphorylates ULK1 on Ser757, which causes an inhibition of the interaction between ULK1 
and AMPK resulting in an inhibition of autophagy (Fig 1.3) (Feng et al., 2014; Kim et al., 
2011). 
 
In addition, the activity of the ULK1/2 complex and its ability to bind FIP200 depends on the 
interaction between ULK1 and ATG13, which in turn relies on the phosphorylation state of 
ATG13. The phosphorylation of ATG13 has been shown to be regulated by mTOR and AMPK. 
More specifically, ATG13 is phosphorylated on the serine residue 258 by mTOR and on serine 
224 by AMPK under nutrient availability thereby inhibiting the ULK1-FIP200-ATG13 
complex formation and attenuating autophagy (Puente et al., 2016). Therefore, under nutrient-
rich conditions mTOR associates with the ULK1-ATG13 complex leading to ATG13 
phosphorylation, causing a disruption of ULK1-ATG13 binding which consequentially 
inactivates the complex. In contrast, under nutrient-deprived conditions, mTOR is released 
from the complex resulting in ATG13 dephosphorylation. This facilitates the binding of 
ATG13 with ULK1 to form an active complex which can then bind and phosphorylate FIP200. 
5 
 
This further results in the recruitment and activation of the VPS34/PI-3 kinase complex at the 
site of autophagosome formation. ULK1 complex has been shown to phosphorylate BECN1 
on the residue S14 to facilitate full autophagic induction in mammalian cells and C. elegans 
(Hosokawa et al., 2009; Itakura and Mizushima, 2010; Koyama-Honda et al., 2013; Ravikumar 
et al., 2009; Rc et al., 2013). 
 
1.2.2. VPS34/PI-3 kinase complex 
 
The core of the VPS34/PI-3 kinase complex consists of VPS34 kinase, BECN1 (Beclin-1) and 
VPS15. This core can then combine with either ATG14, UVRAG or Rubicon, resulting in three 
different complexes. In context of autophagy, the complex with ATG14 constitutes the most 
widely studied, while the functions of the other two complexes have received less attention. 
The activity of the ATG14 complex is regulated by the binding of BECN1 to either AMBRA1 
(activating molecule in BECN1-regulated autophagy protein 1) or BCL2 (B-cell lymphoma 2), 
which results in the activation or inhibition of the complex, respectively (Feng et al., 2014; 
Fimia et al., 2007; Itakura et al., 2008; Weidberg et al., 2011). The activity of this complex is 
essential for autophagy, since the inhibition of the complex by both pan-PI-3-kinase inhibitors 
(3-methyladenine (3-MA) or wortmannin) and VPS-34-specific inhibitors (PIK-III and 
SAR405) block autophagosome formation and LC3 lipidation (Blommaart et al., 1997; Dowdle 
et al., 2014; Ronan et al., 2014). 
 
The primary function of this complex is the synthesis of PI3P at the site of autophagosome 
formation to facilitate canonical autophagy. The generation of PI3P at the autophagosome 
formation site then results in the recruitment of PI3P-binding proteins, like WIPI-family 
proteins (Feng et al., 2014). The recruited PI3P-binding proteins then help the autophagic 
cascade progress further. For instance, WIPI2 was shown to direct the localisation of ATG5-
ATG12-ATG16 complex, which plays an important role in the process of LC3 lipidation (Fig 
1.3) (Dooley et al., 2014). In addition, WIPI2 was also shown to be responsible for the 
trafficking of the transmembrane autophagic protein, ATG9, and depletion of WIPI2 from 
HEK cells causes disruption of retrograde ATG9 trafficking (Orsi et al., 2012). 
 
While all of the above information describes the VPS34-dependent canonical autophagy, it is 
worth noting that there exists a non-canonical autophagic signalling pathway which is known 
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to be VPS34-independent (Codogno et al., 2011). A recent study showed that this non-
canonical autophagic pathway relies on the activity of the PI3P effectors and their ability to 
recognise PI5P generated by PIKfyve (type III phosphatidylinositol 5-kinase) in cells. The 
observed defects in cells with VPS34 depletion were successfully rescued by increasing the 
endogenous levels of PI5P, implicating its important role in the cells (Vicinanza et al., 2015). 
 
1.2.3. ATG5-ATG12-ATG16 complex 
 
The ATG5-ATG12-ATG16 is a trimeric complex consisting of three proteins ATG5, ATG12 
and ATG16. The formation of this complex precedes the LC3 lipidation step in autophagosome 
biogenesis (Fig 1.2). The process involves conjugation of ubiquitin-like molecule ATG12 on 
to ATG5, with the help of enzymes ATG7 (E1-like) and ATG10 (E2-like) (Mizushima et al., 
1998a; Mizushima et al., 1998b; Tanida et al., 2001). The conjugated complex then interacts 
with ATG16 in a non-covalent fashion, inducing oligomerisation and formation of a complex 
of approximately 800kDa size in mammalian cells. The oligomerisation of the complex is 
achieved via the homodimerisation of ATG16, which in turn is facilitated by the presence of a 
coiled-coil (CC) domain at its N-terminus (Mizushima et al., 2003; Zavodszky et al., 2013). 
 
One of the primary functions of ATG16 is to act as a scaffold for the expansion of growing 
autophagosomes along with ATG5-ATG12. ATG16 was shown to generate a two-dimensional 
scaffold that resembles a meshwork (Kaufmann et al., 2014; Mizushima et al., 2001). This 
complex is known to be tethered to the membrane of the immature phagophore but dissociates 
from completed autophagosomes. The membrane binding of this complex has been shown to 
be mediated by ATG5, inhibited by ATG12 and activated by ATG16 (Romanov et al., 2012). 
This complex further acts as an E3-like enzyme during the LC3 lipidation and determines the 
site for LC3-lipidation (Fig 1.3) (Dooley et al., 2014; Fujita et al., 2008). 
 
1.2.4. LC3-PE conjugation system 
 
Subsequent to the ATG5-ATG12-ATG16 complex formation, the process of autophagosome 
formation involves the lipidation of LC3, via a second ubiquitin-like reaction (Fig 1.2). The 
reaction begins with the processing of the precursor LC3 molecule to remove arginine residues 
causing the glycine residue located at the C-terminus to be exposed by ATG4 - a cysteine 
7 
 
protease. The exposed glycine on the processed LC3 (LC3-I) molecule is then activated by the 
E1-like enzyme ATG7 resulting in a transfer of the LC3-I on to ATG3 (an E2-like enzyme). In 
the final step of this process, the activated LC3-I molecule attached to ATG3 is then transferred 
to a phosphatidylethanolamine (PE) molecule to form LC3-II. The site of the LC3 lipidation is 
directed by the ATG5-ATG12-ATG16 complex (Dooley et al., 2014). This marks the 
completion of the cascade and the PE-conjugated LC3-II resides on the autophagosomes until 
they fuse with lysosomes, resulting in its recycling/degradation (Bento et al., 2016b; Feng et 
al., 2014). The difference in the mobilities of LC3-I and LC3-II forms of the protein has been 
exploited to develop a gold-standard assay for assessing autophagy. The assay involves 
checking the levels of LC3-II protein in cells using SDS-PAGE technique. While LC3-II has 
the same molecular weight as LC3-I, it runs faster on SDS-PAGE potentially due to increased 
hydrophobicity as a result of conjugation of LC3-I to PE molecule (Barth et al., 2010). 
 
Besides the LC3-family of proteins, mammalian cells express another sub-family of ATG8-
like proteins, namely the GABARAP-family. The members of this sub-family are also known 
to undergo similar post-translational modifications and might regulate other steps of 
autophagosome formation including phagophore extension and closure (Nguyen et al., 2016; 
Weidberg et al., 2011; Weidberg et al., 2010). 
 
 
 
 
 
 
 
 
8 
 
 
 
 
 Fig 1.2. A schematic depicting the two ubiquitin-like reactions involved during the process of autophagosome 
formation. These reactions involve the transfer of two small ubiquitin-like molecules – ATG12 and LC3 with the 
help of E1-like and E2-like enzymes on to ATG5 and phosphatidylethanolamine molecule respectively. ATG5-
ATG12-ATG16 complex acts as an E3-ligase for the ubiquitin-like reaction that results in LC3 lipidation. The 
enzymes involved in the ubiquitin-like reaction are ATG7 (E1-like)/ATG10 (E2-like) for ATG12-ATG5 
conjugation and ATG7 (E1-like)/ATG3 (E2-like) for LC3 lipidation. 
 
 
 
The aforementioned system defines the core autophagic processes that assist towards de novo 
autophagosome biogenesis and it is worth noting that the proteins involved in this process are 
mostly cytosolic. However, the autophagic system also comprises of the two transmembrane 
proteins, namely ATG9 and VMP1. These proteins constitute the primary focus of my thesis 
and I will now describe the known functions and trafficking routes for both in the next section. 
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Fig 1.3. A brief schematic depicting the important early signalling processes that occur during autophagosome 
biogenesis. The stimulators and inhibitors of mTORC1, an important kinase complex responsible for regulation 
of autophagy, results in the activation/inactivation of downstream autophagy complexes mediated by the 
phosphorylation of their subunits. Activation of these downstream complexes eventually results in the synthesis 
of PI3P on the growing phagophore, which through a series of steps is responsible for the lipidation of LC3-I on 
to phosphatidylethanolamine to form LC3-II. The autophagosomes are therefore identified by the presence of 
lipidated LC3-II molecules on their surface. The phosphorylation of ATG9 (in yeast) by various kinases has been 
shown to assist in the growth of autophagosomes by facilitating membrane delivery to growing autophagosomes 
mediated by vesicles carrying phosphorylated ATG9. Please refer to the abbreviations and the figure legend for 
detailed description of the symbols and section 1.2 for detailed information about the autophagy complexes.  
Autophagosome 
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1.3. Transmembrane proteins in autophagy 
 
1.3.1. ATG9 
 
ATG9 is a multi-pass transmembrane protein involved in the process of autophagy. In 
mammalian cells, two isoforms of ATG9 are expressed namely ATG9A and ATG9B. Of these 
isoforms, ATG9A is the one that is ubiquitously expressed and hence widely studied and will 
now hereafter be referred to simply as ATG9. ATG9 consists of six-transmembrane segments 
with the N- and C-terminus of the protein facing the cytosolic side of the cell (Fig 1.4). 
Interestingly, it has been observed that the transmembrane domains of ATG9 are highly 
conserved whereas the cytosolic loops/domains are widely variant across different species. 
This suggests that the transmembrane domains might play a well-defined static function across 
species whereas the cytosolic domains play a dynamic function based on the evolutionary 
requirements of the organism (Tooze, 2010). 
 
ATG9 has been shown to localise in several compartments in the cell, namely early endosomes, 
recycling endosomes, plasma membrane and the trans-Golgi network (Orsi et al., 2012; Puri et 
al., 2013; Young et al., 2006). More specifically, ATG9 has been identified to traffic through 
the plasma membrane to early endosomes to recycling endosomes where it was shown to meet 
ATG16. Also, the trafficking of ATG9 from the early to recycling endosomes was shown to be 
VAMP3-dependent (Puri et al., 2013). While the larger understanding about the ATG9 
trafficking remains elusive, some of the regulators of ATG9 trafficking have been identified. I 
will now summarise some of the key regulators of ATG9 trafficking that have been studied. 
 
The ULK1 kinase acting during the early stages of autophagy initiation was one of the first 
identified proteins regulating ATG9 trafficking. The knockdown of ULK1 was shown to result 
in the lack of redistribution of ATG9 from the juxta-nuclear trans-Golgi pool to the peripheral 
region (most likely recycling endosomes) in response to starvation (Young et al., 2006). In 
addition, the PI-3 kinase complex has also been shown to regulate ATG9 trafficking. Depletion 
of endogenous levels of the former was also shown to interfere with the redistribution of ATG9 
(Young et al., 2006). Another regulator shown to affect ATG9 trafficking is Endophilin-B1 or 
BIF-1, a membrane-curvature driving protein. BIF-1 was shown to bind BECN1 via UVRAG 
and co-localised with the autophagy proteins LC3, ATG5 and ATG9. It was shown that ATG9 
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undergoes the process of continuous tubulation and fragmentation to form the observed cellular 
cytosolic puncta; this phenomenon, however, was shown to be abrogated when BIF1 levels 
were depleted from the cells (Takahashi, 2011; Takahashi et al., 2007). Another protein shown 
to regulate ATG9 trafficking was α-synuclein, a protein responsible for the pathogenesis of 
Parkinson’s disease. It was seen that overexpression of this protein resulted in distribution of 
ATG9 away from the Golgi-network and a higher co-localisation of ATG9 with LC3 vesicles 
(Winslow, 2010). Consistent with this, it was seen that the D620N mutation in VPS35, which 
is associated with Parkinson’s disease, was seen to impair autophagy and result in an 
accumulation of α-synuclein, which causes ATG9 redistribution. The VPS35 D620N mutation 
was shown to poorly associate with the WASH complex, which is responsible for actin-
remodelling in the cells. This therefore was shown to result in the actin-dependent 
mistrafficking of ATG9 from the endosomal structures (Zavodszky et al., 2014). It was also 
seen that ATG9 is internalised from the plasma membrane via interaction with AP-2, clathrin 
and TBC1D5. This study also showed that the depletion of TBC1D5 resulted in the 
mislocalisation of ATG9 to late endosomes on autophagy activation (Noda, 2017; Popovic and 
Dikic, 2014). Furthermore, one more identified ATG9 trafficking regulator is the TRAPIII 
complex and depletion of its subunits have been shown to result in ATG9 mislocalisation 
(Noda, 2017). Additionally, a much recent study has identified SNX18 to regulate ATG9 
trafficking from the recycling endosomes by binding to Dynamin-2. It was seen that cells 
lacking endogenous SNX18 resulted in the accumulation of ATG9 in recycling endosomes 
(Knævelsrud, 2013; Søreng et al., 2018). Finally, a recent study also identified AP-4, a new 
member of adaptor protein complexes family that are known to help in sorting transmembrane 
proteins, to regulate ATG9 trafficking. The study showed that depletion of AP-4 ε from the 
cells via CRISPR knockout resulted in the redistribution of ATG9 from the peri-nuclear region 
to the Golgi-complex and ATG9 was shown to interact with AP-4 complex via its N-terminal 
YXXØE motif. Deficiency of AP-4 has been shown to be associated with adulthood 
neurological problems and this therefore, could also potentially implicate the role of ATG9 
localisation in the pathogenesis of some forms of complicated hereditary spastic paraplegias 
(Mattera et al., 2017). The studies mentioned above highlight the complexity of ATG9 
trafficking and while the trafficking of ATG9 in mammalian cells has been studied to some 
extent, its function however remains elusive.  
 
It is speculated that the primary function of mammalian ATG9, like its yeast homologue, is 
facilitating membrane delivery from various sources to the growing autophagosomes. The 
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studies identifying ATG9 trafficking pathways therefore play an important role towards 
strengthening the former hypothesis. As mentioned above, ATG9 meets ATG16 in recycling 
endosomes in a VAMP3-dependent fashion (Puri et al., 2013). In addition, subsequent studies 
also propose recycling endosomes as the primary compartment for autophagosome machinery 
assembly and autophagosome formation (Puri et al., 2018). Both of these studies thereby 
indicate the potential role of mammalian ATG9 in delivering membrane towards growing 
autophagosomes. Another study has shown ATG9, via its interaction with AP-1, to assist in 
the transport of lysosomal hydrolases like cathepsin D from the trans-Golgi network to 
endosomes. Depletion of ATG9 in these cells was shown to impair EGFR degradation and 
cathepsin D maturation, suggesting that ATG9 might act as a co-receptor for these hydrolases 
assisting in their export from the trans-Golgi network (Jia et al., 2017). A much recent study 
conducted in Saccharomyces cerevisiae has identified another function for Atg9. According to 
the study, Atg9 plays a vital role in the recruitment of Atg2 to the ends of the growing 
phagophore, which then assists Atg2 to recruit Atg18 leading to formation of a Atg9-Atg2-
Atg18 complex. This complex in turn was shown to be necessary for the establishment and 
stabilisation of the ER-phagophore contact sites contributing towards autophagosome 
biogenesis in yeast (Gómez-Sánchez et al., 2018). 
 
 
Fig 1.4. A schematic showing the known topology of human ATG9 on the plasma membrane. The cylindrical 
structures represent the transmembrane domains, grey lines represent a layer of the lipid bilayer and the green 
lines represent the protein sequence connecting the various domains. The N-terminal region of ATG9 has been 
seen to well-conserved across species whereas the long C-terminal tail, which has been characterised to possess 
an intrinsically disordered structure, has been shown to be less conserved across species and is predicted to adapt 
based on required function. Due to presence of even number (six) of transmembrane domains, both N- and C-
terminus of ATG9 face the same side which is the cytosolic side of the plasma membrane. This figure was adapted 
from Rao et al. (2016).  
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1.3.2. VMP1 
 
The other multi-pass transmembrane protein, VMP1, was recently identified as a protein 
involved in autophagy. The first study identifying the protein showed that the overexpression 
of VMP1 induced autophagy and this effect was reversed on autophagy inhibition by 3-
methyladenine (3-MA). It also showed that silencing the expression of endogenous VMP1 
resulted in the inhibition of autophagy (Ropolo et al., 2007). Further studies showed that VMP1 
consists of a 20-amino acid hydrophilic C-terminus AtgD-domain which facilitates its binding 
to BECN1, a protein involved in autophagy initiation, possibly regulating early stages of 
autophagy and leading to a formation of a complex with VPS34/PI-3 kinase. The VMP1-
BECN1-VPS34 complex was then shown to favour the association of ATG16 and LC3 with 
the autophagosome precursors, and was hence proposed to help in the recruitment of the 
autophagy initiation complexes to the autophagosome formation site (Molejon et al., 2013; 
Ropolo et al., 2007; Vaccaro et al., 2008). Interestingly, while most autophagy proteins in 
mammalian cells show respective homologous proteins in yeast, VMP1 has none, indicating 
that it might be responsible for an alternate pathway for autophagy initiation (Ropolo et al., 
2007; Vaccaro et al., 2008).  
 
However, studies on the VMP1 homologue in lower-order eukaryotic model system, 
Dictyostelium discoideum, has shown it be an ER-resident protein and the cells lacking VMP1 
show multifaceted effects on organelle biogenesis, endocytic pathway and protein secretion. 
This effect was also shown to be rescued by the overexpression of mammalian VMP1 protein 
indicating that the protein function has been evolutionarily conserved (Calvo-Garrido et al., 
2008). Indeed, recent studies in mammalian cells have shown that VMP1 associates with the 
endoplasmic reticulum subdomains that regulates the ER contact sites with other organelles. 
The study further shows that VMP1 localises with to ER-subdomains that are rich in enzymes 
responsible for phospholipid synthesis. Furthermore, depletion of VMP1 was shown to result 
in an irregular distribution of phosphoinositides in the cell affecting cellular trafficking events 
and organelle maturation (Tabara et al., 2018). Another study earlier showed the initiation of 
autophagosome biogenesis on the ER-subdomains that are rich in phospholipid synthesising 
enzymes (Nishimura et al., 2017). Therefore, both of the two independent studies consolidate 
the role of VMP1 in autophagy initiation. 
 
14 
 
Further studies on mice also showed the induction of VMP1 expression and autophagy during 
early cellular events, in pancreatic β-cells of these animals on treatment with streptozotocin, a 
drug known to induce experimental diabetes, indicating the potential role of VMP1 and 
autophagy in cellular defence mechanisms (Grasso et al., 2009). A follow-up study performed 
by the same research group also showed that treatment of pancreatic cancer (PANC-1) cells 
with gemcitabine, a standard chemotherapy drug for pancreatic cancer, induced VMP1 
expression and autophagy during early stages of treatment, leading to autophagy-assisted 
apoptosis of the cancer cells (Pardo et al., 2010). In addition, VMP1 was also shown to be 
responsible for degradation of zymogen granules in pancreatic acinar cells during pancreatitis 
conditions. It was also shown that VMP1 interacts with USP9x, a ubiquitin protease, hinting 
towards an interplay between autophagy and ubiquitination machinery through VMP1 (Grasso 
et al., 2011). Moreover, VMP1 was also shown to modulate the ER-stress response 
independently of autophagy (Gilabert et al., 2013). While some of the above studies provide 
evidence of VMP1-dependent autophagy working towards apoptotic cell death of cancerous 
cells, there have been reports showing pro-survival and initiation role of VMP1 in colorectal 
and pancreatic cancer cells, helping cancer progression (Loncle et al., 2016; Qian et al., 2014). 
A more recent study has now shown that VMP1 together with VAPA and VAPB (VAPs) 
regulates ER-IM (endoplasmic reticulum-isolation membrane) contact sites. The ER-IM sites 
were observed to be stabilised, leading to a reduction in autophagosome formation, under 
VMP1-depleted conditions. Furthermore, depletion of VMP1 also resulted in stabilisation of 
the ER contacts with lipid droplets, mitochondria and endolysosomes, impairing 
autophagosome biogenesis. Similarly, under VAP-depleted conditions the autophagosome 
biogenesis was shown to be abrogated (Zhao et al., 2017; Zhao et al., 2018; Zhao and Zhang, 
2018). 
 
1.4. Membrane origin during autophagosome biogenesis 
 
The origin of membrane of the growing autophagosomes has been one of the key unanswered 
questions in the field. Studies using high-resolution microscopy and biochemical analysis have 
shown various membrane sources to either be in contact with the growing autophagosome or 
be a part of the lipid content of the growing autophagosomes. A list of various organelles 
identified to date that contribute towards growing autophagosomes includes plasma membrane, 
recycling endosomes, endoplasmic reticulum (ER), ER-Golgi intermediate compartment 
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(ERGIC), mitochondria, Golgi complex and endosomes (Bento et al., 2016b; Lamb et al., 
2013). However, an important point to be considered while evaluating whether an organelle is 
a membrane source during autophagosome biogenesis is whether the considered organelle is a 
known substrate for autophagy. This is since membranes of substrates would show association 
with autophagosomes regardless of whether they provide membrane to growing 
autophagosomes. 
 
The first organelle to be proposed as a source of membrane for growing autophagosomes was 
the ER (Mari et al., 2011). Since then, multiple studies have expanded on the hypothesis stating 
ER membrane as a ‘cradle’ for autophagosome formation. The studies involved electron 
tomographic studies which showed the presence of isolation membrane, an early marker for 
autophagosomes, cradled within a subdomain of ER. The study also showed that PI3P, a 
phosphorylated lipid molecule that marks autophagosomes, marked subdomains of the ER 
which can be identified by DFCP1 staining (El et al., 2008; Hayashi-Nishino, 2009; Hayashi-
Nishino et al., 2010). 
 
The role of mitochondria as potential autophagosome formation site was shown by the co-
localisation of ATG5 and LC3 puncta with outer-mitochondrial membrane markers. The 
observation was made during starvation, suggesting its role in starvation-induced autophagy. 
Some studies also show autophagosomes form at the ER-mitochondria sites, during starvation-
induced autophagy, suggesting its role during autophagosome formation. Moreover, disruption 
of these sites resulted in impairment of starvation-induced autophagy (Hailey et al., 2010; 
Hamasaki, 2013). 
 
In addition to the above compartments, the plasma membrane was proposed to contribute 
membrane to autophagosomes. The study involved labelling of the plasma membrane lipids 
and live-cell imaging of the cells. It was seen that the labelled lipids were incorporated into 
growing autophagosomes, suggesting that plasma membrane provides membrane to 
autophagosomes (Ravikumar et al., 2010). Subsequent studies identified autophagy proteins 
ATG9 and ATG16 trafficking from the plasma membrane to different endocytic compartments, 
which corroborate the prior observations. ATG9 was shown to traffic from the plasma 
membrane to early endosomes, while ATG16 was shown to traffic to recycling endosomes 
directly independent of early endosomes. ATG9 was then shown to be trafficked from early 
endosomes to recycling endosomes in a VAMP3-dependent manner, where it meets ATG16, 
16 
 
both of which then contribute to growing autophagosomes. Interestingly, ATG16 was shown 
to traffic directly to recycling endosomes from plasma membrane via clathrin-mediated 
endocytosis. This explains the probable mechanism of the membrane delivery from plasma 
membrane to growing autophagosomes (Moreau et al., 2011; Puri et al., 2013). 
 
Furthermore, a recent study has shown that recycling endosomes contribute membrane towards 
growing autophagosomes and has suggested that this compartment acts as a primary platform 
for de novo autophagosome formation (Puri et al., 2018). This finding also presents a solid case 
for plasma membrane as membrane contributor since both ATG9 and ATG16, proteins known 
to play a role in early stages of autophagosome formation, meet each other in recycling 
endosomes after travelling through the plasma membrane (Puri et al., 2013). 
 
To summarise, multiple organelles have been shown to be involved in the membrane delivery 
process during autophagosome formation so far. However, the overall understanding of the 
process still remains elusive and further investigation using high-resolution imaging and 
sophisticated biochemical techniques is required. 
 
1.5. Cargo receptors and their role in autophagy 
 
Autophagy, during the early years of discovery, was considered to be a non-selective process 
facilitating bulk degradation of cargo via its delivery to lysosomes. However, studies during 
recent years have witnessed a significant progress in helping understand the selectivity of the 
process and the proteins responsible for it. The process of selective autophagy can be identified 
based on the substrate being targeted for degradation. A few examples that have been described 
so far include mitochondria (mitophagy), aggregates (aggrephagy), peroxisomes (pexophagy), 
ribosomes (ribophagy), pathogens (xenophagy), etc. with newer processes being added to the 
list (Stolz et al., 2014). 
 
The process of selective autophagy is mediated by autophagy receptors, a type of protein that 
binds to the cargo destined for degradation. These autophagy receptors act as bridging 
molecules recognising degradation signals on the cargo molecules on one hand and binding 
LC3 on the autophagosomal membrane using LIR (LC3-interacting regions) domain on the 
other, to facilitate the engulfment of the cargo. Over two dozen autophagy receptors have been 
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identified in mammalian cells using yeast two-hybrid systems and proteomic techniques (Stolz 
et al., 2014). Some of these autophagy receptors known to be involved in various forms of 
selective autophagy, such as mitophagy, zymophagy, pexophagy, aggrephagy, etc., are p62, 
NBR1, OPTN, BNIP3, FUNDC1, NIX, HDAC6, NDP52, and ALFY (Rogov et al., 2014). The 
most common form of signal for targeting a substrate for its degradation via autophagy, in 
mammalian cells, is ubiquitination. A common feature that the autophagy receptors share is 
the presence of both, a ubiquitin-binding domain (UBD) and LC3-interacting regions (LIR). 
 
The first identified mammalian selective autophagy receptor shown to play an important role 
in autophagy was p62/SQSTM-1 (sequestosome-1) (Bjørkøy et al., 2005). p62 constitutes one 
of the most widely studied autophagy receptor and consists of an N-terminal PB1 domain 
shown to be necessary for self-oligomerisation of the protein, a C-terminal UBD that has the 
ability to bind ubiquitin conferring the specific cargo selection ability onto p62 and several 
other domains that mediate its binding to other proteins (Rogov et al., 2014; Zaffagnini et al., 
2018). The LIR motif of p62 was identified to possess a core consensus sequence of Φ-X-X-
ψ, where Φ corresponds to aromatic amino acids (W/F/Y), ψ corresponds to hydrophobic 
amino acids (L/I/V) and X corresponds to any amino acid (Pankiv et al., 2007; Rogov et al., 
2014). p62 accumulates into inclusion bodies in autophagy-deficient mice and these structures 
were also shown to be positive for ubiquitin (Komatsu et al., 2007). A different study has also 
shown that the p62 aggregates sequestered the E1-like ATG7 enzyme into these aggregates. It 
also showed that this sequestration is mediated via the interaction of LC3-I with ATG7 and 
that while p62 shows preferential binding towards LC3-II, it is indeed capable of binding to 
the lipidation defective LC3-G120A mutant (Gao et al., 2013). Furthermore, misregulation of 
p62 was shown to have significant implications towards the progression of various 
neurodegenerative diseases due to defective autophagy (Moscat and Diaz-Meco, 2009). 
 
1.6. Post-translational modifications in autophagy 
 
Autophagy is tightly regulated at several stages by post-translational modification of proteins 
involved during the process. The most commonly studied post-translational modification in 
cells is phosphorylation, which involves transfer of a phosphate group to the side chain of an 
amino acid. In eukaryotes, phosphorylation primarily occurs on the side chains of three amino 
acids namely serine, threonine and tyrosine. The phosphorylation of protein results in the either 
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inhibition or activation of the activity of the protein. Usually the phosphorylation status of a 
protein is tightly regulated by a pair of specific kinase and phosphatase, indicating that 
phosphorylation is a reversible process (Xie et al., 2015). The early stages of autophagy are 
finely regulated by phosphorylation of key proteins like mTOR and ULK1 kinase involved in 
the autophagic signalling pathway. A cascade of the phosphorylation events taking place during 
glucose deprivation and nutrient rich conditions that modulate autophagy has been described 
in the section 1.2.1 of this thesis. The example involves phosphorylation of ULK1 kinase, an 
early stage regulator of autophagy, by AMPK in response to the nutrient stimuli around the 
cells. This example provides great insight into the complexity of the process and also highlights 
the level of regulation involved during autophagy modulation (Feng et al., 2014; McEwan and 
Dikic, 2011). 
 
Another common form of post-translational modification includes addition of the small 
molecule, ubiquitin, to proteins. Ubiquitin is a 76-amino acid polypeptide with a molecular 
weight of approximately 8-kDa. The ubiquitination usually occurs on the side chain of the 
amino acid residue, lysine, via a sequence of enzymatic reactions. This form of post-
translational modification governs the degradation of proteins in the cell via its recognition by 
the 26S proteasomal subunit. In addition to the two ubiquitin-like reactions described in above 
sections 1.2.3 and 1.2.4, ubiquitination regulates the activity of proteins like BECN1 and 
ULK1. A well-studied example of ubiquitination is the ubiquitination of BECN1 by TRAF6 
(TNF receptor-associated factor 6, E3 ubiquitin protein ligase) or AMBRA1 at distinct lysine 
residues. This modification was shown to regulate the binding of BECN1 with BCL2, which 
in-turn modulates autophagic regulation (Shi and Kehrl, 2010; Xia et al., 2013). Interestingly, 
TRAF6 and AMBRA1 were also shown to ubiquitinate ULK1 increasing its stability and 
activity during autophagy induction (Nazio, 2013; Xie et al., 2015). In addition to the 
regulatory functions described above, ubiquitination also serves a much more fundamental role 
in autophagy and is required for cargo recognition during selective autophagy. Similar to 
phosphorylation, ubiquitination is tightly regulated by a pair of ubiquitinating and 
deubiquitinating enzymes. For example, BECN1 has been shown to be deubiquitinated by the 
enzymes USP13, USP10 and ataxin-3 leading to autophagy induction (Ashkenazi et al., 2017; 
McEwan and Dikic, 2011; Xie et al., 2015). The above examples, therefore, highlight the 
importance of ubiquitination in the process of autophagy. 
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Another important post-translational modification regulating autophagy is acetylation. The 
process usually involves the transfer of an acetyl group onto the ε-amino group of lysine side 
chain. The donor of the acetyl group is a metabolite produced during cellular processes called 
acetyl-coenzyme A. The transfer of the acetyl group is catalysed by the class of enzymes named 
lysine acetyltransferases. Like phosphorylation and ubiquitination, acetylation too is a 
reversible modification and the dynamic between protein acetylation and deacetylation tightly 
regulates numerous important cellular processes. Various ATG proteins have been shown to 
undergo acetylation/deacetylation resulting in the modulation of autophagy. A notable example 
of the role of acetylation in the regulation of autophagy has been shown in yeast and involves 
the post-translational modification of Atg3. Under conditions where Atg3 is acetylated, on 
lysine residues 19 and 48, by Esa1 acetyltransferase its affinity for LC3 binding increases. In 
contrast, when Atg3 undergoes deacetylation on the same sites as mentioned above by a histone 
deacetylase Rpd3, it results in an inhibition of the autophagic process (Xie et al., 2015; Yi et 
al., 2012). Extending the observation in the mammalian system, in HeLa cells it was seen that 
the knock-down of the EP300 acetyltransferase resulted in an induction of autophagy and the 
mechanism of autophagy inhibition under normal conditions was identified to be via the 
acetylation of core autophagy proteins namely ATG5, ATG7, ATG8 and ATG12 (Lee and 
Finkel, 2009). Similarly, forced deacetylation of these proteins in cells by the overexpression 
of the deacetylase SIRT1 (sirutin-1), resulted in autophagy induction under starvation 
conditions. Moreover, this effect was not observed in SIRT1-null cells as they showed a lack 
of functional autophagy (Lee et al., 2008; Xie et al., 2015). These examples exhibit the level 
of control that acetylation of key proteins can exert on the process of autophagy. 
 
1.7. Signalling pathways involved in autophagy 
 
Autophagy is a complex process that is regulated at several steps via multitude signalling 
processes. These signalling pathways can be broadly classified into mTOR-dependent and 
mTOR-independent pathways. This classification is based on the involvement of the mTORC1 
complex in the regulation of autophagy. It is worth noting that the mTOR-dependent pathways 
were the first to be identified and hence have been studied in more depth compared to mTOR-
independent pathways, both of which will be covered in the section below. 
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1.7.1. mTOR-dependent signalling 
 
The mammalian target of rapamycin (mTOR) is a 289-kDa serine-threonine kinase that 
responds to several environmental cues and belongs to the PI3K- related kinase (PIKK) family 
of proteins. It was named mTOR based on its homology with the yeast TOR gene and its ability 
to bind the peptidyl-prolyl isomerase FKBP12-rapamycin complex. Furthermore, as the name 
suggests it is inhibited by rapamycin (sirolimus), which is an anti-fungal macrolide produced 
by the bacterial species Streptomyces hygroscopicus named after the site of its discovery 
(Saxton and Sabatini, 2017). The kinase mTOR is at the catalytic core of two complexes mTOR 
complex1 (mTORC1) and complex 2 (mTORC2). The components of mTORC1 complex 
include mTOR, Raptor (regulatory protein associated with mTOR) and mLST8 (mammalian 
lethal with Sec13 protein 8). mTORC2 consists of mTOR, mLST8 and Rictor (rapamycin 
insensitive companion of mTOR), however, unlike mTORC1, mTORC2 is known to be 
resistant to inhibition by rapamycin. However, longer treatments of rapamycin inhibits the 
activity of the mTORC2 complex by preventing the incorporation of rapamycin-bound mTOR 
into the newly formed complexes (Ballou and Lin, 2008; Saxton and Sabatini, 2017). 
 
mTORC1 was identified as a key regulator for autophagy and inhibition of its activity results 
in an upregulation of the autophagic process. As mentioned in the above sections, ULK1 is an 
important kinase that initiates and regulates the early stages of autophagy induction. Under 
nutrient-rich conditions, mTORC1 phosphorylates ULK1 at serine-757 which causes it to be 
resistant to activation via AMPK phosphorylation. Under starvation however, mTORC1 is 
inactivated resulting in AMPK-mediated activation of ULK1 and autophagy (Kim et al., 2011; 
Saxton and Sabatini, 2017). In addition, mTORC1 also regulates the phosphorylation status of 
TFEB (transcription factor EB), which in-turn regulates its localisation. It was shown that the 
phosphorylation of TFEB inhibits its translocation to the nucleus and prevents the activation 
of transcription of genes responsible for autophagy and lysosome biogenesis (Roczniak-
Ferguson et al., 2012; Settembre et al., 2012). 
 
The role of mTORC2 on the other hand still remains elusive and possibly works opposite to 
the effect mTORC1 on autophagy, partly because the effects of mTORC2 on autophagy are 
indirect. For instance, it was shown that inhibition of autophagy under the IGF-1 depleted 
conditions was a result of inhibition of mTORC2. The inhibition of mTORC2, then results in 
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reduction of the protein kinase C (PKCα/β), which results in perturbation of actin 
rearrangement dynamics leading to impaired clathrin-mediated endocytosis, resulting in 
impaired autophagosome precursor formation (Bento et al., 2016b; Renna et al., 2013). In 
addition it also was shown that mTORC2 regulates cell survival, metabolism and cytoskeleton 
via phosphorylating multiple kinases like Akt, PKCα, etc. with the overall mechanism still 
unknown (Laplante and Sabatini, 2012a, b). 
 
1.7.2. mTOR-independent signalling 
 
In addition to the mTOR-dependent pathways, several recent studies have described autophagy 
regulation through mTOR-independent routes. The first pathway to be identified involved in 
the mTOR-independent autophagic regulation was the inositol pathway. The presence of higher 
levels of inositol or IP3 (myo-inositol-1,4,5-triphosphate) was shown to inhibit the 
autophagosome biogenesis. Furthermore, inositol-lowering drugs, that are also known to act as 
mood-stabilising drugs, such as lithium, carbamazepine or valproic acid, induced autophagy 
without inhibiting the mTOR activity. The induction of autophagy by lithium was shown to 
work via the inhibition of IMPase leading to an abrogation of inositol recycling causing its 
intracellular depletion (Sarkar, 2013; Sarkar et al., 2005). 
 
Another stimulus shown to affect autophagy independent of mTOR has been the levels of 
calcium inside the cell. Elevated levels of intracellular Ca2+ was shown to inhibit autophagy 
specifically at the stages of formation and fusion of autophagosomes with lysosomes. Drugs 
acting as Ca+2 channel antagonists like verapamil, loperamide, etc. were shown to be inducers 
of autophagy (Williams et al., 2008). The identified mechanism for autophagy inhibition by 
elevated Ca2+ levels was via the Ca2+-dependent cysteine proteases, calpain 1 and calpain 2. 
Inhibition or genetic depletion of these proteases was shown to induce autophagic flux without 
affecting mTORC1 activity. On the other hand, overexpression of a constitutively active form 
of calpain 2 or activation of the calpains was shown to inhibit autophagy (Sarkar, 2013; 
Williams et al., 2008). 
 
As described in section 1.2.2, the PI-3 kinase complex consists of VPS34 and BECN1. The 
activity of this complex is essential for the initiation of autophagosome biogenesis. The binding 
of BECN1 to BCL-2 and BCL-XL via the BH3 domain of BECN1, was shown to inhibit 
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autophagy. Furthermore, BH3 domain mimics compete for the binding of BECN1 to BCL-2, 
leading to activation of autophagy (Maiuri et al., 2007; Malik et al., 2011; Sarkar, 2013). This 
is another example of autophagy regulation in an mTOR-independent fashion. 
 
Autophagy has been shown to be regulated via small molecules like trehalose. Trehalose is a 
disaccharide found in non-mammalian cells species and protects cells from environmental 
stress. It was shown to enhance the clearance of the known autophagy substrates and proteins 
implicated in neurodegenerative diseases like mutant huntingtin and the A30P and A53T 
mutants of α-synuclein (Sarkar, 2013; Sarkar et al., 2007a). Consistent with these observations, 
a bulk of the existing literature reports trehalose to be a potent inducer of autophagy. A recent 
study identified the mechanism of autophagy induction by trehalose via inhibition of glucose 
transporters. Specifically, the study highlighted an inhibition in the activity of glucose 
transporters such as GLUT1, GLUT2, GLUT3, GLUT4 and GLUT8 at the plasma membrane 
upon treating the cells with trehalose. This was then seen to activate AMPK resulting in the 
phosphorylation and activation of ULK1, finally leading to potent autophagy induction 
(DeBosch et al., 2016). A couple of recent studies, however, have shown that trehalose might 
also act as potent blocker of autophagic flux under certain conditions. These studies therefore 
question the effects of trehalose on autophagy and potentially indicate towards a complex 
mechanism of regulation of autophagy (Lee et al., 2018; Yoon et al., 2017). 
 
A selected list of small molecules/compounds that affect autophagy and could act as potential 
therapeutic modulators of the process can be found in Table 1.1. A brief description of the 
proposed site and mechanism of action for each of these compounds has been mentioned in the 
corresponding row. It is worth noting that most of the identified therapeutic modulators of the 
process of autophagy act along the mTOR-independent signalling axis and result in the 
induction of the autophagic response that assists towards clearance of toxic protein aggregates. 
 
 
 
 
 
 
 
23 
 
 
Potential therapeutic 
modulators of autophagy 
Proposed site and 
mechanism of action 
Selected references 
Rapamycin and rapalogs 
Autophagic induction via 
mTORC1 inhibition 
(Ravikumar et al., 2004; 
Williams et al., 2008) 
Lithium 
Autophagic induction by 
lowering inositol and IP3 
levels 
(Sarkar et al., 2005) 
Trehalose 
Autophagic induction via 
unknown mechanism 
(Sarkar et al., 2007a) 
Rilmenidine 
Autophagic induction by 
decreasing cAMP levels 
(Williams et al., 2008) 
Verapamil 
Autophagic induction by 
lowering intracellular 
calcium levels 
(Williams et al., 2008) 
Valproate 
Autophagic induction by 
lowering inositol and IP3 
levels 
(Williams et al., 2008) 
Clonidine 
Autophagic induction by 
lowering intracellular 
calcium levels 
(Williams et al., 2008) 
Carbamazepine 
Autophagic induction by 
lowering inositol and IP3 
level 
(Williams et al., 2008) 
SMER28 
Autophagic induction via 
unknown mechanism 
(Sarkar et al., 2007b) 
Bafilomycin A1 
Autophagic inhibition by 
inhibition of V-type 
ATPase 
(Ebrahimi-Fakhari et al., 
2011; Shacka et al., 2006) 
Chloroquine 
Autophagic inhibition by 
alkalisation of the 
lysosomal pH 
(Ebrahimi-Fakhari et al., 
2011) 
 
Table 1.1 A table enlisting a selected list of chemical compounds that could act as potential therapeutic modulators 
of autophagy. The proposed site of action and mechanism have also been briefly mentioned for these compounds. 
It is worth noting that most of these compounds work towards autophagic induction and in an mTOR-independent 
fashion. Additional details regarding the mechanistic action of these compounds and the corresponding signalling 
pathways they regulate can be found in the selected references as stated in the table above.  
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1.8. Role of autophagy in diseases 
 
Autophagy, as described above, is an important pathway for cell survival and is activated under 
conditions like starvation, stress, infection, protein aggregation, etc. This makes autophagy an 
important housekeeping pathway for normal cellular function. Therefore, autophagy has been 
shown to be affected under many diseased conditions like neurodegeneration, cancer, 
metabolic diseases, autoimmune diseases, etc (Bento et al., 2016b; Rubinsztein, 2006). I will 
now briefly summarise some of these disease links in the context of autophagy. 
 
1.8.1. Autophagy and neurodegeneration 
 
Autophagy was identified as one of the key pathways disrupted in several neurodegenerative 
disease conditions making it an enticing target for developing therapeutic interventions. It has 
been observed that autophagy deficiency leads to an accumulation of protein aggregates which 
is the hallmark for neurodegenerative diseases like Alzheimer’s, Parkinson’s and Huntington’s 
diseases (Rubinsztein, 2006). A selected list of genes, mutations in which are known to impair 
the autophagic process, can be found in Table 1.2 of this thesis together with corresponding 
references describing the pathogenesis of the disease due to the associated mutation. I will now 
describe the most common forms of neurodegenerative diseases and the identified role of 
autophagy in the disease pathogenesis. 
 
Alzheimer’s disease (AD) is characterised by the accumulation of intracellular tau 
neurofibrillary tangles and extracellular amyloid-β (Aβ) aggregates called plaques. It 
constitutes the most common form of neurodegeneration with patients showing progressive 
dementia. The Aβ peptide responsible for formation of plaques is a product of cleavage of the 
amyloid precursor protein (APP). Studies have shown that impaired autophagic process 
enhances the pathogenesis of AD in animal models and cells. In addition, induction of 
autophagy in these models have also shown to lower the Aβ levels (Ravikumar et al., 2008; 
Rubinsztein, 2006). It was seen that neurons from AD patients showed an accumulation of 
autolysosomes/lysosomes (Nixon et al., 2005). In addition, some of the core autophagy proteins 
like LC3, ATG5 and ATG12 were shown to co-localise with the intracellular tau aggregates 
and surprisingly, the extracellular Aβ plaques indicating that autophagy might play a role in 
Aβ secretion and plaque formation (Ma et al., 2010; Nilsson et al., 2013). 
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Parkinson’s disease (PD) constitutes the second most common neurodegenerative disease. The 
patients display bradykinesia, rigidity of muscles and resting tremor. It is characterised by 
progressive loss of dopaminergic neurons in substantia nigra and displays accumulation of 
cytoplasmic aggregates known as Lewy bodies, which are made up of the protein α-synuclein. 
Increased levels of α-synuclein in the cells have been shown to be sufficient to cause PD, and 
overexpression of α-synuclein in cells was shown to impair autophagy and cause ATG9 
mislocalisation (Winslow, 2010). On the contrary, BECN1 overexpression leading to 
autophagic induction reduced α-synuclein accumulation and cell death, indicating that the 
relationship between autophagy and α-synuclein is multifaceted (Spencer et al., 2009; Webb et 
al., 2003). In addition, several other mutations have been described to affect the levels of α-
synuclein leading to PD. For instance, mutations in the ATP13A2, which encodes a lysosomal 
P5-type ATPase that facilitates cation transport, causes autosomal recessive early-onset PD. 
Decrease in the levels of ATP13A2 via decrease in synaptotagmin 11 levels results in an 
impaired lysosomal function and autophagosome degradation, which as a result causes an 
accumulation of α-synuclein (Bento et al., 2016a). 
 
Huntington’s disease is characterised by mutation at the N-terminus polyglutamine (polyQ) 
domain of the huntingtin gene, resulting in increase in the number of repeats and expansion of 
the polyQ tract. The result of an expanded polyQ tract is the formation of mutant oligomers 
which combine to form disruptive aggregates in different parts of the brain (Rubinsztein, 2006). 
It has been shown that autophagy is affected in Huntington’s disease via different mechanisms. 
An example would be the impairment of autophagy by polyQ proteins through Ras homolog 
enriched in striatum (Rhes). Rhes was shown to competitively bind to BECN1, inhibiting 
BECN1 binding with BCL-2, leading to autophagy induction. The polyQ proteins were shown 
to interact with Rhes and causing a reduction in its binding to BECN1, which leads to increased 
binding between BECN1 and BCL-2 resulting in decreased autophagy (Mealer et al., 2014). A 
recent study has shown that ataxin-3 is a positive regulator of autophagy by acting as a 
deubiquitinase for BECN1, thereby preventing its degradation. The ataxin-3-BECN1 
interaction is mediated via the normal polyQ stretch in ataxin-3. In diseased conditions like 
Huntington’s, the polyQ tract expansion of the soluble protein leads to a competition between 
it and ataxin-3 for their binding to BECN1. This causes a reduction in starvation-induced 
autophagy in these model systems, contributing towards disease progression (Ashkenazi et al., 
2017). 
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Gene implicated in 
autophagic impairment 
Identified neurological 
disorder association 
Selected references 
ATG5 Form of ataxia 
(Ebrahimi-Fakhari, 2018; 
Zhu et al., 2018) 
AP4 
Rare form of hereditary 
spastic paraplegia 
(Mattera et al., 2017) 
SPG11, ZFYVE26 (SPG15) 
Hereditary spastic 
paraplegia 
(Ebrahimi-Fakhari, 2018; 
Ebrahimi-Fakhari et al., 
2016) 
p62 
Amyotrophic lateral 
sclerosis (ALS), Fronto-
temporal dementia (FTD), 
p62-associated childhood-
onset ataxia 
(Du et al., 2009; van Beek et 
al., 2018; Zhu et al., 2018) 
WIPI4 
Beta-propeller protein 
associated 
neurodegeneration (BPAN) 
(Ebrahimi-Fakhari et al., 
2016) 
EPG5 Vici Syndrome (Zhao et al., 2013) 
ATG12, ATG7 Parkinson’s disease (van Beek et al., 2018) 
ATP13A2, SYT11 Parkinson’s disease (Bento et al., 2016a) 
SNX14 Cerebellar ataxia (Ebrahimi-Fakhari, 2018) 
 
Table 1.2 A table enlisting selected autophagy genes that have been implicated in the pathogenesis of several 
neurological disorders. The mutations associated with these genes, known to cause defective autophagy, have 
been observed to be associated with a spectrum of neurological disorders, a brief list of which has been mentioned 
above with selected references citing the first studies for each gene. Additional information about the mechanisms 
of pathogenesis of the disease as a result of mutation in the corresponding autophagic gene can be found in the 
corresponding references.  
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1.8.2. Autophagy and cancer 
 
The role of autophagy in various forms of cancer has been studied and shown to act as a double-
edged sword. While autophagy helps stop the cancer disease progression during early stages, 
it has also been shown to assist cancer cell proliferation during the later stages (Jiang and 
Mizushima, 2014). 
 
Autophagy was initially thought to play a protective role acting as a tumor-suppressor. This 
was based on the observation that 40-75% of the reported cases for human prostate, breast and 
ovarian cancers showed monoallelic deletion of the gene encoding core autophagy protein 
BECN1. It was also seen that suppression of autophagy in cells and mouse models with single 
allele deletion of BECN1 (heterozygous mutation) promoted tumor growth, supporting the 
hypothesis. While the exact mechanism of how loss of autophagy promotes tumor growth is 
unclear, it has been shown that loss of autophagy results in higher oxidative stress, activation 
of DNA damage response and genomic instability. The higher oxidative stress then activates 
nuclear factor, erythroid-2-like 2 (NRF2) which promotes tumor growth (Kimmelman and 
White, 2017; White, 2015). 
 
On the other hand, it has been seen that cancer cells show much higher levels of autophagy 
than normal cells and tissues. This has been attributed to the higher metabolic requirements of 
the cancer cells and the hypoxic environment at the core of tumors. It was also shown that in 
RAS-transformed cancer cells autophagy is upregulated to promote their growth and survival. 
It was shown that tumor-specific deletion of ATG7 in mice led to accumulation of 
dysfunctional mitochondria, arrest of cell growth and cell death. More importantly, this also 
led to change in the fate of the tumors from being malignant to benign characterised only by 
the accumulation of dysfunctional mitochondria. This led to development of the concept of 
cancer cells being ‘autophagy addicted’ and RAS-driven cancer cells together with many other 
forms of cancer today are considered as ‘autophagy addicted’ (White, 2015). 
 
1.8.3. Autophagy and immunity 
 
Autophagy plays an important role in the functioning of the immune system. Clearance of 
pathogens, presentation of antigens, control of inflammatory processes and secretion of 
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immune mediators are some of the primary functions of autophagy in regulating the immune 
system (Deretic et al., 2013).  
 
The process of clearance of pathogens by autophagy is a form of selective autophagy known 
as ‘xenophagy’. The general mechanism of this process has been described in the section 1.4 
of this thesis. This form of selective autophagy also plays a significant role in antigen 
presentation. The MHC class II mediated antigen presentation to CD4+ T cells is mediated by 
autophagy. The extracellular antigens can be processed by phagocytosis and subsequent fusion 
with endolysosomal compartments. The processed peptides can then be loaded on to the MHC 
class II molecules for presentation. In addition, autophagy also helps with the presentation of 
intracellular antigens where the autophagosomes directly fuse with MHC class II compartment 
instead of lysosomes (Deretic et al., 2013; Yang et al., 2015). Furthermore, autophagy has been 
shown to be an important contributor towards Crohn’s disease, an autoinflammatory bowel 
disease. Polymorphisms in the gene encoding the core autophagy protein ATG16 was shown 
to be associated with a high risk of Crohn’s disease development in Caucasian population. 
Lower levels of ATG16 have been hypothesised to be unable to inhibit inflammasome 
activation leading to increased cytokine production and repeated inflammation of the gut. 
However, the precise role of ATG16 in the pathogenesis of Crohn’s disease remains unclear 
(Yang et al., 2015). 
 
1.9. Objectives 
 
The transmembrane autophagic protein, ATG9, was identified closely after the identification 
of some of the other core autophagy proteins. However, its function and regulation of 
trafficking remain elusive. Therefore, I decided to work towards understanding the biology of 
the trafficking and regulation of ATG9 function via its post-translational modifications. My 
first results chapter (Chapter 3) of this thesis, therefore, primarily describes the identified 
phosphorylation sites on ATG9 that might potentially affect its trafficking and function in cells. 
To test this, I generated a range of phospho-mimetic and non-phosphorylatable mutants of 
identified phosphorylation sites on ATG9 using site-directed mutagenesis. To aid me towards 
identifying the role of these phosphorylation sites, I also needed to develop a cellular system 
with no endogenous protein expression. Therefore, I generated a ATG9 CRISPR-knockout cell 
line which has been characterised in detail in my second results chapter (Chapter number 4) of 
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this thesis. Furthermore, the mass spectrometric analysis of the ATG9 IP sample also helped 
me identify a putative Ser/Thr kinase, known as DNA-PKcs/PRKDC, which could 
phosphorylate one or few serine residue(s) of ATG9. The interaction of PRKDC with ATG9 
was confirmed using various experimental approaches. However, since the expression levels 
of various phospho-mutants of ATG9 could not be normalised as a result of varying protein 
stability; and since the reduction in the levels of PRKDC also could not be related to the 
perturbations in autophagic flux using multiple strategies, the results were considered to be 
inconclusive. 
 
In my third results chapter (Chapter 5), I’ve studied and described a new role for p62 in 
autophagy-impaired cells that was revealed when I was characterising the ATG9 knockout cells 
that I made. Under autophagy-impaired conditions especially when the lipidation of LC3 is 
affected, the role of p62 remains unknown. In this chapter, I show that p62 forms aggregates 
in autophagy-impaired conditions that can force cells to form LC3-I positive structures. These 
LC3-positive structures on close examination look similar to LC3-II puncta, with a slight 
difference in size that could be potentially misleading. Therefore, I confirm that in cells with 
defective autophagy, p62 aggregate formation leads to the formation of LC3-I puncta like 
structures, thereby making LC3 immunofluorescence studies under these conditions 
unsuitable. My results also identify a novel homeostatic function of p62 in autophagy-impaired 
cells. 
 
Finally, my last results chapter (Chapter number 6) focuses on the trafficking of ATG9 and 
VMP1. VMP1, as described above, is a newly identified transmembrane protein involved in 
autophagy besides ATG9. However, the trafficking of VMP1 and its relation to the only other 
transmembrane autophagy protein hasn’t been identified yet. Therefore, I was interested to 
check if VMP1 shared some biology with ATG9, its importance for the process of autophagy 
and its trafficking. In this chapter, I describe that VMP1 shares the trafficking route and 
interacts with ATG9 inside the cell. Interestingly, I also show that VMP1 overexpression 
induces autophagy and that this induction is dependent on the ATG9 expression in the cells. 
Furthermore, I show that ATG9 traffics via an additional novel trafficking route that is 
dynamin-independent, and that this trafficking route is also shared by VMP1. Moreover, VMP1 
also potentially traffics via a different dynamin-independent route in addition to the one 
formerly mentioned for ATG9. 
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2. Materials and methods 
 
2.1. Cell culture 
 
The cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovine serum, 100 U/ml penicillin-streptomycin and 2 mM L-glutamine, all 
obtained from Sigma, UK. The cell line was maintained by passaging the cells, using Trypsin-
EDTA solution (Sigma), after they are confluent to around 75-90% in T75 (75 cm2 area) flasks 
(Falcon). 
 
The cell line used for the most part of the study was HeLa (Human cervical cancer cells) cell 
line. Once confluent, the media was aspirated with the help of a vacuum pump and the flask 
was washed once with 10 ml Phosphate Buffered Saline (PBS). This step was followed by 
trypsinisation of the cells using 3 ml Trypsin-EDTA solution for 5 minutes at 37°C. The trypsin 
was then inactivated by adding 7 ml of complete DMEM medium.  The number of cells per ml 
was calculated using the countess slides from Invitrogen and the cells were seeded, in 6-well 
plates or coverslips, as per experimental requirement. The CRISPR KO cells were cultured and 
passaged in a similar manner mentioned above. 
 
2.2. Plasmid constructs 
 
The human ATG9-MycDDK plasmid, cloned in a pCMV6-entry vector, together with the 
corresponding empty vector were purchased from Origene, US. The GFP-tagged VMP1 
construct and the corresponding empty vector was also purchased from Origene, US. ATG16-
pEGFP was a kind gift from Dr Y. Takahashi and pEGFP-LC3 and mRFP-GFP-LC3 were kind 
gifts from Dr. T. Yoshimori. The pEGFP-ARF6- wild type, T27N and Q67L inserted into an 
EGFP background vector and the corresponding HA-tagged variants of ARF6 cloned into a 
pcDNA3.1 background vector, were obtained from J.G. Donaldson, National Institutes of 
Health, Bethesda, MD. The pEGFP-Atg16L1 (the cDNA corresponding to the open reading 
frame of mouse Apg16L1 cloned into pEGFP-C1) was obtained from T. Yoshimori, Research 
Institute for Microbial Diseases, Osaka University, Osaka, Japan. The GFP-tagged RavZ 
construct was a kind gift from the Dr. Craig Roy, Yale university school of medicine. 
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2.3. Transformation of bacteria 
 
The plasmids were propagated and purified from bacterial cultures. High-efficiency E.coli 
DH5α competent cells, obtained from Bioline US Inc, were used for the transformation of 
plasmids. 
 
The transformation was performed by adding 10-100 ng of purified plasmid DNA to 50 μl of 
competent cells and incubating this mixture on ice for 30 minutes. Next, the cells were 
subjected to a heat shock for 30 seconds at 42°C in a water bath, followed by 2 minutes of 
incubation on ice. This was followed by the addition of 950 μl of Luria Broth (LB) medium to 
the tubes and the cells were allowed to grow at 37°C for 60 minutes. A 100 μl volume of the 
cell suspension was then plated on a LB-agar plate containing an appropriate selection marker 
(antibiotic) for the plasmid. These plates were then incubated at 37°C for 16-20 hours and 
checked for colonies the next day. 
 
2.4. Plasmid isolation 
 
The plasmids were isolated from the bacteria using a PureLink™ HiPure Plasmid Filter 
Maxiprep Kit from Invitrogen, US. The colonies obtained after transformation were inoculated 
in 200 ml of LB with appropriate antibiotic and incubated at 37°C for 16-20 hours. The cells 
were then harvested by spinning them down at 10000 rpm for 10 minutes in a centrifuge. The 
pellet was then subjected to a series of steps, mentioned in the manufacturer’s protocol, to 
obtain purified plasmid DNA. The protocol is based on the principle of alkaline-lysis method 
of purification of plasmid DNA. The quantification of the plasmid DNA was performed using 
a spectrophotometer (Nanodrop1000, Thermo Scientific) using water or TE buffer (as 
appropriate) as blank. 
 
2.5. Transfection 
 
The HeLa cells were transfected with the purified plasmid using the Mirus TransIT-2020 
transfection reagent. The transfection was performed using optiMEM medium, as per the 
manufacturer’s protocol. 
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A mixture of 100 μl of optiMEM with 1 μg of DNA was prepared and incubated at room 
temperature for 5 minutes. Another mixture containing 100 μl optiMEM with 5 μl of Mirus 
was prepared and incubated for 5 minutes. Both the solutions were then mixed together and 
incubated for approximately 20-25 minutes. The total volume was then added to one well of a 
6-well plate, already containing 1 ml of optiMEM. The amount of DNA generally used for 
transfection was 1 μg. 
 
2.6. siRNA knockdown 
 
The cells for siRNA knockdown were transfected using lipofectamine 2000 transfection 
reagent. The transfection was performed using optiMEM medium, as per the manufacturer’s 
protocol. 
 
A mixture of 100 μl of optiMEM with 3 μl of 20 μM or 1 μl of 100 μM siRNA was prepared 
and incubated at room temperature for 5 minutes. Simultaneously, another mixture containing 
100 μl optiMEM with 5 μl of Lipofectamine 2000 was prepared and incubated for 5 minutes. 
Both the solutions were then mixed together and incubated for approximately 20-25 minutes. 
The total volume was then added to one well of a 6-well plate, already containing 1 ml of 
optiMEM for 4 hours at 37°C. After the incubation, the media was changed and replaced with 
full media. The cells were then harvested after 24 hours of incubation if a single KD was 
desired. For double KD studies, next round of siRNA transfection, following the same protocol 
as mentioned above, was performed 48 hours from the first round. The cells were then split 
and seeded to respective plates or coverslips for further experiments. 
 
siRNA  Type/ Sequence  
scrambled ON-TARGETplus Non-targeting siRNA #1  (Dharmacon) 
p62   ON-TARGETplus Human SQSTM1 siRNA Smartpool (Dharmacon) 
PRKDC ON-TARGETplus Human PRKDC siRNA Smartpool (Dharmacon) 
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2.7. Cell-surface biotinylation 
 
The cell-surface biotinylation assay was used to check the presence of VMP1 on the plasma 
membrane. The technique exploits the interaction between the side chains of the accessible 
lysine residues exposed on the cell membrane and the highly active form of biotin [NHS-LC-
Biotin: (succinimidyl-6-(biotinamido)hexanoate)]. These NHS-activated biotin molecules are 
known to react with the exposed primary amine (-NH2) groups to form stable amide bonds in 
basic environment (Thermo Scientific instructions manual for EZ-Link® NHS-Biotin 
reagents). The side chains of the amino acid lysine or N-terminus of proteins that are exposed 
on the surface of the cell provide free primary amine groups and are therefore good targets of 
labelling by NHS-LC-biotin. The technique then exploits the high affinity interaction between 
biotin and streptavidin to isolate the biotinylated proteins exposed at cell-surface using 
Streptavidin-immobilised agarose/magnetic beads. Variants of this biotin that are membrane 
impermeable are also available to simplify the process of labelling (Thermo Scientific 
instructions manual for EZ-Link® NHS-Biotin reagents). 
 
The cells were washed twice with 1x PBS and incubated in a buffer (1 mM MgCl2, 2 mM 
CaCl2, 150 mM NaCl) supplemented with 0.5 – 1 mg/ml NHS-LC-Biotin for 60-90 minutes at 
4°C. Next, the cells were washed with quenching buffer (1 mM MgCl2, 0.1 mM CaCl2, 100 
mM glycine) twice, to stop the biotinylation of the proteins on the surface, for 10 minutes at 
4°C. Finally, the cells were washed twice with 1x PBS and lysed in RIPA buffer (150 mM 
NaCl, 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 1% Triton X-100, 0.5% deoxycholate, and 
0.1% SDS, cocktail of protease and phosphatase inhibitors) on ice for 30 minutes. The cell 
lysates were then centrifuged at 13000 rpm for 10 minutes at 4°C and the supernatant was 
collected.  The protein concentration was estimated using the Biorad protein assay kit and the 
samples were normalised in protein concentration. 10 µl of the lysate was then collected and 
mixed with 10 µl of the 2X Laemmli buffer to be used as an input control. Meanwhile, 50 µl 
of the Streptavidin-magnetic beads, washed twice with RIPA buffer, were added to the cell 
lysates and the mixture was tumbled at 4°C for 2 hours. The beads were then magnetically 
separated and washed twice with RIPA buffer. Finally, the beads were resuspended in 30 µl of 
2X Laemmli buffer and the streptavidin-biotin complex was denatured by heating the 
resuspended beads at 95°C for 5 minutes.  
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2.8. Immunocytochemistry 
 
The immunocytochemistry analysis was performed on cells grown on 22 x 22 mm coverslips. 
The cells were grown at a confluency of 70-80%, washed once with PBS and then fixed using 
4% PFA for 5-7 minutes. The PFA was discarded in accordance with the safety regulations and 
the cells were washed thrice with PBS. The cells were then permeabilised using 0.5% TritonX-
100 for 5-7 minutes and washed thrice with PBS to remove any residual detergent. A solution 
containing 1% BSA was then added onto the coverslips, as a blocking solution, for reducing 
the non-specific binding of the primary and secondary antibodies and kept for 1 hour at room 
temperature. The blocking solution was then tapped off the slides and the primary antibodies 
at appropriate dilutions were added on the coverslips. The coverslips with primary antibodies 
were incubated at 4°C for 16-20 hours in a moist and humid chamber. The coverslips were next 
washed thrice with PBS and incubated with secondary antibodies containing solution for 1 hour 
at room temperature. (Note that the primary and secondary antibody solutions were made in 
the blocking buffer.) The usual dilution of the secondary antibody in 1% BSA was 1:400. In 
the final step, the coverslips were washed twice with PBS and high purity sterile water, and 
mounted on glass slides using Pro-Long gold anti-fade DAPI mounting medium (Invitrogen, 
US). 
 
The coverslips were then imaged using the Zeiss LSM880 or LSM780 confocal microscope 
using the 63x oil immersion objective. 
 
2.9. Super-resolution microscopy 
 
Samples were seeded onto Zeiss High precision No 1.5 170 + or – 5µm, 18mm X 18mm 
coverslips. Following staining the samples were mounted in Prolong Gold (Life Technologies) 
and left to harden for 3 days to reach a constant Refractive Index (RI) of 1.46.  Samples were 
imaged using Structured Illumination on the Elyra PS1 (Carl Zeiss Microscopy). Following 
stage alignment, laser lines of 405,488 and 561nm were used to image a bead stack in order to 
correct for chromatic aberration using the channel alignment algorithm. Z stacks were acquired 
at 5 phases and 5 rotations of the illumination grid and subsequently processed and aligned 
using the ZEN Black Elyra edition software (Carl Zeiss Microscopy). 
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2.10. PI3P staining 
 
PI3P molecules constitute an integral part of the autophagy signalling pathway and are 
synthesised on the growing phagophore by the PI3K-VPS34 kinase complex (Bento et al., 
2016b). Since PI3P molecules, in general, form an important of the cellular signalling process, 
levels of PI3P puncta in a cell therefore represent the signalling activity of the cell at a given 
time. Thus, to stain for the PI3P puncta in ATG9 wild-type and knockout HeLa cells, they were 
fixed in 2% paraformaldehyde and permeabilised with 20µM digitonin in buffer A (20 mM 
PIPES pH 6.8, 137 mM NaCl, 2.7 mM KCl). Then cells were blocked with buffer A 
supplemented with 5% (v/v) FBS and 50 mM NH4Cl. Anti-PI3P antibodies from Echelon (for 
1 h, 1:300) and secondary antibodies were applied in buffer A with 5% FBS. Cells that 
underwent post-fixation for 5 min in 2% paraformaldehyde, were washed with PBS containing 
50 mM NH4Cl, then were washed once with water and then mounted with Mowiol (Hammond 
et al., 2009). 
 
2.11. Western Blot 
 
The levels of proteins of interest in cells were determined using western blots. The technique 
involves separation of protein samples based on their molecular weight (M.W.) using SDS-
PAGE and transferring them on a PVDF membrane. The membrane is then incubated with 
primary, secondary antibodies and developed to detect the levels of protein of interest. 
 
The sample preparation for the western blots required cell lysis and the buffer used to lyse the 
cells was chosen based on the downstream processing required. For instance, 1X Laemmli 
Buffer was generally used to lyse the cells, but in a case where protein quantitation using 
Bradford’s method was essential, RIPA buffer had to be used. Therefore, the optimum buffer 
for the cell lysis was tested and selected based on the application. After the cells were lysed, 
20-30 μl of samples were loaded onto a 10-well, 12-15% SDS-PAGE and run at 100-120 V. A 
standard M.W. ladder was loaded along with the samples to keep a track of the movement of 
the proteins in the gel. Meanwhile, a PVDF membrane (Immobilon-FL membrane, Millipore) 
of appropriate size was cut and activated by soaking it in pure methanol for 5 seconds. The 
membrane was then equilibrated by soaking it in 1X transfer buffer for a few minutes. After 
the desired separation of the proteins was achieved, the proteins were transferred onto the 
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activated PVDF membrane in a tank containing 1X transfer buffer run at 100 V for 60 minutes. 
The transfer unit was also surrounded by ice, since lower temperatures increase the efficiency 
of transfer. Furthermore, care was taken about the methanol percentage in the transfer buffer 
based on the protein to be transferred. The transfer for small M.W. proteins required higher 
percentage of methanol in the transfer buffer as compared to large M.W. proteins; since, 
methanol interferes with SDS-binding to the protein and a higher percentage could lead to 
precipitation of large M.W. protein. The membrane was removed on completion of the transfer 
and was soaked in 5% skimmed milk for blocking the non-specific binding sites, for 1 hour at 
room temperature and the solution was then discarded. Next, a solution containing specific 
primary antibody (prepared in 5% skimmed milk or in 10% BSA based on the manufacturer’s 
instructions) at an appropriate dilution was added on to the membrane for overnight incubation 
at 4°C. Next day, the primary antibody was collected and stored at -20° until further use. The 
membranes were then washed thrice with PBST (Phosphate buffer saline + 0.1% Tween-20) 
before the addition of secondary antibody. The secondary antibody, also prepared in 5% 
skimmed milk, was incubated with the membrane for 1 hour at room temperature. The dilution 
of the secondary antibody was generally kept at 1:4000 for enhanced chemiluminescence 
(ECL) HRP-conjugated antibodies and 1:5000 for LICOR fluorophore-conjugated antibodies. 
The membranes were then washed again with PBST multiple times and developed using a 
mixture of equal volumes of developing solutions 1 and 2 for ECL or imaged directly for 
fluorescence signal detection using LICOR Image Studio software (LICOR, US). 
 
2.12. Proximity ligation assay 
 
This assay helps identify the interacting protein partners inside the cell. The technique was 
published in 2006 (Söderberg et al., 2006) and utilises the binding proximity of antibodies 
raised in two different species to target proteins. The primary antibodies are recognised by 
secondary antibodies that have been tagged with oligonucleotides. A linker DNA solution then 
links and ligates the two oligonucleotides, when present in close proximity, with the help of a 
DNA ligase. The ligated dsDNA is used as a template for rolling circle replication by the 
polymerase and the replicated DNA is recognised by a red fluorescent ssDNA probe. 
 
The experiments were performed as per the manufacturer’s instructions (Duolink). The 
reaction volume used was 80μl and the reaction was performed on coverslips. The blocking 
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buffer and antibody diluent provided with the kit were used, whereas PBS was used instead of 
wash buffers A and B. The primary antibody dilution used was 1:200 for ATG9 (Abcam), 
1:100 for PRKDC/DNA-PKcs (Thermo) and 1:200 for GFP (Living colors, Clontech) to detect 
overexpressed VMP1-GFP. The coverslips were finally mounted on glass slides using Pro-
Long gold anti-fade DAPI mounting medium (Invitrogen). 
 
2.13. Immunoprecipitation 
 
This technique exploits the binding affinity of proteins, like Protein A, G and L, for the 
antibody heavy chains (Fc region). The Fc-binding proteins are immobilised onto magnetic 
beads and are used for purifying/isolating the protein of interest. This technique is also useful 
to identify interactions between protein pairs, a modified technique, termed as co-
immunoprecipitation. 
 
The immunoprecipitation was performed using a confluent 10 cm dish of cells. The cells were 
scraped and lysed in 1ml of IP buffer, which is specific for the protein to be 
immunoprecipitated. The solution was then transferred to a 1.5 ml eppendorf tube and was 
incubated on ice for 30 minutes. The cell debris was separated by centrifuging the lysate at 
10000 rpm for 10 minutes. 100 µl of the supernatant was then collected in an eppendorf tube 
to be used as input control. The remaining supernatant was distributed equally in 3 tubes. The 
antibody against the protein to be isolated was added to the first vial, while a non-specific 
antibody like anti-FLAG/GFP/IgG was added to the second vial; the dilutions of the antibodies 
was always kept 1:100 or as mentioned on the MSDS. No antibody was added to the third vial 
and the eppendorf tubes were tumbled for overnight at 4°C. Meanwhile, 30 µl of Protein A/G 
(chosen based on the antibody isotype) magnetic beads were washed with 100 µl IP buffer 
thrice. The lysates in the sample and control tubes were then added to the washed beads and 
tumbled for 2 hours at 4°C. After the incubation period, beads were collected at the side of the 
tube using a magnetic stand and the solution was discarded. These beads were then washed 
with 100 µl IP buffer thrice and were finally resuspended in 50µl of 1X Laemmli buffer. The 
tubes were vortexed to make sure that all the beads are resuspended in the buffer and the tubes 
were then heated at 100°C for 5 minutes to detach the antibody complexes from the beads. 
Finally, the buffer was separated from the beads using a magnetic stand and the IP samples 
were immediately loaded onto SDS-PAGE for separation or stored at -20°C until further use. 
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2.14. Click-IT®  chemical assay 
 
The protein synthesis rates in cells were determined using the Click-IT® reaction kit. The 
protocol was followed as per the manufacturer’s instructions. 
 
Briefly, the cells were grown in a methionine-free media for 1 – 2 hours to deplete the 
methionine reserves in the cells. Next, media containing L-AHA (L-azidohomoalanine), an 
azido moiety containing biomolecule which serves as a replacement for methionine, was added 
to the cells for 4 hours to label newly synthesised proteins. The cells were then collected, lysed 
and the lysates were processed through different solutions provided in the Click-IT® protein 
reaction buffer kit resulting in isolation of the labelled newly synthesised proteins. The protein 
samples were then loaded on to the gel (SDS-PAGE) and immunoblotted for the proteins of 
interest. 
 
2.15. Membrane fractionation 
 
The membrane fraction was isolated and purified based on the subcellular fractionation 
protocol provided by Abcam®. 
 
Briefly, cells grown on a 10cm dish were lysed using 500µl of the fractionation buffer the 
composition of which is as follows: 
 
Fractionation buffer  Stocks  50ml 1x solution 
250 mM Sucrose  -  4.28 g 
20 mM HEPES (pH7.4) 1 M  1 ml 
10 mM KCl   -  0.0373g 
1.5 mM MgCl2  0.1 M  750 µl 
1 mM EDTA   0.5 M  100 µl 
1 mM EGTA   0.1 M  500 µl 
 
At the time of use, the fractionation buffer was supplemented with 10 µl of 1M DTT stock and 
50 µl of protease inhibitor cocktail (III). The cells were scraped and the suspension was 
transferred into a 1.5 ml Eppendorf tube. The cells were then lysed by passing the suspension 
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through a 25 Ga needle 10 times using a 1 ml syringe. The lysate was allowed to sit on ice for 
20 minutes. The nuclear fraction was then removed by centrifuging the samples at 3000 rpm at 
4°C for 5 minutes. The pellet was discarded, and the supernatant was transferred to a fresh 
Eppendorf tube. This lysate was then centrifuged at 8000 rpm at 4°C for 5-10 minutes. The 
pellet constitutes the mitochondrial fraction and the supernatant is the cytosol + membrane 
fraction of the cell. The pellet was then discarded, and the supernatant was transferred to an 
ultracentrifuge tube. The membrane fraction was then separated by centrifuging the supernatant 
at 40000 rpm (100000g) at 4°C for 1 hour. After centrifugation, the supernatant was collected 
and stored as the cytosolic fraction. The pellet was washed by adding 400 µl of fractionation 
buffer and resuspended with pipetting. The solution was then passed through the 25Ga needle 
as used earlier. The samples were then re-centrifuged for 45 minutes and the supernatant was 
discarded. The pellet was then resuspended in 25-50 µl of 2X Laemmli buffer to load onto the 
gel. 
 
2.16. Plasma membrane protein purification 
 
The proteins from the plasma membrane were purified using the ‘plasma membrane protein 
extraction kit’ from Abcam®. The kit helps in the extraction of all the cellular proteins which 
can be further used to purify proteins that reside at the plasma membrane. The kit claims to 
purify proteins with high yield and purity (over 90%) and the protocol was performed 
according to manufacturer’s instructions. 
 
2.17. CRISPR knock-out cell line generation 
 
Generating the CRISPR knock-out requires a guide RNA targeting an exonic region of the gene 
to be deleted (Ran et al., 2013). This designing was performed using the online tool developed 
by the Zhang Lab (Hsu et al., 2013). The top three single guide RNA (sgRNA) hits were 
modified manually to add BbsI restriction sites and were ordered from Invitrogen. The 
restriction site was added by addition of the overhang CACC to the forward sgRNA and a ‘G’ 
nucleotide if the guide does not contain one. 
 
sgRNA-Fw:   5’ CACC(G)…..3’ 
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The addition of the ‘G’ nucleotide is known to increase the specificity and the efficiency of the 
system (Ran et al., 2013). Similarly, the reverse sgRNA was obtained by reverse 
complementing the top strand and an overhang of AAAC was added to the 5’ end. 
 
sgRNA-Rv:   5’ AAAC….3’ 
 
The sgRNA of desalted purity were then ordered from Invitrogen. The sequences used for 
ATG9 CRISPR knockout were as follows: 
 
 Sequences (5' to 3') 
Guide1 
CACCGCTGTTGGTGCACGTCGCCGA 
AAACTCGGCGACGTGCACCAACAGC 
Guide2 
CACCGTGTTGGTGCACGTCGCCGAG 
AAACCTCGGCGACGTGCACCAACAC 
Guide3 
CACCGCGCGGATCTCCGGAGGATAT 
AAACATATCCTCCGGAGATCCGCGC 
 
The highlighted nucleotides indicate the added overhangs as per the requirements mentioned 
above. The sgRNAs were then ligated in the psCas9-2A-puromycin backbone obtained from 
Addgene plasmid repository. The forward and reverse sgRNAs were first allowed to anneal in 
a temperature-controlled PCR reaction as follows: 
 
Annealing  
8.5 µl oligo1 (100 µM) 
8.5 µl oligo2 (100 µM) 
2 µl 10X T4 DNA Ligase buffer (NEB) [NOTE: Aliquot the T4 DNA ligase buffer before 
using. Multiple freeze-thaw cycles render the buffer non-functional) 
1 µl ddH2O 
(The final concentration of oligos comes to approx.45 µM of each primer in mix) 
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PCR program  
Lid heated 
37°C 1 hour 
95°C 5 minutes 
ramp down to 25°C at 5°C/minute (= 0.1°C per second) 
This reaction mixture was then kept at 4°C until further use. 
 
The backbone and the annealed sgRNAs were then digested using BbsI restriction enzyme, 
creating a symmetric cleavage site in the backbone and the sgRNAs. After completion of 
digestion, a ligation reaction was setup to generate a construct containing sgRNAs. It is to be 
noted that an empty vector digestion was also set up in parallel to the test samples to check the 
efficiency of digestion and ligation steps. The volumes of different components of the reaction 
mixture are mentioned below: 
 
Cas9 digestion 
2 µl 10x Buffer NEB 2.1 
1 µl BbsI 
X µl pX335 1(µg) 
make volume up to 20 µl H2O  
37°C 1 hour 
 
Ligation 
To all of the above digestion reactions add: 
2.5 µl 10x T4 Ligase buffer 
1 µl annealed oligo (1:5 dilution in ddH2O from 45 µM stock) to get approx. 0.4 µM final 
concentration 
1.5 µl T4 DNA ligase 
37°C 1 hour 
 
The ligated product (2 µl) was then transformed in gold efficiency E.coli competent cells 
purchased from Bioline, US. The transformants were grown in 10ml of LB and the plasmid 
was isolated using the miniprep kit (Qiagen,DS) the next day.  
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The insertion of sgRNA in the plasmid backbone was then checked by digestion of the isolated 
plasmid with two restriction enzymes BbsI and BglII and the digestion product was loaded on 
1.5 % agarose gel, containing Midori green nucleic acid stain, together with Cas9 empty vector 
control. The insertion of the sgRNA into the backbone causes the disruption of BbsI restriction 
site leading to visualisation of just one band on the gel of size 8.5 kb, caused due to digestion 
with BglII. However, an unsuccessful ligation reaction would result in two bands on digestion 
of sizes 1.4 and 7.1 kb respectively. The digestion reaction was set up as follows: 
 
Digestion with BglII+BbsI 
1 µl Buffer 2 by NEB 
2 µl DNA (from miniprep) 
0.3 µl BbsI 
0.6 µl BglII 
6 µl water 
37°C for 2 hours 
 
The successfully ligated plasmids together with empty Cas9 vector control were then 
transfected in HeLa cells and the expression was allowed for 24 hours. The transfected cells 
were then selected by adding puromycin to the cells at a final concentration of 2-4 µg/ml. The 
cells were allowed to grow until all the non-transfected cells are dead. The positive cells were 
then trypsinised and the cell number was counted using Invitrogen Countess slides (10 µl 
homogenous cell suspension + 10 µl Trypan blue). Based on the live cell population, 0.2x104 
cells were aspirated and serially diluted in a 96-well plate to obtain single cell colonies. The 
serial dilution was always 1:1 and the final volume in each well at the end of dilution was kept 
to 200 µl. The dilution was first performed horizontally by adding 200 µl of fresh complete 
medium in rows A2-A11. Next, the cell suspension containing 0.2x104 cells was added in the 
A1 well and the volume was made up to 400 µl using fresh complete medium. Next, 200 µl of 
the diluted cell suspension was added from A1 to A2 and was mixed well with pipetting. In the 
next step, 200 µl of the suspension from A2 was then added to A3 and so on, until A12 contains 
200 µl of medium. Now using a multi-channel pipette, 100 µl of diluted cell suspension from 
A1-A12 was aspirated and added to the wells B1-B12 already containing 100 µl of media. 
Similarly, the dilution was performed until the wells H1-H12 contained 100 µl of diluted cell 
suspension. 
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These cells were allowed to attach to the substrate and grow for 24-48 hours. The wells were 
seen under the microscope using a low magnification objective and the wells containing 
colonies growing from single cells were marked.  
 
When these colonies grow big, the cells were trypsinised and transferred to a 12-well plate for 
increasing the number of cells for analysis. When the wells get approximately 80% confluent, 
the cells were trypsinised using 100 µl of Trypsin-EDTA solution and a fresh 12-well plate is 
seeded using 20 µl of the cell suspension. The remaining 80 µl of the suspension was lysed 
using 100 µl of 2X LB and the samples are loaded on SDS-PAGE, transferred to a membrane 
to check for the knock-out of the protein of interest. 
 
The identified knockout clonal pairs for ATG9 were not tested for off-target effects, however, 
both the ATG9 knockout cell lines generated showed similar level of the LC3-I and LC3-II 
protein in the cell lysates when visualised using western blotting, increasing my confidence in 
the data generated from the knockout cells. 
 
2.18. Statistical analysis 
 
The statistical significance levels for comparisons between two groups were estimated using 
two-tailed t-test. The conventions used to depict the results across the thesis are as follows: *p 
≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 and the error bars represent standard deviation or standard 
deviation of the mean based on the experiment. 
 
2.19. Antibodies 
 
The antibodies used in this work are listed in the table below: 
Primary 
Antibodies 
Proteins/organelles 
detected 
Host species Dilution Source 
LC3 LC3-I and LC3-II Mouse 1:200 (IF) 
Nanotools, 
Germany 
LC3 LC3-I and LC3-II Mouse 1:1000 (WB) 
Novus 
Biologicals, UK 
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LC3 LC3-I and LC3-II Rabbit 1:200 (IF) Abcam, UK 
DNA-
PKcs/PRKDC 
DNA-dependent 
protein kinase 
catalytic subunit 
Mouse 
1:100 (IF) 
1:100 (PLA) 
1:1000 (WB) 
Thermo 
Scientific, US 
Actin Actin Rabbit 1:1000 (WB) Sigma, US 
ATG9 ATG9 Rabbit 
1:200 (IF) 
1:100 (IP) 
1:1000 (WB) 
1:200 (PLA) 
Abcam, UK 
EEA1 
Early endosome 
marker 
Mouse 1:200 (IF) Abcam, UK 
RAB11A 
Recycling endosome 
marker 
Rabbit 1:200 (IF) Abcam, UK 
CD63 Lysosomal marker Mouse 1:200 (IF) - 
GFP 
Green fluorescent 
protein 
Mouse 1:200 (IF) ClonTech, US 
ULK1 ULK1 Rabbit 1:100 (IF) 
Novus 
Biologicals, UK 
ATG16 ATG16 Rabbit 1:200 (IF) 
MBL 
International 
corporation, US 
VPS26 VPS26 Rabbit 1:200 (PLA) Abcam, UK 
VPS35 VPS35 Mouse 1:200 (PLA) Abcam, UK 
WIPI2 WIPI2 Mouse 1:200 (IF) Abcam, UK 
VMP1 VMP1/TMEM49 Rabbit 1:100 (IF) 
Novus 
Biologicals, UK 
BECN1 BECN1 Rabbit 1:200 (IF) Invitrogen, US 
MHC-I 
MHC class I – pan-
conformational 
(W6/32) 
Mouse 1:50 (IF) 
Kind gift from 
Prof. Paul 
Lehner, CIMR 
45 
 
ARF6 
ADP-ribosylation 
factor 6 
Mouse 1:50 (IF) 
Santa Cruz 
biotechnology, 
Inc. 
p62 p62 Mouse 
1:100 (IF) 
1:1000 (WB) 
BD Biosciences 
Calnexin ER, MAM Mouse 
1:200 (IF) 
1:1000 (WB) 
BD Biosciences 
GAPDH GAPDH Mouse 1:1000 (WB) Abcam, UK 
Tubulin α-Tubulin Mouse 1:1000 (WB) Sigma, US 
 
 
Secondary 
antibodies 
Antigen 
Host species 
generated 
Dilution Source 
ECL-IgG-HRP 
Rabbit (ECL) 
Rabbit primary 
antibody 
Donkey 1:4000 
GE Healthcare 
UK Limited 
ECL-IgG-HRP 
Mouse (ECL) 
Mouse primary 
antibody 
Donkey 1:4000 
GE Healthcare 
UK Limited 
Alexa goat anti-
rabbit 488 (IF) 
Rabbit primary 
antibody 
Goat 1:400 Invitrogen, US 
Alexa goat anti-
mouse 488 (IF) 
Mouse primary 
antibody 
Goat 1:400 Invitrogen US 
Alexa goat anti-
rabbit 555 (IF) 
Rabbit primary 
antibody 
Goat 1:400 Invitrogen, US 
Alexa goat anti-
mouse 555 (IF) 
Mouse primary 
antibody 
Goat 1:400 Invitrogen, US 
Alexa goat anti-
rabbit 647 (IF) 
Rabbit primary 
antibody 
Goat 1:400 Invitrogen, US 
Alexa goat anti-
mouse 647 (IF) 
Mouse primary 
antibody 
Goat 1:400 Invitrogen, US 
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Goat anti-rabbit IR 
Dye 680 (LI-COR) 
Rabbit primary 
antibody 
Goat 1:5000 
Odyssey, LI-
COR 
Biosciences, US 
Goat anti-mouse IR 
Dye 680 (LI-COR) 
Mouse primary 
antibody 
Goat 1:5000 
Odyssey, LI-
COR 
Biosciences, US 
Goat anti-rabbit IR 
Dye 800 (LI-COR) 
Rabbit primary 
antibody 
Goat 1:5000 
Odyssey, LI-
COR 
Biosciences, US 
Goat anti-mouse IR 
Dye 800 (LI-COR) 
Mouse primary 
antibody 
Goat 1:5000 
Odyssey, LI-
COR 
Biosciences, US 
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3. Studying ATG9 phosphorylation in HeLa cells 
 
3.1. ATG9 is phosphorylated on multiple serine residues under different 
conditions 
 
Recent studies have shown the importance of post-translational modifications in autophagy. 
The post-translational modifications like phosphorylation, glycosylation, ubiquitination, 
acetylation, etc. have been shown to modulate the interaction between various proteins 
regulating autophagy (Xie et al., 2015). Of these modifications, phosphorylation constitutes the 
most common method employed by the cells for regulation of protein trafficking, in which one 
or more phosphate group(s) is added to the protein. The existing literature consists little 
information on how ATG9 trafficking is being regulated inside the cell. This led me to think 
that the trafficking of ATG9 could possibly be regulated by its phosphorylation. 
 
Therefore, I checked the phosphorylation status of ATG9 under various conditions via mass 
spectrometry. I performed immunoprecipitation of endogenous ATG9 protein from HeLa cells 
grown in either full media, EBSS (starvation medium) for 4 hours or 100 mM trehalose for 16 
hours. The samples were then digested with trypsin and subjected to mass spectrometric 
analysis to identify ATG9 residues that are phosphorylated under these conditions. The 
condensed raw results showing at least 1 unique peptide detected for each phosphorylation site 
has been summarised in Table 3.1 a. The results showed the presence of 4 phosphorylated 
serine residues common to all the three conditions. When compared to the phosphorylation 
status in starved condition, basal condition showed phosphorylation of 1, while the trehalose 
treatment showed presence of 3 exclusively phosphorylated serine residues (Table 3.1 b). 
Interestingly, all of the identified phosphorylation sites were located in long C-terminal 
cytosolic tail of ATG9, with the exception of 2 sites located in the short N-terminal cytosolic 
fragment (Table 3.1 b). 
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a Sequence Modifications Start Stop 
Position 
identified 
Basal 
(R)LEAsYSDSPPGEEDLLVHVAEGSK(S) Phospho (+80) 11 34 S14 
(R)SFsPLQPGQAPTGR(A) Phospho (+80) 654 667 S656 
(R)REsDESGESAPDEGGEGAR(A) Phospho (+80) 733 751 S735 
(R)ESDESGEsAPDEGGEGAR(A) Phospho (+80) 734 751 S741 
(R)HPEPVPEEGsEDELPPQVHKV(-) Phospho (+80) 819 839 S828 
      
Starvation 
(R)LEAsYSDSPPGEEDLLVHVAEGSK(S) Phospho (+80) 11 34 S14 
(R)SFsPLQPGQAPTGR(A) Phospho (+80) 654 667 S656 
(R)REsDESGESAPDEGGEGAR(A) Phospho (+80) 733 751 S735 
(R)HPEPVPEEGsEDELPPQVHKV(-) Phospho (+80) 819 839 S828 
      
Trehalose 
(R)LEAsYSDsPPGEEDLLVHVAEGSK(S) 
Phospho (+80), 
Phospho (+80) 
11 34 S14, S18 
(R)RESDEsGEsAPDEGGEGAR(A) 
Phospho (+80), 
Phospho (+80) 
733 751 S738, S741 
(R)SFsPLQPGqAPTGR(A) Phospho (+80) 654 667 S656 
(R)LEASYSDsPPGEEDLLVHVAEGSK(S) Phospho (+80) 11 34 S18 
(R)SFsPLQPGQAPTGR(A) Phospho (+80) 654 667 S656 
(R)REsDESGESAPDEGGEGAR(A) Phospho (+80) 733 751 S735 
(R)HPEPVPEEGsEDELPPQVHKV(-) Phospho (+80) 819 839 S828 
 
 
 
 
Table 3.1:  a) Table showing the summary for at least 1 unique peptide identified per phosphorylation residue of 
ATG9. The protein IP sample was digested with trypsin and the digest was subjected to mass spectrometry to 
identify phosphorylated sites. The identified phosphorylation sites in the sequence are shown in lower case letters. 
b) Table depicting the various phosphorylation sites on ATG9 identified under various conditions using mass 
spectrometry. 
Residues Identified 
Basal S14 - S656 S735 - S741 S828 
Starved S14 - S656 S735 - - S828 
Trehalose S14 S18 S656 S735 S738 S741 S828 
a) 
b) 
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To test the role of these phosphorylation sites, I generated phospho-mimetic and non-
phosphorylatable mutants by site-directed mutagenesis of the human WT ATG9-MycDDK 
(purchased from Origene, US). The parental construct was tested for its expression and 
distribution in the cell together with calnexin, an ER resident protein. ATG9-MycDDK showed 
no co-localisation with calnexin and displayed peri-nuclear localisation similar to the 
endogenous ATG9 staining, confirming that the protein is not stuck in the ER and is being 
synthesised and trafficked normally (Fig 3.1 a). The phospho-mimetic mutants were generated 
by substituting the serine residue with a glutamate, since the side chain of glutamate resembles 
a phosphate group and is negatively charged. Similarly, the non-phosphorylatable mutants were 
generated by substituting the serine residue with alanine, eliminating the side chain and the 
ability of the kinase to phosphorylate the protein. All of the mutants generated were confirmed 
using DNA sequencing. The mutants were then tested for their expression levels in the cells by 
transfecting the same amount of DNA in the cells. The cells were then harvested and probed 
for the transfected protein expression using an antibody against the DDK tag. All of the mutants 
showed varying expression levels (Fig 3.1 b). To normalise the expression levels of the mutants 
the approximate amount of DNA to be transfected was calculated based on the expression 
levels of the WT construct, however, it did not result in any change in the variance of 
expression. This might be due to a change in the protein stability or turnover rate caused by the 
introduced mutations making the screening of the mutants difficult. 
 
In order to test the mutants effectively, I generated ATG9 knockout cell lines using the CRISPR 
technique. The results of the cell line characterisation and studies are described in detail in 
chapter 4 of this thesis. To perform a mutant screen with the normalised amount of DNA, 
ATG9 mutants were transfected into ATG9 CRISPR knockout cells and the levels of LC3-II 
were assessed. Unfortunately, the levels of LC3-II did not correspond to the levels of ATG9 
mutant expression (Fig 3.2 a and b). 
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Fig 3.1: a) Representative images of HeLa cells grown in full media that were transfected with ATG9-MycDDK 
construct. Cells were fixed and stained using an antibody against calnexin and FLAG (DDK-tag) to detect the 
transfected protein. The scale bars represent a distance of 10 µm. b) Representative western blot showing the 
expression levels of the ATG9 mutants generated using site-directed mutagenesis. The cells were transfected with 
1 µg of DNA of each mutant and the cell lysates were probed with an antibody against the DDK tag. The arrow 
marks the band corresponding to the correct molecular weight of ATG9. 
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Fig 3.2: a) Representative western blot to assess LC3-II levels on transfection of ATG9 mutants in ATG9 CRISPR 
KO cells. ATG9 knockout cells were transfected with normalised amount of ATG9 mutants and were harvested 
16-24 hours after transfection. b) The western blots were quantified for LC3-II and tubulin levels the using 
LICOR-imaging software and using tubulin as loading control, the ratio of LC3-II to tubulin was plotted. 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
Em
p
ty
A
TG
9
S1
4
A
S1
4
D
S1
8
A
S1
8
D
S6
5
6
A
S6
5
6
D
S7
3
5
A
S7
3
5
D
S8
2
8
A
S8
2
8
D
Em
p
ty
A
TG
9
S1
4
A
S1
4
D
S1
8
A
S1
8
D
S6
5
6
A
S6
5
6
D
S7
3
5
A
S7
3
5
D
S8
2
8
A
S8
2
8
D
(-)BAF (+)BAF
LC
3
 II
 /
Tu
b
u
lin
 r
at
io
a) 
b) 
52 
 
3.2. ATG9 interacts with DNA-dependent protein kinase (PRKDC) 
 
The mammalian ATG9 sequence was checked for motifs known to be phosphorylated by 
specific kinases using the Scansite 4.0 algorithm (Obenauer et al., 2003). This algorithm 
searches the protein sequence for conserved motifs, using a reference proteome and lists the 
putative kinases with their corresponding phosphorylation sites. It also takes into account the 
surface accessibility of the site to solvents while calculating the percentile score of the kinase. 
Interestingly, a recent study showing ATG9 phosphorylation under hypoxic conditions by 14-
3-3ζ kinase was predicted by this algorithm with a strong percentile score (Weerasekara et al., 
2014). The results obtained using Scansite have been summarised in a table below (Table 3.2). 
Interestingly, all the sites that were found to be phosphorylated using mass spectrometry (Table 
3.1 b) were listed, in addition to serine-761 that was shown to be phosphorylated specifically 
under hypoxic conditions (Weerasekara et al., 2014). 
 
Meanwhile, I performed mass spectrometry of the ATG9 IP samples to check for its binding 
partners. The list of proteins was sorted and checked for the proteins with highest iBAQ value, 
which corresponds to the sum of all peptide intensities divided by the number of observable 
peptides of a protein (Fabre et al., 2014), between ATG9 IP and non-specific IP sample. 
Interestingly, DNA-dependent protein kinase (PRKDC) was found to be a hit with highest 
iBAQ value and specificity. PRKDC is a serine/threonine kinase that acts as a sensor for DNA 
damage and plays a role in DNA repair. It is involved in non-homologous end joining (NHEJ) 
of the double-stranded DNA breaks (Meek et al., 2007). 
 
I confirmed the interaction between ATG9 and PRKDC using co-immunoprecipitation and 
proximity ligation assay, showing the interaction between ATG9 and PRKDC to be highly 
specific (Fig 3.3 a and b). The interaction between VPS26 and VPS35, components of the 
retromer complex, was used as a positive control for the proximity ligation assay (Zavodszky 
et al., 2014). 
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3.3. PRKDC knockdown blocks autophagy 
 
The effect of the putative identified kinase PRKDC on autophagy was checked by knocking it 
down using siRNA SMARTpool. The knockdown of PRKDC resulted in reduction of 
approximately 60% of the protein accompanied by cell death of approximately 30% of the 
cells. The PRKDC knockdown samples showed approximately 12% higher levels of LC3-II in 
conditions without BAF compared to control. Under BAF conditions however, the levels of 
LC3-II were the same as control, indicating that PRKDC knockdown causes a block in LC3-II 
degradation (Fig 3.4 a, b and c). This could be caused due to defective transport of 
autophagosomes to lysosomes or defective degradation of the autophagosomes. The statistical 
analysis of the repeats, however, indicates that the observed difference was non-significant. 
This was most likely a result of cell death of the population that had effective PRKDC depletion 
and survival of the cells that had insufficient knockdown of PRKDC. 
 
Therefore, an alternative strategy was used to suppress PRKDC activity in the cells. A chemical 
inhibitor, NU7026, was used as a selective small-molecule inhibitor of PRKDC in a study that 
implicated PRKDC as a potential therapeutic target for leukaemia (Veuger et al., 2003; 
Willmore et al., 2004). The molecule was shown to be specific and effective at a concentration 
of 10 µM in the study. Therefore, HeLa cells were treated with 10 µM of NU7026 for 1 hour 
and the effect on LC3 levels were checked. Surprisingly, no effect on the levels of LC3 were 
observed on treatment. Hence, a dose response experiment, with a higher starting 
concentration, was setup to find the optimal inhibitory concentration of NU7026 in HeLa cells. 
As seen from Fig 3.5 a and b, NU7026 has almost no effect at 25 µM, a mild effect at 50 µM 
and a strong effect at 100 µM on LC3-II levels. However, a concentration of NU7026 this high 
is known to non-specifically inhibit other PI-3 kinases, ATM and ATR. Therefore, the 
approach of using the inhibitor to specifically suppress PRKDC activity in the cells failed. 
Moreover, when the cells were treated with 100 µM NU7026 for 1 hour it resulted in 
mislocalisation of EEA1, an early endosomal marker protein, indicating a defect in endocytic 
pathway. Interestingly, ATG9 was also found to be mislocalised in cells treated with the 
NU7026 inhibitor, however, due to lack of specificity of the inhibitor nothing can be concluded 
from the observations (Fig 3.5 c). In addition, a PRKDC-GFP overexpression construct was 
obtained from the lab of Prof. Katheryn Meek, however, since the molecular weight of PRKDC 
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is 450 kDa, the overexpression construct was approximately 17 kb. As a result of unusually 
large size of the plasmid, the purification of the plasmid resulted in fragmentation of the DNA. 
 
 
Identified serine 
residue Score Percentile Sequence SA Enzyme Gene card 
S656 0.5819 2.942% ASALRSFSPLQPGQA 0.787 14-3-3 Mode 1 YWHAZ 
S656 0.5759 2.800% ASALRSFSPLQPGQA 0.787 Protein Kinase A  PRKACG 
       
S14 0.4601 1.111% EYQRLEASYSDSPPG 1.884 PKC epsilon  PRKCE 
S14 0.6012 4.276% EYQRLEASYSDSPPG 1.884 Casein Kinase 2  CSNK2B 
       
S18 0.6045 4.511% LEASYSDSPPGEEDL 1.626 Casein Kinase 2  CSNK2B 
S18 0.6148 2.254% LEASYSDSPPGEEDL 1.626 GSK3 Kinase  GSK3A 
S18 0.5369 0.879% LEASYSDSPPGEEDL 1.626 Erk1 Kinase  MAPK3 
S18 0.6192 3.502% LEASYSDSPPGEEDL 1.626 Cdk5 Kinase  CDK5 
       
S735 0.4633 0.791% HVWHRRESDESGESA 4.037 Protein Kinase A  PRKACG 
       
S828 0.5434 1.051% EPVPEEGSEDELPPQ 2.636 DNA PK  PRKDC 
S828 0.6213 4.009% EPVPEEGSEDELPPQ 2.636 ATM Kinase  ATM 
S828 0.3944 0.154% EPVPEEGSEDELPPQ 2.636 Casein Kinase 2  CSNK2B 
       
S761 0.2096 0.013% QSIPRSASYPCAAPR 0.54 14-3-3 Mode 1  YWHAZ 
S761 0.5446 1.886% QSIPRSASYPCAAPR 0.54 Protein Kinase A  PRKACG 
S761 0.5724 0.712% QSIPRSASYPCAAPR 0.54 Akt Kinase  AKT1 
S761 0.6224 0.793% QSIPRSASYPCAAPR 0.54 AMP_Kinase  PRKAA1 
       
S738 0.4767 0.353% HRRESDESGESAPDE 2.04 DNA PK  PRKDC 
 
 
Table 3.2:  Table depicting the predicted kinases and the corresponding phosphorylation sites on ATG9 as 
identified by Scansite. The percentile score indicates the confidence of the hit based on all the results obtained 
from the proteome database. Highlighted rows indicate the putative kinase of interest that was pursued for further 
studies. 
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Fig 3.3: a) Representative western blot of the immunoprecipitation experiment showing the interaction of 
endogenous ATG9 with endogenous PRKDC. ATG9 was immunoprecipitated from HeLa cells grown in full 
media and the samples were separated using SDS-PAGE. b) Representative images of the proximity ligation assay 
to confirm the interaction between endogenous ATG9 and PRKDC. The proteins VPS26 and VPS35 are 
components of the retromer complex and were used as a positive control for the assay (Zavodszky et al., 2014). 
The scale bars represent a distance of 10 µm. 
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Fig 3.4: a) Representative western blot showing the effect of PRKDC knockdown on LC3-II levels. HeLa cells 
were transfected with the scrambled/PRKDC siRNA using lipofectamine-2000 and the proteins in the lysates were 
separated using SDS-PAGE and probed for antibodies against tubulin and LC3-II. b) The levels of protein were 
quantified with tubulin as loading control using the LICOR-imaging software and the ratio of LC3-II to tubulin 
was plotted (n.s. = non-significant). c) Representative western blot showing the efficiency of PRKDC knockdown 
upon transfection of PRKDC SMARTpool siRNA using lipofectamine-2000. The levels of tubulin were used as 
a loading control. 
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Fig 3.5: a) Representative western blot showing the dose dependent effect of the PRKDC inhibitor, NU7026, on 
LC3-II levels. HeLa cells were treated with either 25, 50 or 100 µM of NU7026 for 1 hour with DMSO as control. 
The cell lysates were collected and the proteins were separated using SDS-PAGE. b) Levels of protein were 
quantified with tubulin as loading control using the LICOR-imaging software and the ratio of LC3-II to tubulin 
was plotted. The graph lacks error bars since the experiment was only performed once due to the non-specific 
inhibition of PRKDC by the NU7026 inhibitor at higher concentrations. c) Representative immunofluorescence 
images showing the effect of NU7026 on EEA1 and ATG9 localisation in HeLa cells. HeLa cells were treated 
with 100 µM NU7026 and DMSO as control for 1 hour and labelled with antibodies against endogenous EEA1 
and ATG9. The scale bar represents a distance of 10 µm. 
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This led me to try generating a PRKDC CRISPR knockout cell line. However, the knockout of 
the gene was lethal and no knockouts survived. This is consistent with the observation of high 
cell death on PRKDC knockdown indicating that the cell death was probably a result of higher 
knockdown levels of PRKDC, since it’s an essential kinase for cell survival. Owing to the lack 
of viable strategies for PRKDC depletion and mutant screening, the project was not pursued 
any further. 
 
To summarise, the results in this chapter show that mammalian ATG9 is phosphorylated on 
multiple serine residues. A few of these sites were found to be specifically phosphorylated 
upon starvation and trehalose treatment. It was also observed that mutating the sites to generate 
phospho-mimetic and non-phosphorylatable mutants resulted in affecting the stability/turn-
over rate of the mutant ATG9 in the cells, indicating a potential regulatory role for some of 
these sites on protein stability. The Scansite and mass spectrometry results hinted towards 
PRKDC as a putative kinase and an interacting partner of ATG9. This interaction was then 
confirmed using immunoprecipitation and proximity ligation experiments. Furthermore, 
PRKDC knockdown showed a small non-significant increase in LC3-II level compared to 
control, potentially indicating that it might be a blocker of autophagy. This however could not 
be confirmed, since higher levels of PRKDC knockdown resulted in cell death, also resulting 
in the generation of PRKDC CRISPR cell line strategy non-viable. Moreover, the working 
PRKDC inhibitor concentration in HeLa cells was found to be in a range where its effects were 
non-specific and therefore, as mentioned above, this project was not pursue any further. 
However, this project led me to generate ATG9 CRISPR knockout cell line, which as a result 
helped me identify an important phenotypic anomaly in autophagy-impaired cells. The detailed 
characterisation of the ATG9 knockout cell line together with the observed phenotype has been 
described in depth the next two chapters of this thesis. 
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4. Characterisation of the ATG9 CRISPR knockout cell line 
 
To study the role of site-specific ATG9 phosphorylation in its trafficking and function (as 
described in chapter 3 of this thesis), I needed to test the generated phospho-mimetic and non-
phosphorylatable mutants of ATG9 in an endogenous ATG9-null background. Therefore, I 
aimed towards generating a ATG9 knockout cell line using the CRISPR gene editing technique. 
 
The CRISPR-mediated gene editing has been established as a powerful and precise genome-
engineering technique in the recent years. The technique, originally identified as a part of the 
microbial adaptive immune system, was modified and adapted to edit mammalian genomes 
using target sequence-specific RNA (Hsu et al., 2013). The CRISPR gene-knockout strategy 
involves the recognition of target sequence by a single-guide RNA (sgRNA) molecule, which 
results in the cleavage of target sequence. This process is mediated by the RNA-guided 
nuclease Cas9 which introduces a double-stranded break (DSB) in the target genome-sequence. 
The introduction of a DSB results in the activation of the DNA-damage repair pathways that 
introduce mutations such as insertion-deletion(s), frameshift or insertion of premature stop 
codons, thereby facilitating a desired genetic-knockout (Hsu et al., 2013; Ran et al., 2013). To 
obtain a genetic knockout of the endogenous ATG9 gene in HeLa cells, I therefore, transfected 
the wild-type cells with a construct designed to express sgRNA against the ATG9 gene. I then 
selected the transfected cells by adding puromycin to the growth medium. I further trypsinised 
the antibiotic-selected cells and serially diluted them in a 96-well plate in a fashion that 
maximises the likelihood of each well of the plate to consist of a single cell at the end of serial 
dilution procedure. These cells were then allowed to attach to the substrate and grow for 24-48 
hours to form a distinct colony. The wells with a single colony, which arose from a single cell 
were marked and the selected colonies were then tested for the knockout of ATG9. Following 
this protocol, I was able to obtain 2 pairs of ATG9 wild-type and knockout single-cell derived 
clonal populations that were negative for endogenous ATG9 expression amongst the total of 
25 pairs of colonies that were screened for ATG9 knockout. A detailed protocol of the process 
of the CRISPR-mediated ATG9 knockout cell line generation has been described in the 
Materials and methods - section 2.17 of this thesis for more information. 
 
This chapter will now describe the observed results of the characterisation of the generated 
ATG9 wild-type and knockout HeLa cells. 
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4.1. ATG9 knockout cells show impaired autophagy and abnormally 
large LC3 puncta 
 
The 2 clonal pairs of ATG9 wild-type and knockout cells amongst the total of 25 clonal pair of 
cells were selected by checking for the expression of ATG9 on a western blot using an antibody 
developed against the human endogenous ATG9 protein. The selected clonal pairs were then 
tested for autophagic function, using a standard autophagy assay which relies on checking the 
levels of LC3-I and LC3-II in the presence and absence of the lysosomal pH inhibitor, 
BafilomycinA1 (BAF) (that blocks LC3-II clearance by blocking autophagosome-lysosome 
fusion, Fig 1.1 b). The LC3-I and LC3-II levels for each pair were then quantified separately 
relative to the levels of the loading control, tubulin and the data was plotted in the form of a 
histogram to visualise the difference in the levels of LC3-I and LC3-II. Both ATG9 knockout 
cell lines, which were a part of the two identified ATG9 wild-type and knockout cells clonal 
pairs, were seen to behave in a similar fashion and showed an impaired autophagic response 
compared to their respective wild-type control cells (Fig 4.1 b, c, e and f). Interestingly, both 
of these ATG9-knockout cell lines did not respond to BAF treatment, which was seen as the 
levels of LC3-II remained unchanged upon treating the cells with BAF for 4 hours (Fig 4.1 b, 
c, e and f). It is worth noting at this point that the two ATG9 knockout cells of each clonal pair 
also show significantly higher levels of LC3-I compared to their respective controls, the 
significance of which has been explored in further details in chapter 5 of this thesis (Fig 4.1 d 
and g). Upon closer examination, it was seen that the clonal pair 2 of the ATG9 wild-type and 
knockout cells showed a relatively lower difference in LC3-levels accompanied with an unclear 
response related to autophagic impairment compared to the clonal pair 1. Therefore, to 
maximise the chances of seeing a real difference in phenotype and the effects of ATG9 
knockout, all the experiments from this point henceforth were exclusively performed using the 
clonal pair 1 of the ATG9 wild-type and knockout cells. Interestingly, upon further 
investigation it was seen that these ATG9 knockout cells not only show an impaired autophagic 
response and higher levels of LC3-I, but also showed the presence of fewer but larger LC3 
puncta compared to control cells, which were identified upon immunostaining of these cells 
using an antibody against LC3 which recognises both LC3-I and LC3-II forms of the protein 
(Fig 4.1 h, i and j). 
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To confirm that the effects seen on the LC3-I and LC3-II levels on a western blot were 
specifically a result of the lack of ATG9 expression in the knockout cells, I tried to rescue the 
observed phenotype using ATG9-GFP. Therefore, I overexpressed empty-pEGFP and ATG9-
GFP in ATG9 knockout cells and showed that the LC3-I and LC3-II levels can be successfully 
rescued in cells upon ATG9-GFP but not empty-pEGFP overexpression (Fig 4.2 a and b). To 
further confirm impaired autophagy in these cells, clearance of overexpressed GFP-tagged 
exon-1 of huntingtin with 72 CAG repeats (EGFP-Q74) (a mutant form of huntingtin associated 
with Huntington’s disease and an accepted autophagic cargo) was tested in clonal pair of 
control and ATG9 knockout cells. It was observed that there was excessive aggregate 
accumulation in ATG9 KO cells compared to control cells (Fig 4.2 c).  
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Fig 4.1 a) Representative western blot showing the efficiency of the CRISPR knockout cells by immunoblotting 
for the levels of endogenous ATG9 in the CRISPR knockout clones and their corresponding wild-type (control) 
cells (clonal pairs). 2 out of 25 screened cell lines lacking endogenous ATG9 expression were successfully 
generated using the CRISPR technique and these knockout cell lines together with their respective wild-type 
(control) cells have been labelled as clonal pair 1 and clonal pair 2. b) A representative western blot showing the 
levels of the two LC3 isoforms in ATG9 wild-type (control) and knockout cells of the clonal pair 1. c) 
Quantification of the intensities of the LC3-II bands for the clonal pair 1, observed in panel b) of this figure, was 
performed using the LICOR-imaging software. The LC3-II values were then plotted against the values of the 
loading control, tubulin. The data is from the quantification of three experiments performed in triplicates and the 
error bars represent the standard error of the mean (SEM). d) Quantification of the intensities of LC3-I bands for 
the clonal pair 1, observed in panel b) of this figure, was also performed using the LICOR-imaging software. The 
LC3-I values were then plotted against the values of the loading control, tubulin. The data represents the 
quantification of three experiments performed in triplicates and the error bars represent SEM (* = p < 0.05, ** = 
p < 0.01, *** = p < 0.001). e) A representative western blot showing the levels of the two LC3 isoforms in ATG9 
wild-type (control) and knockout cells of clonal pair 2. f) Quantification of the intensities of the LC3-II bands for 
the clonal pair 2, observed in panel e) of this figure, was performed using the LICOR-imaging software. The LC3-
II values were then plotted against the values of the loading control, tubulin. The data is from the quantification 
of three experiments performed in triplicates and the error bars represent the standard error of the mean (SEM). 
g) Quantification of the intensities of LC3-I bands for the clonal pair 2, observed in panel e) of this figure, was 
also performed using the LICOR-imaging software. The LC3-I values were then plotted against the values of the 
loading control, tubulin. The data represents the quantification of three experiments performed in triplicates and 
the error bars represent SEM (* = p < 0.05, ** = p < 0.01, *** = p < 0.001). It is worth noting that both clonal 
pairs of ATG9 wild-type and knockout cells i.e. 1 and 2, show similar effects on the levels of LC3-I and LC3-II 
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on the western blots, however, since the effect of ATG9 knockout in the clonal pair 1 was much clearer, it was 
selected for all the future experiments. h) Representative immunofluorescence images showing LC3 puncta 
staining in ATG9 control and knockout cells (clonal pair 1). ATG9 control and knockout cells were fixed and 
labelled for endogenous LC3 with an antibody that recognises both the forms of LC3. i), j) The quantification of 
the LC3 puncta size and number of the images shown in h) was performed using ImageJ quantification tool (** = 
p < 0.01, *** = p < 0.001). The quantification data represents the puncta size and number generated from the 
population after excluding the background (very small puncta) by setting a threshold value of 0.0009 as a cut-off 
size for puncta recognition. Quantification was performed based on the results from 3 experiments with more than 
25 cells quantified per experiment per condition. The error bars represent standard deviation (SD). 
 
Fig 4.2 a) A representative western blot depicting the levels of LC3-I and LC3-II upon rescue of the selected 
ATG9 knockout cells using ATG9-GFP construct in the absence and presence of BAF. b) Quantification of the 
LC3-II levels of the control and knockout cells, as seen in panel a) of this figure, was performed using the LICOR-
imaging software (* = p < 0.05, n.s. = non-significant). The data represents the quantification performed from 
three independent experiments performed in triplicates and the error bars represent SEM. c) Graph showing the 
difference in the percentage of cells with Q74-GFP aggregates between ATG9 wild-type and knockout cells (* = 
p < 0.05). The data has been obtained from the quantification of two experiments performed in triplicates and the 
error bars represent SEM. 
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4.2. ATG9 knockout cells show lower number of PI3P and WIPI2 puncta 
 
As described in the last section, ATG9 knockout cells show impaired autophagy as observed 
using the standard LC3-II western blot assay. However, another way of confirming the 
autophagic response in cells relies on the quantification of the PI3P puncta formation in 
response to starvation conditions, as increased PI3P synthesis correlates with autophagosome 
formation and is an important marker of growing autophagosomes. It is known that PI3P 
generation leads to recruitment of WIPI-family of proteins like WIPI2 and further studies have 
shown that WIPI2 assists in the recruitment of the ATG5-ATG12-ATG16 complex. This 
complex was then shown to dictate the site of LC3 lipidation (Bento et al., 2016b; Dooley et 
al., 2014; Vicinanza et al., 2015).  
 
My results show that the ATG9 knockout cells of the clonal pair show less generation of PI3P-
positive structures compared to the respective control cells under both basal and starvation 
conditions (Fig 4.3 a and b). However, an observed increase in the starvation induced PI3P 
puncta formation in ATG9 knockout cells possibly hints that the general population of PI3P-
positive puncta do not represent a population of functional autophagosomes and hence, this 
might not be an autophagy-specific assay. It could also indicate that contrary to the existing 
hypothesis in the field, ATG9 perhaps does not play a very important role in starvation-induced 
autophagy in HeLa cells. To therefore consolidate the relevance of decrease in PI3P puncta 
formation on functional autophagy levels in the ATG9 knockout cells, the effect of starvation 
on WIPI2 puncta formation was tested. While changes in the levels of PI3P synthesis could be 
an effect of perturbations of various cellular processes, reduction in the levels of WIPI2 puncta 
formation is a direct indicator of LC3 lipidation and therefore, autophagy. Interestingly, the 
WIPI2 puncta formation in ATG9 knockout cells upon autophagic stimulation by starvation 
was also seen to be significantly impaired compared to the control cells of the pair (Fig 4.3 c 
and d). 
 
4.3. The LC3 puncta in ATG9 knockout cells co-localise with p62 
 
To test whether the abnormally large LC3-positive puncta were a result of defective trafficking 
or increased binding affinity of LC3 with proteins/organelles involved in endocytic trafficking, 
I checked the co-localisation of these LC3-positive puncta with the endosomal markers known 
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to play a role in the trafficking of important autophagy proteins. For instance, the co-
localisation of LC3 puncta with RAB5 and RAB11 was checked, since ATG9 and ATG16 were 
shown to meet at recycling endosomes (Puri et al., 2013); and recycling endosomes have been 
also proposed to be a primary platform for autophagosome formation (Puri et al., 2018). The 
co-localisation of these LC3 puncta was also checked with syntaxin-17, since perturbations in 
the levels of SNX17 was shown to result in accumulation of LC3-positive structures (Hegedűs 
et al., 2013). In addition, the co-localisation of these puncta was also checked with p62 to 
understand if these puncta were simply aggregates. The co-localisation between 2 markers was 
confirmed by visualising the pixels that co-localise in two different fluorescence signal 
channels. These co-localisation pixels were identified and a profile was generated and 
visualised using an unsupervised ImageJ plugin algorithm called ‘colocalization’, which was 
developed by Pierre Bourdoncle (Institut Jacques Monod, Service Imagerie, Paris; 2003-2004). 
The algorithm allows manual thresholding of the acquired images, facilitating the elimination 
of background noise based on pixel intensities of different channels. The threshold for the pixel 
intensities can be adjusted within range of 0-255 and two pixels above threshold value are 
considered to be co-localised if their ratio of intensity is higher than the set value, which was 
set to the default value of 50%. The algorithm finally generates a profile with grey pixels 
representing exclusive co-localisation between the two markers. It was observed that while the 
LC3-positive puncta show no specific co-localisation with any endosomal markers or STX17, 
these puncta however showed a near complete co-localisation with p62 (Fig 4.4). This was a 
very interesting observation and its significance will be described in further details in chapter 
5 of this thesis. 
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Fig 4.3 a) Representative immunofluorescence images showing PI3P staining in representative ATG9 wild-type 
and knockout cells under basal and starvation conditions. b) Quantification of the number of PI3P puncta from 
the images shown in panel a) performed using the ImageJ quantification tool software (* = p < 0.05, ** = p < 
0.01). The quantification was performed on the data from 3 independent experiments with at least 25 cells 
quantified for per experiment per condition. The error bars represent the standard deviation (SD). c) 
Representative immunofluorescence images showing WIPI2 staining in representative ATG9 wild-type and 
knockout cells under starvation conditions. It is important to consider that the WIPI2 puncta are only visible upon 
starvation. d) The quantification of the number of WIPI2 puncta from the images shown in panel c) was performed 
using the ImageJ quantification tool software (*** = p < 0.001). Quantification performed from the data from 3 
independent experiments with at least 25 cells quantified for each condition. The error bars represent standard 
deviation (SD) and the scale bars represent a distance of 10µm. 
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4.4. ATG9 knockout cells show lower protein synthesis and RavZ mimics 
the LC3 phenotype in wild-type cells 
 
To identify whether the decrease in the observed levels of LC3 due to defective autophagy was 
also being affected due to an overall reduction in protein synthesis, I performed a Click-IT® 
chemical assay to check the levels of newly synthesised proteins in the ATG9 wild-type and 
knockout cells. The Click-IT® assay is a non-radioactive assay based on the principle of a 
pulse-chase assay, therefore capable of labelling freshly synthesised proteins. These proteins 
can then be isolated and detected using SDS-PAGE. I observed that the ATG9 knockout cells 
showed a massive reduction in the protein synthesis levels of LC3-I and LC3-II compared to 
control cells (Fig 4.5 a and b). 
 
To further understand whether the observed phenotype in ATG9 null cells (as previously shown 
in Fig 4.1) is a result of LC3-I accumulation together with impaired autophagy, I tried to mimic 
this effect in control cells using RavZ overexpression. RavZ is a bacterial effector protein, 
produced by Legionella pneumophila, which was shown to inhibit autophagy. More 
specifically, this protein was shown to catalyse the hydrolysation of the amide bond between 
C-terminal glycine and an adjacent aromatic amino acid residue in LC3, producing a version 
that is non-conjugatable thereby inhibiting autophagy (Choy et al., 2012). On overexpression 
of GFP-RavZ in HeLa cells, I observed that the LC3 puncta staining resembled the phenotype 
observed in ATG9 knockout cells (Fig 4.5 c). Consistent with the identified mechanism of 
RavZ activity, it was observed that cells expressing RavZ-GFP showed impairment of 
autophagy together with a distinct increase in the levels of LC3-I on western blot (Fig 4.5 d). 
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Fig 4.4 Representative immunofluorescence images showing the co-localisation of LC3 puncta with various 
endosomal markers, syntaxin-17 and p62 in representative ATG9 knockout cells using co-localisation profile 
generation. The co-localisation pixels were identified and a profile was generated using an unsupervised ImageJ 
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plugin algorithm called colocalization, which was developed by Pierre Bourdoncle (Institut Jacques Monod, 
Service Imagerie, Paris; 2003-2004). The algorithm allows manual thresholding of the acquired images that 
facilitates the elimination of background noise based on pixel intensities of different channels to generate a profile 
with grey pixels representing co-localisation of the markers. Briefly, the cells were fixed with PFA and labelled 
for endogenous LC3 which recognises both forms of LC3 viz. LC3-I and LC3-II together with antibodies against 
small molecule GTPase effectors which act as conventional markers for respective endosomal compartments such 
as RAB5 for early endosomes, RAB7 for late endosomes and RAB11 for recycling endosomes. The co-
localisation between the LC3 puncta was also tested against the SNARE-protein STX17, that was identified to 
play a role in autophagosome-lysosome fusion. Finally, the co-localisation was tested between LC3 and the 
common autophagy receptor, p62 in the knockout cells which show impaired autophagy. The co-localisation 
between the different marker pairs was then visualised by looking at the grey pixels in the co-localisation pixels 
panel. As mentioned above, the grey pixels represent the identified pixels above threshold that are present in both 
green and red channels and therefore, represents co-localisation between the used markers. The scale bars in the 
images represent a distance of 10µm.  
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Fig 4.5 a) A representative western blot depicting the levels of LC3-I and LC3-II protein synthesis in ATG9 wild-
type and knockout cells. GAPDH was immunoblotted to be used as a loading marker for quantification. b) The 
quantification of the blot was then performed using the LICOR-imaging software. The data represents the 
quantification from two experiments performed in duplicates and the error bars represent SEM (** = p < 0.01, 
*** = p < 0.001). c) Representative immunofluorescence images showing the effect of overexpression of empty-
pEGFP or GFP-RavZ on LC3 staining in representative wild-type HeLa cells. d) A representative western blot 
showing the effect of empty-pEGFP or GFP-RavZ overexpression on LC3-I and LC3-II levels in HeLa cells. 
GAPDH was immunoblotted to be used as a loading control. RavZ was shown to inhibit autophagy via the 
hydrolysation of the amide bond between C-terminal glycine and an adjacent aromatic amino acid residue in LC3 
producing non-conjugatable LC3-I molecules. The experiment was performed twice in duplicates. The scale bars 
represent a distance of 10µm. 
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To summarise, the ATG9 knockout cells showed an impaired autophagic process 
corresponding to their wild-type partners. Moreover, these ATG9 knockout cells also showed 
a distinct lack of an autophagic response upon BAF treatment, which is known to result in an 
accumulation of LC3-II in the wild-type cells. Furthermore, these knockout cells showed much 
higher levels of LC3-I compared to control cells. More interestingly, the lower levels of LC3 
in the knockout cells corresponded to an increase in the LC3 puncta size and a decrease in the 
number of LC3 puncta, upon visualisation using immunofluorescence, compared to wild-type 
cells. This phenotype was then seen to be mimicked in wild-type HeLa cells by overexpression 
of the Legionella protein RavZ, which results in generation of non-conjugatable form of LC3 
similar to LC3-I. This, therefore, indicates that the abnormal LC3-puncta phenotype observed 
in ATG9 knockout cells using immunofluorescence is related to the corresponding higher 
levels of LC3-I in knockout cells upon western blotting of the cell-lysates. Moreover, the 
abnormal levels of LC3 and lack of BAF response observed in ATG9 knockout cells was seen 
to be rescued by overexpression of ATG9-GFP and not empty-pEGFP. Consistent with the 
observation of impaired autophagy in ATG9 knockout cells, these cells also showed lower 
levels of PI3P and much lower levels of WIPI2 puncta formation upon starvation. Finally, the 
aberrant LC3 puncta observed in the ATG9 knockout cells were seen to not co-localise with 
any conventional endosomal markers such as RAB5, RAB7 and RAB11 but were seen to co-
localise almost completely with p62.  
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5. LC3-I associates with p62 in autophagy-impaired cells 
 
The ubiquitinated cargoes destined for degradation by autophagy have been shown to bind to 
p62 cargo receptor via the UBA-domain. p62 also binds to both forms of LC3, with a preference 
for LC3-II upon autophagic stimulation, using the LIR domain to help the engulfment of the 
cargo into the growing autophagosomes and its subsequent degradation (Ciuffa et al., 2015; 
Gao et al., 2013; Ichimura, 2008; Moscat and Diaz-Meco, 2009; Pankiv et al., 2007; Zaffagnini 
et al., 2018). The completed autophagosomes appear as punctate structures in cells when 
visualised using LC3-II as the marker. However, my results in this chapter show that ATG9-
null and ATG16-null cells (i.e. autophagy-impaired cells) are capable of forming LC3-positive 
structures. Interestingly, these structures are also p62 and ubiquitin positive. It has been shown 
that p62 forms inclusion bodies in autophagy-deficient mice and these structures were also 
shown to be positive for ubiquitin (Komatsu et al., 2007). A different study has also shown that 
the p62 aggregates sequestered the E1-like ATG7 enzyme into these aggregates. It also showed 
that this sequestration is mediated via the interaction of LC3-I with ATG7 and that while p62 
shows preferential binding towards LC3-II, it is indeed capable of binding to the lipidation 
defective LC3-G120A mutant (Gao et al., 2013). My results thereby confirm this observation 
that LC3-I can form a complex with p62 under autophagy-impaired conditions such as those 
that exist in ATG9- and ATG16-knockout cells. Therefore, results from experiments involving 
autophagy-impaired cells should be carefully assessed to avoid confusion of considering LC3-
I positive structures as mature autophagosomes. 
 
5.1. Autophagy-impaired cells show aberrant LC3-positive puncta 
 
As mentioned in the ATG9 knockout cells characterisation chapter of this thesis, the ATG9 
knockout cells showed lower levels of LC3-II compared to control cells (Fig 4.1 b and c). This 
led me to check the morphology and number of the LC3-II puncta in these cells. Interestingly, 
the LC3-II puncta formed in these cells were much bigger and fewer in number compared to 
control cells (Fig 5.1 a, b and c). However, more interestingly, the ATG9 knockout cells also 
showed very high levels of LC3-I compared to control cells (Fig 4.1 b and d). I tried to confirm 
this observation using immunofluorescence, however, the overall cytosolic staining 
representing LC3-I did not change in ATG9 knockout cells (Fig 5.1 a). This, therefore, hints 
towards LC3-I existing in a form other than the conventional cytosolic form.  
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To confirm this hypothesis, I checked the LC3 staining pattern in ATG16 knockout cells, which 
were generated, validated and published in a study from the Rubinsztein laboratory (Fig 5.1 e) 
(Bento et al., 2016a). These cells only possess LC3-I and completely lack the presence of LC3-
II, due to a defect in the common lipidation process that requires ATG16 expression and are 
therefore autophagy-impaired. Based on the conventional view, I expected to observe no 
puncta formation due to defective LC3 lipidation and only cytosolic staining for LC3-I. 
However, contrary to my expectations the ATG16 knockout cells showed presence of rather 
large and distinct LC3-positive structures (that are LC3-I). These LC3-I structures did not seem 
to accumulate or change when the cells were treated with compounds that inhibit autophagic 
flux like BAF and ammonium chloride (NH4Cl) (Fig 5.1 d).  
 
To confirm that this observation was not an artefactual, the LC3 staining in these cells was 
tested using 2 different antibodies obtained from Abcam® and NanoTools. These antibodies 
require different fixation of the samples. The rabbit Abcam® antibody requires 4% PFA 
fixation while the mouse NanoTools antibody requires the cold-methanol fixation of the cells. 
Regardless of the antibody however, the observation of large LC3-positive structures in the 
autophagy-impaired cells was found to be consistent (Fig 5.1 f). However, since PFA fixation 
was more suitable for the staining of the other antibodies used in various experiments 
throughout the study, the rabbit Abcam® antibody was the primarily used antibody across this 
thesis unless mentioned otherwise. 
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Fig 5.1: a) Representative immunofluorescence images showing LC3 staining in representative ATG9 control 
and knockout cells. ATG9 control and knockout cells were fixed and labelled for endogenous LC3. b), c) 
Quantification of the LC3 puncta size and number of the images in a) performed using ImageJ quantification tool 
(** = p < 0.01, *** = p < 0.001). Quantification performed from 3 experiments with at least 25 cells quantified 
for each condition. The error bars represent standard deviation (SD). d) Representative immunofluorescence 
images showing LC3 staining in representative ATG16 control and knockout cells. Cells were fixed with methanol 
and labelled for endogenous LC3. Please note that the antibody against LC3 used here is a mouse monoclonal 
antibody from Novus Biologicals and needs methanol fixation of the samples. e) Representative western blot 
showing the ATG16 expression levels in ATG16 CRISPR knockout cells used for throughout the studies in this 
thesis. f) Representative immunofluorescence images showing LC3 staining in representative ATG16 control and 
knockout cells using two different antibodies requiring different fixation conditions. The cells were fixed with 
either 4% PFA or cold-methanol (as per manufacturer’s instructions) and labelled for endogenous LC3. The scale 
bar represents a distance of 10 µm. 
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5.2. Overexpression of mutant non-conjugatable forms of LC3 results in 
formation of distinct LC3 structures in autophagy-impaired cells 
 
To confirm whether the observed endogenous-LC3 positive structures in autophagy-impaired 
cells were LC3-I structures, I overexpressed mutant non-conjugatable forms of LC3 such as 
GFP-LC3G120A and myc-LC3G120A-ΔC22 in control and autophagy-impaired cells. These 
mutants cannot be lipidated since the glycine residue located at 120th position has been mutated 
to alanine, hence the protein cannot be cleaved, activated and conjugated (Wang et al., 2013). 
After transfection, the cells were allowed to express mutant protein for 24 hours and the cells 
were then visualised for LC3 structures using the GFP signal or an antibody against the myc-
tag (Fig 5.2 a, b and d). It was observed that these non-conjugatable forms of mutant LC3 forms 
structures that resemble the LC3 phenotype observed in autophagy-impaired cells as seen in 
Figs 5.1 a and d. It is worth noting that the staining of the LC3-positive structures formed in 
control cells is much lighter than ATG9 and ATG16 knockout cells is due to the lack of 
functional autophagy in the knockout cells. This also further confirms the hypothesis that LC3-
I exists not simply in a cytosolic form. In addition, while these structures were observed to not 
co-localise with any of the conventional endosomal markers or lipid droplets, upon 
overexpression of RAB5-Q69L-GFP dominant-negative mutant in ATG16 knockout cells, the 
size of LC3-positive structures was observed to decrease (Fig 5.2 a, b, c, e and f and Fig 4.4). 
 
5.3. LC3-I accumulates in autophagy-impaired cells and is associated 
with the membranous fraction 
 
Since the observations seen above indicate towards a sub-population of LC3-I that exists in 
non-cytosolic form, I performed a membrane fractionation experiment to check if LC3-I is 
associated with the membranous fraction within the autophagy-impaired ATG9 and ATG16 
knockout cells (Fig 5.3). The membrane fraction obtained using the protocol consists of the 
total membrane constituent of the cells excluding the nuclear membrane fraction. The purified 
membranous fraction was checked for purity using calnexin as a marker while tubulin was used 
as a marker to assess the purity of the cytosolic fraction. Interestingly, LC3-I was seen to be 
associated with the membranous fraction in both ATG16 knockout and ATG9 knockout cells. 
Furthermore, quantification of the normalised ratio of LC3-I/Calnexin, which indicates the 
association of LC3-I with the membrane fraction, in the ATG9 and ATG16 knockout cells 
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showed a statistically significant increase in the knockout cells compared to their respective 
control cells. In addition, the ATG16 knockout cells showed much lower LC3-II/Calnexin ratio 
compared to control cells and is consistent with the fact that these cells only consist of LC3-I 
(Fig 5.3). This result potentially indicates that LC3-I is being recruited to the membrane prior 
to its lipidation to LC3-II. It is also worth noting that the ATG9 knockout cells showed much 
higher overall LC3 levels than ATG9 control cells. But, the statistics for LC3-II/Calnexin for 
ATG9 knockout cells show the difference in the ratios to be non-significant due to high 
variance between repeats. A possible reason that might explain this is that ATG9 knockout 
cells possess a residual level of autophagy and therefore the LC3-II levels in these cells on a 
western blot represents a snapshot of the LC3-II association with membrane. This can be 
confusing and highly variable based on the stimuli that cells receive prior to lysis and/or the 
phase of the cell cycle the cells are in. 
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Fig 5.2: a), b) Representative immunofluorescence images showing the GFP-LC3G120A and early endosomal 
marker, EEA1 staining in representative ATG9 and ATG16 knockout cells with their respective controls. Cells 
were fixed with PFA and stained with antibodies against endogenous EEA1 and GFP signal. c) Representative 
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immunofluorescence images showing constitutively active Rab5Q79L-GFP and endogenous LC3 staining in 
representative ATG16 control and knockout cells. Cells were fixed with PFA and stained with antibodies against 
endogenous LC3 (Abcam®). d) Representative immunofluorescence images showing Myc-LC3G120A-ΔC22 
staining in autophagy impaired ATG9 and ATG16 knockout cells. Cells were fixed with PFA and stained with 
antibody against the myc-tag. The scale bar represents a distance of 10 µm. e) Representative 
immunofluorescence images showing LC3 and lipid droplets stained using BODIPY stain in representative ATG9 
and ATG16 knockout cells. Cells were fixed with PFA and stained with antibodies against endogenous LC3 and 
BODIPY. f) Representative immunofluorescence images showing LC3 and the recycling endosome marker, 
RAB11 staining in representative ATG9 and ATG16 knockout cells. Cells were fixed with PFA and stained with 
antibodies against endogenous LC3 and RAB11. It is worth noting that the mouse monoclonal antibody for 
endogenous LC3 staining works well only under methanol fixed conditions however, the endogenous RAB11 
antibody does not work under methanol fixed conditions. Therefore, the cells had to be fixed with PFA, which 
made the LC3 puncta less visible. The scale bar represents a distance of 10 µm. 
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Fig 5.3:  Representative western blot to check the association of LC3-I with membranous fraction in the 
autophagy-impaired cells viz. ATG9 and ATG16 knockout cells using a membrane fractionation protocol. The 
membrane fraction here represents total membrane constituent of the cells except the nuclear fraction. To confirm 
the purity of these fractions, tubulin was used as a purity marker for the cytosolic fraction while calnexin was used 
as a purity marker for the membrane bound fraction. The graphs represent the quantification and plots of the 
normalised ratios of LC3-I/Calnexin and LC3-II/Calnexin for the membrane fraction. It is worth noting that the 
levels of LC3-I associated with the membrane fraction are consistently higher in the knockout cells compared to 
control cells and are statistically significant. Also, the ATG16 knockout cells show no presence of LC3-II in 
soluble or membrane fractions with statistically significant quantification values. The statistics for LC3-
II/Calnexin, however, show the difference in the ratios to be non-significant due to high variance between repeats. 
A possible reason that might explain the variance between the repeats is that since the ATG9 knockout cells 
possess a residual basal level of autophagy, the LC3-II levels in these cells on a western blot represents a snapshot 
of the LC3-II association with membrane. This can be confusing and highly variable based on the stimuli that 
cells receive prior to lysis and/or the phase of the cell cycle the cells are in.  
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5.4. The LC3-I structures are p62 positive 
 
Since the observed structures did not co-localise with most of the conventional endosomal 
markers, I checked whether these LC3-I positive structures co-localise with p62. Since the cells 
are autophagy-impaired, I expected LC3 to be not associated with p62 in ATG16 knockout 
cells due to the lack of LC3 lipidation and hence, functional autophagy (Bento et al., 2016b). 
However, immunofluorescence studies showed that these structures showed high co-
localisation with p62 in both ATG9 knockout and ATG16 knockout cells (Fig 5.4 a). These 
p62 structures looked like p62 aggregates which have formed as a result of defective 
autophagy. Recent studies have shown that p62 aggregate formation is accelerated under the 
presence of ubiquitinated substrates (Ciuffa et al., 2015; Zaffagnini et al., 2018), therefore I 
checked whether these p62 structures are positive for ubiquitin. Indeed, the 
immunofluorescence imaging showed that these p62 aggregates formed in ATG9 knockout and 
ATG16 knockout cells were positive for ubiquitin (Fig 5.4 b). 
 
To further understand the morphology of the p62 aggregates and the localisation of LC3 within 
the aggregates, I performed super-resolution microscopy on the ATG9 and ATG16 knockout 
cells stained for endogenous LC3 and p62 (Fig 5.5 a, b and c). The images showed the presence 
of LC3 in association with the p62 aggregates. The aggregates were much smaller in ATG9 
knockout cells compared to ATG16 knockout cells. Moreover, some ATG16 knockout cells 
showed much larger aggregates but the number of these cells in the population was few. It 
could also be seen that smaller p62 aggregates are associated with more LC3 compared to 
larger p62 aggregates, which had fewer LC3 molecules associated with them. This is consistent 
with the observations from a recent study, that showed that the p62 aggregates need 
ubiquitinated-substrates to oligomerise and higher levels of LC3 inhibit the growth of the p62 
aggregates (Zaffagnini et al., 2018). 
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Fig 5.4: a) Representative immunofluorescence images showing the co-localisation of LC3-positive structures in 
autophagy-impaired cells with p62. Cells were fixed with PFA and stained with antibodies against endogenous 
LC3 and p62. Please note that the LC3 antibody used here is the rabbit monoclonal antibody (Abcam) which 
needs the samples to be fixed with PFA b) Representative immunofluorescence images showing the co-
localisation of p62 structures in autophagy-impaired cells with ubiquitin. Cells were fixed with PFA and stained 
with antibodies against endogenous p62 and ubiquitin. The scale bar represents a distance of 10 µm. 
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Fig 5.5: a) Representative super-resolution immunofluorescence images showing the co-localisation of LC3-
positive structures with p62 in ATG9 knockout cells. Cells were fixed with PFA and stained with antibodies 
against endogenous LC3 (Abcam®) and p62. b) Representative super-resolution immunofluorescence images 
showing the co-localisation of LC3-positive structures with p62 in ATG16 knockout cells. Cells were fixed with 
PFA and stained with antibodies against endogenous LC3 and p62. c) Representative super-resolution 
immunofluorescence images showing the co-localisation of LC3-positive structures with p62 in ATG16 knockout 
cells. Cells were fixed with PFA and stained with antibodies against endogenous LC3 and p62. 
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5.5. p62 depletion reduces the number and decreases the size of the LC3-
positive puncta 
 
To understand whether p62 is responsible for formation of these LC3-I puncta under 
autophagy-impaired conditions, I depleted the levels of the endogenous p62 using SMARTpool 
siRNA and checked the size and number of LC3 positive structures in ATG9 and ATG16 
knockout cells. 
 
Interestingly, the observed LC3-I positive structures under autophagy-impaired conditions 
decrease in number and size upon p62 depletion (Figs 5.6 and 5.7 a, b and c). The effect was 
more pronounced in ATG16 knockout cells where the cells show only cytosolic LC3 staining 
and no LC3-I structures whatsoever. This observation indicates that p62 aggregates formed 
under autophagy-impaired conditions are able to bind to LC3-I and form LC3-positive 
structures. It is worth noting that while the levels of p62 in ATG9 knockout cells are lower than 
control cells in this western blot other repeats of the experiment show the levels to be the same. 
This possibly indicates that ATG9 knockout cells show the presence of residual autophagy and 
ATG9 is not absolutely essential for autophagy. On the contrary, the levels of p62 in ATG16 
knockout cells show a clear increase compared to control indicating that ATG16 is 
indispensable for the process.  
 
My results, therefore, show the drawbacks of LC3 immunofluorescence as an autophagy assay 
when designing experiments involving autophagy-impaired conditions or autophagy-null cells. 
 
 
5.6. p62 overexpression increases the number of LC3-I positive vesicles in 
ATG16 knockout cells 
 
To assess whether the effect of p62 knockdown on LC3-I positive structures is specific, a 
reverse approach involving the p62 overexpression was used. The idea behind this experiment 
was that if p62 aggregation results in the LC3-I binding and vesicle formation, overexpression 
of a functional p62 protein in the cells would result in an accumulation of these LC3-I positive 
structures, thereby leading to an increase in the observed number of LC3-I vesicles. As 
expected the number of LC3-I positive structures increased dramatically on p62 overexpression 
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and it was observed that the area of the p62 aggregates and LC3-I vesicles also increased (Fig 
5.8 a and b). Furthermore, a lot more smaller aggregates led to the formation of smaller LC3-I 
structures, which led to an overall decrease in the average size of the LC3-I vesicles, owing to 
which I observed no apparent change in the average size of the LC3-I vesicles on p62 
overexpression (Fig 5.8 b). 
 
Overall my results identify a novel potential homeostatic role of p62 in autophagy-impaired 
cells. While p62 has been shown to aid cytoplasmic inclusion formation in autophagy-impaired 
conditions (Komatsu et al., 2007), in this situation the cytoplasmic inclusions formed by the 
excess LC3-I due to its association with p62 is being targeted for degradation to maintain 
cellular homeostasis. This mechanism, therefore, regulates the cellular levels of LC3 under 
autophagy-impaired conditions via its sequestration into aggregates by p62 and hence, its 
probable degradation by the proteasomal pathway. 
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Fig 5.6: a) Representative immunofluorescence images showing the morphology of LC3-I positive structures 
under control and p62 knockdown conditions in representative ATG9 knockout cells. Cells were fixed with PFA 
and stained with antibodies against endogenous LC3 and p62. b) Quantification of the LC3-positive structures’ 
size and number under control and p62 knockdown conditions using ImageJ quantification tool (** = p < 0.01, 
*** = p < 0.001). Quantification performed from 3 experiments with at least 25 cells quantified for each condition. 
The error bars represent standard deviation (SD). c) Western blot showing that the knockdown of p62 was 
successful in ATG9 control and knockout cells. It is worth noting that while the level of p62 in ATG9 knockout 
cells are lower than control cells in this western blot, similar repeats show the levels to be the same. This possibly 
indicates that ATG9 knockout cells show the presence of residual autophagy and ATG9 is not absolutely essential 
for autophagy. The scale bar represents a distance of 10 µm. 
0
5
10
15
20
25
30
35
40
45
50
cont KD p62 KD
ATG9 KO
A
ve
ra
ge
 n
o
 o
f 
LC
3
 d
o
ts
/c
e
ll
*** 
0
0.5
1
1.5
2
2.5
3
cont KD p62 KD
ATG9 KO
A
ve
ra
ge
 s
iz
e
 o
f 
LC
3
 d
o
ts
 (
m
m
2 )
* 
a) 
b) 
c) 
kDa 
Control KD si-p62 
Tubulin 
p62 
55 
55 
70 
Sc
ra
m
b
le
d
 K
D
 
p
6
2
 K
D
 
A
TG
9
 K
O
 
DAPI LC3 p62 Merge 
91 
 
 
  
 
Fig 5.7: a) Representative immunofluorescence images showing the morphology of LC3-I positive structures 
under control and p62 knockdown conditions in ATG16 knockout cells. Cells were fixed with PFA and stained 
with antibodies against endogenous LC3 and p62. b) Quantification of the LC3-positive structures’ size and 
number under control and p62 knockdown conditions using ImageJ quantification tool (** = p < 0.01, *** = p < 
0.001). Quantification performed from 3 experiments with at least 25 cells quantified for each condition. The error 
bars represent standard deviation (SD). c) Western blot showing that the knockdown of p62 was successful in 
ATG16 control and knockout cells. The levels of p62 are higher in the ATG16 knockout cells confirming that 
ATG16 is indispensable for autophagy. The scale bar represents a distance of 10 µm. 
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Fig 5.8: a) Representative immunofluorescence images showing the morphology of LC3-I positive structures 
under control and p62 overexpression conditions in representative ATG16 knockout cells. Cells were fixed with 
PFA and stained with antibody against endogenous LC3. b) Quantification of the LC3-positive structures’ total 
area and number under control and p62 overexpression conditions using ImageJ quantification tool (* = p < 0.05, 
*** = p < 0.001, n.s = non-significant).  Quantification performed from 3 experiments with at least 25 cells 
quantified for each condition. The error bars represent standard deviation (SD). The scale bar represents a distance 
of 10 µm. 
 
 
LC3 p62 Merge 
Em
p
ty
 G
FP
 
p
6
2
-G
FP
 
A
TG
1
6
 K
O
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
empty p62 O.E.
ATG16 KO
A
ve
ra
ge
 t
o
ta
l a
re
a 
o
f 
LC
3
 p
u
n
ct
a/
ce
ll 
(i
n
ch
2 )
*** 
0
5
10
15
20
25
empty p62 O.E.
ATG16 KO
A
ve
ra
ge
 n
u
m
b
e
r 
o
f 
LC
3
 p
u
n
ct
a/
ce
ll
* 
a) 
b) 
0
5
10
15
20
25
30
35
empty p62 O.E.
ATG16 KO
A
ve
ra
ge
 s
iz
e
 o
f 
LC
3
 v
e
si
cl
e
s/
ce
ll 
(m
m
2 )
n.s 
93 
 
 
 
  
p62 LC3 Merge 
C
o
n
tr
o
l K
D
 
si
-A
TG
7
/s
i-
A
TG
1
0
 
a) 
b) 
c) 
GAPDH 
ATG7 
ATG10 
55 
55 
70 
100 
kDa 
55 
kDa 
16 
GAPDH 
LC3-II 
(Low exposure) 
(-) BAF (+) BAF 
LC3-I 
LC3-II 
(High exposure) 16 
94 
 
 
 
 
 
Fig 5.9: a) Representative immunofluorescence images showing the morphology of LC3-positive structures under 
control and ATG7/10 knockdown conditions in representative HeLa cells. Cells were fixed with PFA and stained 
with antibody against endogenous LC3 (Abcam®) and p62. b) Representative western blot showing the changes 
in the levels of LC3-I and LC3-II in HeLa cells upon ATG7/ATG10 knockdown compared to control. The longer 
exposure of the blot is shown to facilitate the visualisation of the LC3-I band. c) Representative western blot 
showing the efficiency of ATG7/ATG10 knockdown. d) Quantification of the LC3-II/GAPDH ratio for the 
control and ATG7/10 knockdown conditions in the absence and presence of BAF showing an impaired autophagic 
response upon ATG7/10 knockdown in HeLa cells. e), f) Quantification of the LC3-positive structures’ area and 
number, respectively, under control and ATG7/10 knockdown conditions using ImageJ quantification tool (* = p 
< 0.05). Quantification was performed from 3 experiments with at least 20 cells quantified for each condition. 
The error bars represent standard deviation (SD). The scale bar represents a distance of 10 µm.  
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5.7. The number and area of LC3-positive structures increase upon 
autophagy impairment in HeLa cells 
 
To further test whether the cells knocked down for essential autophagy genes would show 
similar phenotype, I knocked down the ATG7 and ATG10 autophagy proteins. These two 
proteins, as mentioned in the introduction section, are responsible for the conjugation of ATG5-
ATG12, which is indispensable for LC3 lipidation and hence autophagosome biogenesis. As 
mentioned earlier, p62 aggregates have been shown to sequester the E1-like ATG7 enzyme. It 
has also been shown that this sequestration is mediated via the interaction of LC3-I with ATG7 
and that while p62 shows preferential binding towards LC3-II, it is indeed capable of binding 
to the lipidation defective LC3-G120A mutant (Gao et al., 2013). Therefore, my observations 
and results of the experiments mentioned so far in this chapter together with the existing 
literature point towards the LC3-I association with p62 under autophagy-impaired conditions. 
And if this hypotheses were correct, I would expect a decrease in the levels of LC3-II on 
western blot but an increase in the number and overall area of LC3 puncta in the cells. Indeed, 
upon siRNA mediated depletion of two core autophagy proteins ATG7 and ATG10 for 48 
hours the levels of LC3-II, tested using western blotting, under knockdown conditions decrease 
compared to control (scrambled siRNA) (Fig 5.9 a, b, c and d). Interestingly, on imaging these 
cells for LC3-puncta there was a corresponding increase in the number of LC3-positive 
structures and the overall area of these structures under knockdown conditions was much 
higher (Fig 5.9 e and f). The results of this experiment thereby depict why immunofluorescence 
studies on cells knocked down for essential autophagic genes can be potentially misleading. 
 
The possible scenarios of LC3-I sequestration by p62 in cells with functional, impaired or 
abrogated autophagy have been described schematically in Fig 5.10 for reference. 
Conventionally, the LC3-I molecules are lipidated to LC3-II that marks the autophagosomes 
and hence, as mentioned above, LC3 immunocytochemistry is a widely technique used for 
quantifying the number of autophagosomes in the cells at a given time. Upon autophagy 
impairment or abrogation, however, the p62 levels increase that lead to the sequestration of 
excess of LC3-I from the cytosol into the insoluble aggregates. While these structures show an 
increase in the size compared to conventional autophagosomes, they still could easily be 
confused for mature autophagosomes to an untrained eye while performing LC3 
immunocytochemistry, thereby confounding the recorded results. 
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Fig 5.10: A schematic describing the process of LC3-I molecule sequestration by the p62 aggregates in autophagy-
impaired and autophagy-null cells. The process of autophagy involves the lipidation of the cytosolic form of LC3 
viz. LC3-I on to a phosphotidylethanolamine molecule (located on the growing phagophore) to form LC3-II. The 
visualisation of LC3-II molecules using immunocytochemistry techniques are therefore considered to be a gold-
standard assay to assess the autophagosome number in cells. Under conditions where autophagy is fully 
functional, LC3-I molecules get lipidated to form LC3-II, which primarily results in the recruitment of 
ubiquitinated p62 molecules attached to cargoes destined for degradation to the growing autophagosomes. The 
LC3-II molecules then get recycled/degraded to replenish the pool of cytosolic LC3-I in these cells. However, 
under conditions where LC3-I accumulates in cells as a result of autophagic impairment or complete abrogation, 
p62 aggregates formed as a result of dysfunctional autophagy sequester the excess LC3-I molecules forming 
structures that resemble mature autophagosomes in autophagy-impaired and autophagy-null cells. While these 
strcutures show an increased size compared to conventional autophagosomes, their presence might mislead an 
untrained eye and might result in recording of confounding results.  
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To summarize, my results in this chapter identify a new role for p62 in autophagy-impaired 
cells. I begin with showing the aberrant accumulation of LC3-positive structures in autophagy-
impaired cells. I confirm this observation by exogenously expressing non-conjugatable forms 
of LC3 in autophagy-null cells. I then proceed to show that these LC3-positive structures show 
co-localisation with p62 in autophagy-null cells and depletion of endogenous p62 in these cells 
abrogates formation of the LC3-positive structures. I then show that overexpression of p62 in 
autophagy-null cells increase the number and area of the LC3-positive structures observed. 
Finally, I show that an experimental setup involving depletion of core autophagy proteins 
ATG7 and ATG10 results in lower levels of LC3-II on blots but higher number and total area 
of LC3-positive structures in cells. These results together suggest that p62 associates with LC3-
I under autophagy-impaired conditions that results in the formation of LC3-positive structures 
in these cells. Therefore, one must be careful while interpreting results from an LC3 
immunofluorescence experiment since these LC3-I structures could be mistaken for mature 
autophagosomes confounding the outcome of the experiment.  
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6. Studying ATG9 and VMP1 trafficking in HeLa cells 
 
As mentioned earlier in the introduction section, the trafficking of ATG9 and VMP1 remains 
to be completely explored and understood. Moreover, the relationship between these two 
transmembrane proteins has not been described yet. Therefore, I aimed to explore new 
trafficking route for these proteins and understand the relation between these proteins. The 
results will now be described in this chapter. 
 
6.1. VMP1 traffics through the plasma membrane 
 
VMP1 is a transmembrane protein with a noticeable cytosolic domain, similar to the core 
autophagy protein, ATG9 (Fig 1.4). It has been shown that ATG9 traffics via plasma membrane 
to early and recycling endosomes during autophagosome formation (Puri et al., 2013; Puri et 
al., 2018). Therefore, I checked whether VMP1 traffics via the same route. To begin with, I 
performed plasma membrane protein extraction (see methods) and checked for the presence of 
VMP1 in the extracted fraction. It was observed that VMP1 is present in the protein pool 
extracted from the plasma membrane (Fig 6.1 a). Next, to confirm the above observation, I 
performed a cell-surface biotinylation experiment to test the presence of VMP1 on the plasma 
membrane. In this experiment, I also tested whether the levels of VMP1 change when the cells 
were treated with different conditions like basal, starvation and the dynamin inhibitors, 
dynasore and dyngo. The rationale behind using dynamin-inhibitors was to identify whether 
VMP1 travels from the plasma membrane into the cells via trafficking route similar to ATG9. 
Consistent with the above observation, it was seen that VMP1 is present on the plasma 
membrane (Fig 6.1 b). Unfortunately, the beads showed some non-specific affinity towards 
VMP1 which can be seen in the negative control and was consistent across the repeats. 
However, since the positive control for the experiment, NHE1 – a plasma membrane resident 
sodium-hydrogen antiporter 1, showed no pull down in the negative control (Fig 6.1 c) and the 
observed difference in the levels of pulled-down VMP1 was significantly higher in biotinylated 
samples compared to negative control, the pull down of biotinylated VMP1 was specific. It is 
also worth noting that the levels of VMP1 at the plasma membrane in cells treated with the 
inhibitors of dynamin showed no difference (Fig 6.1 b). 
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6.2. VMP1 traffics through early and recycling endosomes 
 
The next step towards the characterisation of VMP1 trafficking was to check the co-localisation 
of VMP1 with the endosomal markers for early and recycling endosomes, viz. EEA1 and 
RAB11A respectively. In addition, based on a recent study that proposes recycling endosomes 
as the platform for autophagosome formation (Puri et al., 2018), the co-localisation of VMP1 
with RAB11A and BECN1 would also indicate its role in autophagosome formation. It was 
observed that VMP1 co-localises with the endosomal markers EEA1 and RAB11A (Fig 6.2 a 
and b). At the recycling endosomes, VMP1 was also seen to co-localise with BECN1, an early 
autophagy protein known to be associated with recycling endosomes. (Puri et al., 2018). The 
co-localisation between VMP1, RAB11A and BECN1 could be clearly visualised by plotting 
the intensities of various channels as a function of distance using the ZEN imaging software 
(Fig 6.2 c). The results from the section 6.1 and 6.2 therefore suggest that VMP1 may follow 
a similar trafficking route like ATG9 as it localises to plasma membrane, early and recycling 
endosomes. 
 
6.3. VMP1 interacts with ATG9 
 
After confirming that both ATG9 and VMP1 traffic through the endosomal pathway and the 
plasma membrane, I speculated whether the two proteins would physically interact. I, therefore, 
immunoprecipitated endogenous VMP1 and the checked the IP sample for the presence of 
ATG9. Interestingly, ATG9 was seen to co-immunoprecipitate with VMP1. The 
immunoprecipitation was then performed the other way around and it was seen that VMP1 co-
immunoprecipitates with ATG9 in the IP sample (Fig 6.3 a and b). In addition, when VMP1-
GFP was overexpressed in HeLa cells, endogenous ATG9 co-immunoprecipitates with VMP1-
GFP and similarly, overexpressed VMP1-GFP co-immunoprecipitates with endogenous 
ATG9, further confirming the interaction between the two proteins (Fig 6.3 c and d). It was 
also observed that overexpressed VMP1 showed varying mobility/molecular weight on western 
blots between various experimental repeats. Upon excluding the obvious possibilities such as 
non-specific antibody binding and breakdown products, it was concluded that the 
overexpressed VMP1 potentially undergoes reversible post-translational modifications that 
affect its mobility on the gel. Based on the molecular weight shift, it could be likely that 
overexpressed VMP1 is glycosylated in HeLa cells.  
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Fig 6.1 a) Representative western blot depicting the presence of VMP1 in plasma membrane fraction after 
extraction using the Abcam® plasma membrane protein extraction kit. b) Representative western blots of the 
repeats showing the presence of VMP1 on the plasma membrane using the cell-surface biotinylation assay. The 
experiment is based on isolating the biotinylated proteins on the plasma membrane by exploiting the high affinity 
interaction between biotin and streptavidin. Different conditions were tested to check enrichment of VMP1 on the 
plasma membrane upon varying stimuli. c) Representative western blot depicting the pull-down of the biotinylated 
cell-surface sodium-hydrogen antiporter1 (NHE1), acting as a positive control for the biotinylation experiment. 
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Fig 6.2 a) Representative immunofluorescence images showing the co-localisation of VMP1 with the early 
endosomal marker, EEA1. b) Representative immunofluorescence images showing the co-localisation of VMP1 
with the recycling endosomal marker, RAB11 and the core autophagy protein, BECN1. c) Intensities of RAB11, 
BECN1 and VMP1 channels plotted as a function of distance, measured using ZEN Imaging software by Zeiss. 
The scale bar represents a distance of 10µm. 
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6.4. VMP1 overexpression induced autophagy is ATG9-dependent 
 
The first study that described VMP1 as an autophagy protein, also showed that its 
overexpression results in the induction of autophagy. The studies were conducted in the context 
of a condition called acute pancreatitis, which shows higher levels of VMP1 expression 
(Ropolo et al., 2007). However, since then, not much has been described about VMP1 
overexpression induced autophagy. I show that not only does VMP1 physically interact with 
ATG9 (Section 6.3), but also that the VMP1-overexpression induced autophagy is ATG9-
dependent. When VMP1 was overexpressed in the ATG9 knockout cells, there was no increase 
in the autophagic flux compared to control cells (Fig 6.4 a and b). 
 
 
 
Fig 6.3 a) Representative western blot showing the co-immunoprecipitation of VMP1 with ATG9. b) 
Representative western blot showing the co-immunoprecipitation of ATG9 with VMP1. c) Representative western 
blot showing the co-immunoprecipitation of ATG9 with VMP1-GFP. d) Representative western blot showing the 
co-immunoprecipitation of VMP1-GFP with ATG9. It is worth noting that the band of VMP1-GFP shows a slight 
variation in the size between experiments. This observation potentially indicates that VMP1 undergoes some post-
translational modifications in the cell, with glycosylation being a primary form of modification. 
VMP1 
148 
98 
50 
ATG9 
kDa 
148 
98 
98 
kDa 
64 
ATG9 
VMP1-GFP 
ATG9 
VMP1-GFP 
148 
98 
98 
kDa 
64 
ATG9 
VMP1 
148 
98 
50 
kDa a) 
b) 
c) 
d) 
103 
 
 
 
Fig 6.4 a) Representative western blot showing that the induction of autophagy on VMP1 overexpression is ATG9 
dependent and can be seen in the presence of BAF. b) Quantification of the western blot performed using the 
LICOR-imaging software. The data is from the quantification of two experiments in triplicates and the error bars 
represent SEM. (* = p < 0.05, n.s = non-significant) 
 
6.5. VMP1 trafficking is dynamin-independent 
 
As observed in Fig 6.1 b, VMP1 does not accumulate on the plasma membrane under 
conditions of dynamin inhibition. I confirmed this observation by treating the cells with the 
dynamin inhibitor, dynasore, and checking the co-localisation between the adaptor protein AP2 
and endogenous VMP1, using TIRF microscopy. The protein AP2 is a member of the clathrin 
adaptor-family of proteins that is known to help with the endocytic trafficking of 
transmembrane and membrane-associated proteins together with the help of clathrin. 
Consistent with the previous observation, VMP1 did not seem to accumulate on the plasma 
membrane and co-localise with AP2 on dynasore treatment (Fig 6.5 a and b). The inhibitory 
effect of dynasore was confirmed by checking the uptake of labelled transferrin ligand into the 
cells (Fig 6.5 c). Since dynamin is an important component of the pathways like clathrin-
mediated and caveolin-mediated endocytosis, I tested whether VMP1 traffics through 
dynamin-independent endocytic pathways. There are 2 major dynamin-independent endocytic 
pathways identified till date, namely ARF6-associated and the CLIC/GEEC pathway.  
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ARF6-pathway relies on the activation and inactivation of ARF6, a small molecule GTPase. 
More specifically, it was shown that in most cases, ARF6 activation was required for the 
recycling cargo whereas its inactivation is required for the sorting of the cargo after its 
internalisation. The CLIC/GEEC pathway on the other hand, requires the activities of GRAF1 
and ARF1. This pathway is mainly responsible for the internalisation of lipid-anchored proteins 
such as GPI-anchored proteins and fluid phase endocytosis (Mayor et al., 2014).  
 
Based on this information, I tested if VMP1 traffics via one of these dynamin-independent 
endocytic pathways. The standard method used to detect whether a protein traffics via the 
ARF6 pathway is to check whether the protein of interest co-localises with ARF6 and its 
mutants. The GTP-binding defective mutant, ARF6-T27N, localises to tubular membrane 
compartment while the constitutively active mutant, ARF6-Q67L, localises to internal vacuolar 
compartment enriched in PIP2 (phosphatidylinositol-4,5-bisphosphate). Additionally, the cells 
could be treated with the actin inhibitor cytochalasinD (cytoD) which shifts the distribution of 
ARF6 to a tubular membrane compartment that origins from juxtanuclear region of the cells, 
that  resembles the phenotype observed on the overexpression of ARF6-T27N (Radhakrishna 
and Donaldson, 1997). A control that is also quite commonly used to test the ARF6-pathway 
is to treat the cells with the inhibitor, BrefeldinA (BFA). BFA is known to inhibit ARF1 but 
not ARF6, therefore, the localisation of the protein of interest should not change (Donaldson, 
2003; Mayor et al., 2014; Radhakrishna and Donaldson, 1997). Based on the above 
information, I observed that VMP1 co-localises with ARF6-GFP, ARF6-T27N-GFP and 
ARF6-Q67L-GFP. It was also observed that VMP1 co-localises with overexpressed ARF6-
GFP under cytoD treated conditions and its localisation does not change under BFA treated 
conditions (Fig 6.6). Furthermore, VMP1 co-localises with MHC-I, which is a known cargo 
protein that traffics via ARF6-associated pathway (Radhakrishna and Donaldson, 1997) and 
the co-localisation of VMP1 with MHC-I does not change upon its treatment with cytoD (Fig 
6.7 a). In addition, the co-localisation of VMP1 with endogenous ARF6 under cytoD treated 
conditions shows a small but non-significant increase compared to DMSO (Fig 6.7 b). 
However, it is important to note that the antibodies for both endogenous MHC-I and ARF6 
have a very diffuse cytosolic staining, skewing the co-localisation under untreated conditions 
towards higher levels, thereby making the magnitude of difference in co-localisation between 
proteins lower (Fig 6.7 a and b). 
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6.6. ATG9 also traffics via ARF6-associated endocytic pathway 
 
Since I identified that VMP1 traffics through the dynamin-independent ARF6-associated 
endocytic pathway and that it physically interacts with ATG9, I tested whether ATG9 traffics 
through the ARF6-associated pathway too. Studies till date have identified ATG9 trafficking 
only through the dynamin and clathrin-dependent endocytic routes from the plasma membrane 
(Puri et al., 2013). Interestingly, ATG9 co-localises with ARF6-GFP, ARF6-T27N-GFP and 
ARF6-Q67L-GFP, indicating that it also traffics through the ARF6-associated dynamin-
independent endocytic pathway (Fig 6.8). In addition, the distribution of ATG9 changes 
completely on treatment of cells with cytoD and it resembles the distribution pattern of ARF6-
GFP, with no change in this distribution on treatment with brefeldin A (Fig 6.8). Furthermore, 
ATG9 also co-localises with MHC-I under DMSO and cytoD treatment, with the co-
localisation increasing under the cytoD treated conditions (Fig 6.9 a). However, since the co-
localisation of ATG9 and MHC-I under basal state is very high, the magnitude of increase in 
co-localisation between ATG9 and MHC-I is non-significant. Furthermore, ATG9 was also 
seen to co-localise with endogenous ARF6. However, when the cells were treated with cytoD 
to disrupt ARF6 pathway the co-localisation of ATG9 with ARF6 decreased, indicating that 
this might not be the predominant trafficking pathway for ATG9 in the cells (Fig 6.9 b). Finally, 
ATG9 was also seen to co-localise with VMP1-GFP and ARF6-T27N-HA confirming they co-
traffic via this pathway (Fig 6.10 a). 
 
Finally, in addition to the ARF6-mediated endocytic pathway, VMP1 was also seen to co-
localise with GRAF1-BAR-PH-GFP (GRAF1 missing the GAP, proline rich and SH3 domain), 
a protein that acts in dominant-negative fashion and labels stabilised early endosomal tubular 
structures (Fig 6.10 b) (Lundmark et al., 2008). However, further experiments need to be 
performed to confirm if VMP1 traffics via the CLIC/GEEC pathway in addition to ARF6-
associated endocytic pathway. It is also worth noting that these observations are consistent with 
the previous study showing the role of ARF6 and GRAF1 proteins in autophagy regulation 
(Moreau et al., 2012). 
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Fig 6.5 a) Representative immunofluorescence images showing the localisation of VMP1 and AP2 under DMSO 
and dynasore treated conditions using TIRF microscopy. b) Quantification of the mander’s co-localisation co-
efficient was performed using the Volocity quantification tool and the data was plotted (* = p < 0.05). 
Quantification performed from 3 experiments with at least 25 cells quantified for each condition. The error bars 
represent standard deviation (SD). c) Representative immunofluorescence images showing the effect of dynasore 
on labelled transferrin uptake. The scale bar represents a distance of 10µm. 
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Fig 6.6 Representative immunofluorescence images showing the localisation of VMP1 with ARF6-GFP, ARF6-
T27N-GFP, ARF6-Q67L-GFP and with ARF6-GFP under cytochalasinD and brefeldinA treated conditions. The 
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cytochalasinD treatment is known to resemble the phenotype of the cells upon ARF6-T27N-GFP overexpression, 
whereas treatment with brefeldinA was used as a control due to its specificity against ARF1 and not ARF6. The 
co-localisation pixels were identified and a profile was generated using an unsupervised ImageJ plugin algorithm 
called colocalization, which was developed by Pierre Bourdoncle (Institut Jacques Monod, Service Imagerie, 
Paris; 2003-2004). The algorithm allows manual thresholding of the acquired images that facilitates the 
elimination of background noise based on pixel intensities of different channels to generate a profile with grey 
pixels representing co-localisation of the markers. Briefly, the cells were fixed with PFA, labelled and imaged for 
endogenous VMP1 and the overexpressed GFP signal. The co-localisation between the two channels was then 
visualised by looking at the grey pixels in the co-localisation pixels panel. As mentioned above, the grey pixels 
represent the identified pixels above threshold that are present in both green and red channels and therefore, 
represents co-localisation between the used markers. The scale bar represents a distance of 10µm. 
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Fig 6.7 a) Representative immunofluorescence images showing the co-localisation of VMP1 with MHC-I under 
DMSO and cytochalasinD treated conditions. b) Representative immunofluorescence images showing the co-
localisation of VMP1 with endogenous ARF6 under DMSO and cytochalasinD treated conditions (n.s = non-
significant). Quantification performed from 3 experiments with at least 25 cells quantified for each condition. The 
error bars represent standard deviation (SD). The scale bar represents a distance of 10µm. 
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Fig 6.8 Representative immunofluorescence images showing the localisation of ATG9 with ARF6-GFP, ARF6-
T27N-GFP, ARF6-Q67L-GFP and with ARF6-GFP under cytochalasinD and brefeldinA treated conditions. The 
cytochalasinD treatment is known to resemble the phenotype of the cells upon ARF6-T27N-GFP overexpression, 
whereas treatment with brefeldinA was used as a control due to its specificity against ARF1 and not ARF6. The 
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co-localisation pixels were identified and a profile was generated using an unsupervised ImageJ plugin algorithm 
called colocalization, which was developed by Pierre Bourdoncle (Institut Jacques Monod, Service Imagerie, 
Paris; 2003-2004). The algorithm allows manual thresholding of the acquired images that facilitates the 
elimination of background noise based on pixel intensities of different channels to generate a profile with grey 
pixels representing co-localisation of the markers. Briefly, the cells were fixed with PFA, labelled and imaged for 
endogenous ATG9 and the overexpressed GFP signal. The co-localisation between the two channels was then 
visualised by looking at the grey pixels in the co-localisation pixels panel. As mentioned above, the grey pixels 
represent the identified pixels above threshold that are present in both green and red channels and therefore, 
represents co-localisation between the used markers. The scale bar represents a distance of 10µm. 
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Fig 6.9 a) Representative immunofluorescence images showing the co-localisation of ATG9 with MHC-I under 
DMSO and cytochalasinD treated conditions. b) Representative immunofluorescence images showing the co-
localisation of ATG9 with endogenous ARF6 under DMSO and cytochalasinD treated conditions (* = p <0.05, 
n.s = non-significant). Quantification performed from 3 experiments with at least 25 cells quantified for each 
condition. The error bars represent standard deviation (SD). The scale bar represents a distance of 10µm. 
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Fig 6.10 a) Representative immunofluorescence images showing the co-localisation of ATG9 with VMP1-GFP 
and ARF6-T27N-HA. b) Representative immunofluorescence images showing the co-localisation of VMP1 with 
GRAF1-BAR-PH-GFP. The GRAF1-BAR-PH-GFP (GRAF1 missing the GAP, proline rich and SH3 domain) 
protein overexpression acts in dominant-negative fashion and labels stabilised early endosomal tubular structures. 
The scale bar represents a distance of 10µm. 
 
a) 
b) 
ARF6-T27N-HA VMP1-GFP ATG9 Merge 
GRAF1-BAR-PH-GFP VMP1 Merge Co-localized pixels 
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To summarize, in this chapter I show that VMP1 traffics in the cell through plasma membrane, 
early endosomes and recycling endosomes. This trafficking pathway highly resembles the 
trafficking route of ATG9. I then show that these two transmembrane proteins physically 
interact with each other in the cell. Next, I show that the induction of autophagy on VMP1 
overexpression, as shown by previous studies, is dependent on the expression of ATG9 in the 
cells, since ATG9 knockout cells show no autophagy induction on VMP1 overexpression. 
Finally, I show that VMP1 trafficking is unaffected on dynamin-inhibition and that it traffics 
in the cells via dynamin-independent ARF6-associated pathway. I also show that ATG9 traffics 
via the same pathway and both ATG9 and VMP1 co-localise with ARF6-T27N mutant, MHC-
I and endogenous ARF6. A schematic depicting the proposed trafficking for ATG9 and VMP1 
via the ARF6-associated endocytic pathway has been shown in the Fig 6.11. 
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Fig 6.11 A schematic depicting the proposed trafficking route for the two transmembrane proteins ATG9 and 
VMP1. Current literature has established the trafficking of ATG9 via the dynamin-dependent pathway from the 
plasma membrane to early endosomes to recycling endosomes. At recycling endosomes, ATG9 was shown to 
meet ATG16 which also travels from the plasma membrane via a different route that was seen to be clathrin-
dependent and hence, dynamin-dependent, directly to recycling endosomes (Puri et al., 2013). My results from 
this thesis identify a dynamin-independent route for the trafficking of the autophagy proteins ATG9 and VMP1 
(a protein whose trafficking pathway remains unexplored). Different mutants were used during the study to block 
specific ARF6-mediated trafficking routes and their corresponding sites of action to block trafficking have 
therefore been shown in the schematic. Finally, MHC-I which is a known protein that traffics via ARF6-mediated 
pathway has been shown for better understanding of the process. Please refer to the legend for description of the 
various symbols used in the schematic. This schematic has been adapted from Sannerud et al. (2011). 
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7. Discussion 
 
In this chapter, I will discuss the results in context of the published literature and its impact on 
some of the hypotheses that exist in the field of autophagy. I will also try to present a few ideas 
based on my results that would need further experimentation for consolidation. 
 
7.1. Human ATG9 has multiple serine residues that undergo 
phosphorylation upon autophagic stimulation 
 
The role of various post-translational modifications, especially phosphorylation, in protein 
trafficking and function has been well-documented in the literature and some of the key 
phosphorylation events affecting the autophagic process have also been briefly described in 
section 1.6 of this thesis. The trafficking of the transmembrane autophagy protein, ATG9, was 
recently characterised and was shown to involve its movement from the plasma membrane to 
early endosomes, to finally meet ATG16 in recycling endosomes (Puri et al., 2013). Subsequent 
studies have then hypothesised recycling endosomes as a platform for de-novo autophagosome 
formation indicating a potential role of ATG9 and ATG16 in autophagosome formation (Puri 
et al., 2018). Therefore, understanding the regulation of trafficking of ATG9 from the plasma 
membrane to recycling endosomes could provide vital information about the events that 
regulate early stages of autophagosome formation. 
 
I, therefore, decided to test the role of phosphorylation in the regulation of ATG9 trafficking 
and my results from chapter 3 of this thesis indicate the presence of multiple phosphorylation 
sites on ATG9 which are potentially regulated by various stimuli, differentially. The results 
showed that under basal conditions, ATG9 was found to be potentially phosphorylated on 5 
different residues namely serine 14, 656, 735, 741 and 828. Similarly, under starvation, ATG9 
was observed to be phosphorylated on 4 different residues, namely serine 14, 656, 735, and 
828. Furthermore, upon stimulating the cells with trehalose, ATG9 was observed to be 
phosphorylated on 7 different residues namely serine 14, 18, 635, 735, 738, 741, and 828. Of 
these sites, only two residues (serine 14 and 18) were observed to be located on the N-terminus 
of ATG9 while the rest of the sites (serine 635, 735, 738, 741, and 828) were located at the C-
terminus. This might be in correlation with the shorter length of the N-terminal of ATG9 as 
opposed to the much longer C-terminal tail of the protein. It is also worth noting that ATG9 
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was observed to be phosphorylated on one residue less upon stimulating the cells with 
starvation compared to basal conditions. This might indicate towards a potential upregulation 
of the ATG9 function, and thereby autophagy, via dephosphorylation of a site. The role of 
phosphorylation, in general, implies an activation upon phosphorylation and deactivation upon 
dephosphorylation, of the substrate. Therefore, activation of ATG9 upon starvation via 
dephosphorylation could potentially indicate a rather unusual mode of regulation of ATG9 
function/activity.  
 
To test the importance of identified phosphorylation sites on ATG9, various non-
phosphorylatable and phospho-mimetic mutants were generated. These were then transfected 
in ATG9 CRISPR knockout cells to identify mutants that could rescue the LC3-II or LC3-I 
levels of these cells. However, upon examination of the expression levels of various ATG9 
mutants in these cells, it was observed that the level of expression of the mutant ATG9 proteins 
is affected by the state of phosphorylation of these sites. The results indicated that while these 
sites were thought to be the primary regulators of the trafficking, they might also be responsible 
for maintaining the stability of ATG9. Indeed, regulation of protein stability via 
phosphorylation of proteins has also been widely considered as an important cellular pathway 
regulating processes such as cell proliferation, apoptosis, etc (Xu et al., 2009). Therefore, 
studying the phosphorylation of ATG9 might provide us with information more than just the 
regulation of trafficking and could implicate ATG9 as a potential substrate for an important 
kinase in the various cellular signalling axes. 
 
Finally, my results, through mass spectrometry, indicated towards a kinase (PRKDC) that 
might be responsible for the potential phosphorylation of one or more sites on ATG9. This 
interaction was seen to be highly specific based when confirmed using other biochemical and 
immunofluorescence techniques. Interestingly, the identified kinase is known to be an 
important player regulating the repair mechanism upon DNA-damage and therefore, is known 
to primarily localise to the nucleus of the cell. However, the function of the cytosolic population 
of PRKDC remains unexplored. The specific interaction of PRKDC with the transmembrane 
protein ATG9 could therefore potentially hint towards one of its function in the cytosol. 
Furthermore, upon testing the ATG9 sequence for potential consensus sequences for various 
kinases, a potential site that resembles the consensus sequence for PRKDC was also found 
supporting the hypothesis of ATG9 phosphorylation by PRKDC under certain conditions. 
However, as the kinase performs an essential function in cell survival, various strategies to 
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decrease the activity of the kinase resulted either in cell death or accumulation of non-specific 
phenotypes in cells, thereby making the study of the effect of the potential phosphorylation by 
PRKDC on ATG9 difficult. Further experiments, perhaps involving the use of inducible 
PRKDC-knockout systems could facilitate the investigation of involvement of the kinase in the 
regulation of autophagy via ATG9 phosphorylation. 
 
7.2. p62 – a homeostasis maintaining protein in autophagy-
impaired cells 
 
One of the key requirements for maintaining cellular homeostasis is the removal of aggregated 
proteins since aggregated proteins are associated with the pathologies of various 
neurodegenerative conditions (Bento et al., 2016b). The eukaryotic cells remove the aggregated 
proteins via two primary pathways namely the ubiquitin-proteasome system (UPS) and 
autophagy. The UPS involves ubiquitination of the cargo destined for degradation, which is 
recognised by the proteasome and subsequently degraded. Autophagy, on the other hand, is 
known to engulf proteins and other cellular constituents, that could also be ubiquitinated, 
destined for degradation with the help of autophagy receptor proteins like p62 and their 
subsequent delivery to lysosomes for degradation. The ubiquitin linkage pattern on the 
substrate determines its fate of degradation either by UPS or autophagy. The current knowledge 
indicates that K48 linkage, the primary form of ubiquitination, is associated with UPS while 
K63 linkage is associated with autophagic degradation of the cargo. Studies have also shown 
that these degradative processes work together to maintain homeostasis, acting as a backup for 
each other (Lilienbaum, 2013). It is worth noting that while p62 plays a defined role in cells 
with functional autophagy (Bento et al., 2016b), its role in cells lacking autophagy remains 
unknown. In cells with functional autophagy, p62 as autophagy receptors but the autophagy 
receptor proteins also act as a substrate for autophagy themselves. A lack of functional 
autophagy, therefore, results in the accumulation of autophagy receptors such as p62. 
 
My results in chapter 5 of this thesis identify a potential role for p62 in autophagy-impaired 
cells. It was observed that cells with defective autophagy, due to lack of a core autophagy 
protein expression like ATG9 or ATG16, accumulate a lot more of the unconjugated-form 
(LC3-I) compared to PE-conjugated form (LC3-II). This effect is more pronounced in ATG16 
null cells due to the lack of functional lipidation machinery. Since LC3 is primarily degraded 
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by the autophagosomes fusing with lysosomes, a cell with defective autophagy would lead to 
a large accumulation of LC3. This could potentially result in formation of large aggregates in 
the cells that interfere with various cellular processes and homeostasis. My results show that 
under conditions where the ever-growing pool of LC3 cannot be degraded by autophagy, LC3 
(more specifically LC3-I) associates itself with p62. Since p62 forms aggregates which were 
seen to be ubiquitinated, it is likely that these aggregates are then directed for degradation by 
the UPS; however, more experiments need to be performed in order to confirm this hypothesis. 
This, therefore could be another example of the interplay between the process of autophagy 
and UPS to maintain cellular homeostasis. 
 
A gold standard way of measuring the autophagic synthesis in cells is to test the levels of LC3-
II in cells treated with or without drugs that block autophagosome-lysosome fusion such 
bafilomycin A1 (BAF). Autophagic flux measures the autophagic degradation activity and 
treating the cells with BAF inhibits the degradation and therefore, resulting in an accumulation 
of autophagosomes, making it a suitable assay to measure autophagic flux (Rubinsztein et al., 
2009). Another gold standard assay to check the effect of various experimental 
conditions/treatments on autophagy is via the staining, visualisation and subsequent 
quantification of endogenous LC3 vesicles in the cell using immunofluorescence assay 
(Klionsky et al., 2016). However, the only known limitation of this assay is that it cannot be 
used to assess the autophagic flux. My results from chapter 4 highlight another important 
drawback of the LC3-immunofluorescence assay. Under conditions where the autophagic 
activity decreases, I show that LC3-I appears on discrete structures that are associated with 
p62. Although at first sight these structures might resemble the canonical morphology of LC3-
II puncta, these structures tend to be larger and were exclusively dependent on the levels of 
p62 in these cells. These LC3-I positive structures in autophagy-impaired cells could easily be 
confused as mature autophagosomes. Thus, my results highlight that LC3 immunofluorescence 
assays are unsuitable under conditions where the cells being tested lack autophagy partially 
(ATG9 knockout) or completely (ATG16 knockout). 
 
A recent study characterising the p62 filaments show that while the presence of LIR (LC3-
interacting region) motif in p62 is crucial for its cluster formation, in the presence of mCherry-
LC3B cluster formation of p62 is inhibited (Zaffagnini et al., 2018). In line with these 
observations, my results potentially show that larger p62 aggregates show much lower levels 
of LC3 association with them compared to ‘growing’ p62 aggregates. This can be visualised in 
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the super-resolution images of ATG16 null cells (Fig 5.5 b and c), where larger p62 aggregates 
show lower levels of association with LC3 compared to smaller ‘growing’ p62 aggregates. 
However, further experimentation is needed to show that this indeed is the case. A schematic 
representing the possible homeostatic role of p62 is shown in Fig 7.1  
 
I will now try to present some of the open questions relevant to my study with potential answers 
in context of the existing literature. The study that describes the p62 cluster formation 
propensities in the presence of LC3 and ubiquitin molecules explains the broader phenomenon 
of p62 aggregate formation/nucleation very clearly (Zaffagnini et al., 2018). However, it would 
be interesting to understand how p62 differentiates between the forms of LC3 viz. LC3-I and 
LC3-II and understand their respective binding affinities with p62. Furthermore, if under steady 
state there exists an equilibrium between the levels of two forms of LC3, that dictates their 
binding with p62, how does it get perturbed under conditions where autophagy is affected under 
conditions such as rare form of hereditary spastic paraplegia caused due to AP-4 deficiency. 
Moreover, while my results show that p62 acts as a platform that associates with LC3-I, it 
would be interesting to understand the requirement of LC3 for the growth of p62 aggregates. 
It could be possible that LC3-I molecules binding to p62 facilitate its aggregation dynamics 
and act as potential nucleators for the process but are also counter-productive at later stages 
due to steric hindrance between these proteins. Another interesting idea, which could 
potentially resolve the problem of ambiguous LC3 recognition in immunofluorescence assays, 
is whether the topology/conformation of PE-conjugated LC3 molecule could be used as an 
epitope to develop antibodies that can effectively distinguish between the two forms of LC3. 
 
Another important question to answer would be whether this phenomenon is exclusive to p62 
amongst other autophagy receptors and is this observation cell-line specific. The family of 
autophagy receptors in the mammalian system includes several members like p62/SQSTM1, 
NBR1 (neighbour of BRCA1), optineurin (OPTN), NDP52, etc. These members show 
presence of conserved UBD and LIR motifs to facilitate the engulfment of the cargo into the 
autophagosomes (Rogov et al., 2014; Stolz et al., 2014). Therefore, it is possible that the 
homologous partners of the autophagy receptors spread across different species might perform 
a homeostatic role similar to the one discussed above for p62 under autophagy-impaired 
conditions. 
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Fig 7.1 A schematic depicting the possible roles of p62 in cells. The homeostatic role of p62 is likely activated 
under conditions where autophagic degradation of substrate/cargo is affected. Under these conditions, p62 
associates with the excess LC3-I and possibly helps towards its degradation via the ubiquitin-proteasomal 
pathway. The possible functions played by p62 also point towards the possible interplay between the two major 
protein degradation pathways viz. autophagy and ubiquitin-proteasomal pathway. Please refer to the legend for 
description of the various symbols used in the schematic. 
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7.3. Possible functions of ATG9 
 
Although ATG9 has been described as a core-autophagy protein for almost two decades, the 
understanding of its function remains limited. My results in chapter 3 provide some insight 
towards the possible functions of ATG9. I will now discuss some of the possible functions of 
ATG9 based on my observations and mention potential experiments that could provide us with 
more information about ATG9 function. 
 
An important observation in ATG9 knockout cells was the high levels of LC3-I compared to 
control cells. During the process of autophagosome formation, LC3-I gets converted to LC3-II 
by its conjugation to a phosphatidylethanolamine molecule (please refer to section 1.2.4 of this 
thesis for more details). LC3-II is considered as the primary marker for the autophagosomes in 
cells. After the autophagosomes are fused with the lysosomes, some of the LC3-II molecules 
on the autophagosome are recycled back via its deconjugation to the cytosolic LC3-I pool and 
these molecules can then re-enter the process of conjugation as needed (Yu et al., 2012). The 
observation of higher levels of LC3-I in ATG9 knockout cells could therefore either indicate a 
defect in the lipidation capability of the cells or an increased/premature recycling of LC3-II 
from the autophagosomes. It is also worth noting that depending on stage of autophagy where 
ATG9 acts would also give us information about its activity at either early stages of 
autophagosome formation or at later stages of autophagosome maturation/fusion. Simple tests 
such as checking the levels of ATG5-ATG12-ATG16 complex, WIPI2 localisation, ATG4B 
levels could provide us with information if the lipidation machinery is intact in ATG9 knockout 
cells. Another experiment that could potentially identify if ATG9 facilitates the LC3-lipidation 
directly would be an in-vitro liposome lipidation experiment (Zens et al., 2015). This 
experiment could potentially be setup in the presence or absence of ATG9 and the lipidation 
machinery with a C-terminal GFP-tagged LC3 as a substrate for the reaction. As the LC3-gets 
conjugated, it would lose its GFP-tag and the fluorescence of the free GFP molecules can be 
used to estimate the efficiency of the reaction in the presence or absence of ATG9. These 
experiments could provide us with the information about the role of ATG9 in lipidation. The 
role of ATG9 in the recycling of LC3-II from the autophagosomes could be studied by the live-
cell imaging of cells transfected with GFP-LC3. Tracking the start and endpoints of lipidation 
events in the cells based on puncta appearance and disappearance could provide us with the 
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information about the dynamics of the autophagic process in general together with the time-
points where LC3-II gets recycled to LC3-I in the presence or absence of ATG9. 
 
Another interesting observation associated with the ATG9 knockout cells was their lack of a 
response to bafilomycin-A1 (BAF) treatment. BAF is a lysosomal V-type H+ ATPase inhibitor 
that increases the lysosomal pH (inhibiting its acidification) thereby inhibiting the fusion 
between autophagosomes and lysosomes. The observation might therefore indicate towards 
impaired fusion between the autophagosomes and lysosomes in ATG9 knockout cells. Indeed, 
a recent study has shown that ATG9, present at the TGN, plays an important role in the exit of 
the newly synthesised lysosomal hydrolases from the TGN. They support the claim by showing 
that ATG9 expression in mammalian system is required for the lysosomal degradation activity 
using EGFR degradation assay and cathepsin D and L maturation. They also show that this 
reduced degradation was not a result of lysosomal pH since the pH was seen to be unchanged 
upon ATG9 knockdown (Jia et al., 2017). These results together with the observation of 
unchanged lysosomal pH upon ATG9 knockdown might also hint towards a mechanism that 
involves regulation of autophagosome fusion depending on the maturation of lysosomal 
hydrolases. Furthermore, it is worth noting that compared to ATG16 knockout cells, ATG9 
knockout cells show some amounts of residual autophagy, indicating that ATG9 is not essential 
for basal levels of autophagy and might only be needed when the autophagic process needs to 
be upregulated under conditions like starvation. 
 
7.4. Novel trafficking routes for ATG9 and VMP1 
 
The presence of multiple transmembrane domains in ATG9 and VMP1 make them unique in 
the autophagic system. The trafficking of ATG9 has been studied to a great extent as described 
in the section 1.3.1 of introduction, and my research identifies a novel trafficking pathway for 
ATG9 that it shares with VMP1. This identified pathway is a dynamin-independent and ARF6-
associated endocytic pathway that eventually merges with the conventional destinations of the 
endocytic pathway i.e. early and recycling endosomes. 
 
The current understanding of ATG9 trafficking shows it to traffic from the plasma membrane 
to early endosomes and finally recycling endosomes (Puri et al., 2013). Additionally, ATG9 
was also seen to localise in the trans-Golgi network and it possibly redistributes on autophagy 
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induction to the plasma membrane and eventually endosomes from the TGN (Young et al., 
2006). It is worth noting that all these trafficking events rely on the activity of dynamin for 
their functioning. My results in chapter 6 identify a novel clathrin and dynamin-independent 
trafficking pathway for ATG9 (Fig 6.11). Furthermore, I also show that VMP1, trafficking of 
which remains unknown to date, shares its trafficking route with ATG9 and both these 
transmembrane autophagy proteins traffic through the ARF6-associated pathway. 
Interestingly, a published study has shown the ARF6 and GRAF1 proteins to regulate 
autophagosome biogenesis mainly by regulating endocytosis, PIP2 levels and phospholipase 
D activation. Interestingly, the same study also identified ATG16 to co-localise with 
overexpressed ARF6-GFP, hinting towards its trafficking via the ARF6-associated pathway 
(Moreau et al., 2012). In the light of these results, an important challenge would be therefore 
to understand the functional significance of trafficking of these autophagic proteins through 
this mode of dynamin-independent endocytosis. My results in conjunction with the published 
observations might indicate one of the additional ways through which ARF6 could potentially 
regulate autophagosome biogenesis. Depletion of ARF6, leading to disruption of this pathway, 
might lead to mislocalisation of the pool of ATG9, VMP1 and ATG16 trafficking through this 
pathway. This mislocalisation could prevent the proteins from being trafficked to their 
respective destinations and could therefore be responsible for lower autophagosome 
biogenesis. Another question raised due to the identification of this pathway would be to 
understand whether this pathway traffics a unique pool of ATG9 that performs an exclusive 
function or does it simply act as a backup pathway in case of the primary endocytic pathway 
failure. This also opens the possibility of regulation of the process of autophagy by a specific 
class of proteins involved in dynamin-independent endocytosis. 
 
VMP1 overexpression has been shown to induce autophagy (Ropolo et al., 2007). My results 
extend the observation by showing that VMP1 overexpression needs ATG9 expression in cells 
to induce autophagy. My results also show that ATG9 and VMP1 physically interact with each 
other in the cell. It would therefore be interesting to identify which domains in each of these 
proteins are involved in this physical interaction. It could also be then checked how expression 
of specific-peptide representing various domains, for ATG9 and VMP1, would affect the 
autophagy induction on VMP1 overexpression. While the domain structure for human ATG9 
is partially known (Fig 1.4) (Tooze, 2010), the domain organisation of VMP1 is relatively 
unclear. It is also important to note that VMP1 showed a physical interaction with GFP-tagged 
ATG9 that was cloned from the mouse genome. The mouse ATG9 protein when studied for 
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conserved domains compared to other species, shows the lack of the long C-terminal tail that 
is a characteristic of human ATG9 (Fig 1.4), indicating that this region might not be important 
towards the interaction with VMP1. An experiment involving the cloning of various domains 
of ATG9 and VMP1 and checking their interactions would provide us with valuable 
information about the importance of different peptide sequences in these proteins. Importantly, 
this experiment could also give us information about the nature of the interaction between 
ATG9 and VMP1. It could be possible that these proteins do not interact with each other 
directly and involves a third-party that facilitates the interaction between these two. It would 
also be very interesting to check whether ATG9 interacts with VMP1 while they co-traffic 
together though their newly identified dynamin-independent trafficking routes and whether that 
interaction plays a specific function towards autophagic regulation. If it does, this might hint 
towards a specialised pool of ATG9 that regulates autophagy together with VMP1 by 
trafficking through ARF-6 associated pathway. Additionally, ATG16 trafficking through the 
ARF6 pathway (Moreau et al., 2012) could play an important role in facilitating the ATG9, 
VMP1 interaction. 
 
Finally, I also show that it is highly likely that VMP1 also traffics via the CLIC/GEEC pathway 
in addition to ARF6-assoicated pathway. This pathway functions independently of the AR6-
associated pathway and is mainly responsible for fluid phase and GPI-linked protein 
endocytosis (Mayor et al., 2014). This raises questions about VMP1 trafficking, similar to 
ATG9, of whether there are two distinct pools of VMP1 which perform two independent 
functions. Also, which of these pathways act as a dominant pathway for VMP1 trafficking. The 
identification of the dynamin-independent pathway for trafficking of some autophagy proteins 
opens a new avenue for exploring the regulatory components for autophagy and answers to 
some of these questions might provide us with a deeper insight into the regulation of autophagy. 
This would also provide impetus towards searching new regulators of ATG9/VMP1 trafficking 
and function along the dynamin-independent pathway. 
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Appendix 
 
Abbreviations 
 
AD - Alzheimer’s Disease  
ADP - adenosine diphosphate  
AMBRA1 - activating molecular in BECN-1 regulated autophagy protein 1  
AMPK - adenosine monophosphate-dependent protein kinase  
AP2 – adaptor complex 2  
APP - amyloid precursor protein  
ATG - autophagy related protein/gene  
ATG16 KO – ATG16 CRISPR knockout cell line 
ATG9 KO – ATG9 CRISPR knockout cell line 
ATP - adenosine triphosphate  
Baf/BAF - bafilomycin A1  
BECN-1 - beclin-1  
Bcl-2 - B-cell lymphoma 2  
4E-BP1 - eukaryotic translation initiation factor 4E-binding protein 1  
BSA - bovine serum albumin  
Ca2+ - calcium  
CMA - chaperone mediated autophagy  
DAPI - 4',6-diamidino-2-phenylindole 
DMEM - Dulbecco’s modified eagle media  
DMSO - dimethyl sulfoxide  
DNA - deoxyribonucleic acid  
EDTA - ethylenediaminetetraacetic acid  
ER - endoplasmic reticulum  
FBS - foetal bovine serum  
FIP200 - focal adhesion kinase family kinase-interacting protein of 200 kDa  
GABARAP - γ-aminobutyric-acid-type-A-receptor-associated protein 
GAPDH - glyceraldehyde 3-phosphate dehydrogenase  
GATE16 - Golgi-associated ATPase enhancer of 16 kDa 
GDP - guanosine diphosphate  
GFP - green fluorescent protein  
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GTP - guanosine triphosphate  
HBSS - Hank’s balanced salt solution  
HD - Huntington’s Disease  
HEK – human embryonic kidney cells 
HeLa - human epithelial cervical cancer cells 
Hsc- heat shock cognate  
hsp – heat shock protein  
IP - immunoprecipitate  
K+ - potassium  
kDa - kilo Dalton  
LAMP - lysosomal-associated membrane glycoprotein  
LC3 - microtubule-associated protein 1A/1B-Light Chain 3  
LIR - LC3-interacting region 
MEFs - mouse embryonic fibroblasts  
mTOR - mechanistic/mammalian target of rapamycin  
mTORC - mTOR complex  
NBR1 - neighbour of BRCA1 gene 1 
p53 - phosphoprotein 53 
p62/SQSTM1- sequestosome 1 
PAS - pre-autophagosomal structure/phagophore assembly site  
PBS - phosphate buffered saline  
PD - Parkinson’s Disease  
PE - phosphatidylethanolamine  
PFA - paraformaldehyde 
PH - pleckstrin homology  
PI3P - phosphatidylinositol 3-phosphate  
PI3K - phosphatidylinositol-4,5-bisphosphate 3-kinase  
PS - phosphatidylserine   
PTM - post-translational modification  
PVDF - polyvinylidene fluoride  
Rab - Ras superfamily of monomeric G proteins 
Rap - rapamycin 
RAPTOR - regulatory-associated protein of mTOR  
RFP - red fluorescent protein  
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p70 S6K1 - ribosomal protein S6 kinase, 70 kDa, polypeptide 1  
RICTOR - rapamycin-insensitive companion of mammalian target of rapamycin  
RNA - ribonucleic acid 
SDS-PAGE - sodium dodecyl sulphate-polyacrylamide gel electrophoresis  
SNAP - soluble NSF attachment protein  
SNARE - SNAP receptor  
TGN - trans-Golgi network  
TSC1 - tuberous sclerosis 1 
UBA domain - ubiquitin-associated domain 
ULK1 - unc-51-like autophagy activating kinase   
UPS - Ubiquitin proteasome system 
UVRAG - UV radiation resistance associated is a protein-coding gene 
VAMP - vesicle-associated membrane protein  
VPS - vacuolar protein sorting  
WD40 - tryptophan-aspartic acid repeat-containing proteins  
WD - tryptophan-aspartic acid (motif)  
WE - tryptophan-glutamate (motif)  
WIPI - WD repeat domain phosphoinositide-interacting protein  
 
